QUEEN
R
854
.C3
C37
2000

IC

CANADIAN CLINICAL TRIALS
FACILITIES & CAPABILITIES
2000

LIFE SCIENCES RESEARCH INVESTMENTS
IS A JOINT VENTURE OF THE MEDICAL RESEARCH COUNCIL OF CANADA,
INDUSTRY CANADA AND THE INVESTMENT PARTNERSHIPS CANADA

HOLLAND CROSS, TOWER B, 4TH FLOOR, 1600 SCOTT STREET, POSTAL LOCATOR 3105A
OTTAWA ONTARIO K1A OW9
TEL: (613) 954-5320, FAX: (613) 941-1040, E-MAIL: wthomson@mrc.gc.ca

CANADIAN CLINICAL TRIALS

FACILITIES & CAPABILITIES

2000

LIFE SCIENCES RESEARCH INVESTMENTS

IS A JOINT VENTURE OF THE MEDICAL RESEARCH COUNCIL OF CANADA, INDUSTRY CANADA AND THE INVESTMENT PARTNERSHIPS CANADA

HOLLAND CROSS, TOWER B, 4TH FLOOR, 1600 SCOTT STREET, POSTAL LOCATOR 3105A

OTTAWA ONTARIO K1A OW9

TEL: (613) 954-5320, FAX: (613) 941-1040, E-MAIL: wthomson@mrc.gc.ca

CANADIAN CLINICAL TRIALS

FACILITIES & CAPABILITIES 2000

TABLE OF CONTENTS

Industry Canada
Library - Queen

NOV 0 6 2007

Industrie Canada
Bibliothèque - Queen

PostFax
MONTREAL, H1J 2K9
CR213-10W

Benefits of Conducting Clinical Trials in Canada

- Newly reformed regulatory environment (Sept 2000)
  - 48 hour review target for Phase I Trials in healthy volunteers
  - 30 day review target for other Phase I and Phase II to IV Trials
- ICH Guidelines including GCP have been adopted
- Investigators with long experience with FDA requirements are plentiful in major centres
- Strong domestic and international CRO's, SMO's and clinical trial support companies are located in Canada
- All services are available in major Canadian cities including pre-clinical drug metabolism and animal pharmacokinetics, drug discovery, analytical, Phase I pharmacokinetics/pharmacodynamics, Phase II to IV, biostatistics, clinical data management and regulatory affairs
- Excellent hospital sites with clinical trial units and broad therapeutic experience
- National healthcare system of Canada provides single set of clinical standards across country
- 14 major Canadian cities are the main catchment areas for patient populations
- Multi-ethnic patient base including significant populations of: northern European, Asian, Caribbean, western European founder populations provides scope for wide variety of trials
- Exchange rate of Canadian dollar provides 40% more purchasing power than US
- Scientific Research and Experimental Development Tax Credits are available to eligible sponsoring companies when trials involve original research undertaken in Canada
- National ethical review standard is in place across Canada
- Medical Research Council of Canada can share funding with industry partners for clinical trials in health care which are randomised or hypothesis driven

Executive Summary

Canadian Clinical Trials Facilities and Capabilities 2000 is a guide for companies and institutions to clinical research services in Canada. It captures most of the existing facilities that are centres for clinical trials as well as contract research companies that manage trials in Canada and the relevant support services. It also highlights the changes in the Canadian regulatory environment for clinical trials for expedited review that will be adopted in September 2000. The document has been developed with great cooperation of hospital sites, CRO's, and the Therapeutic Products Program of Health Canada.

In the year 2000, the health research sector in Canada is very active with the creation of:

- Canadian Institutes of Health Research (CIHR),
- Genome Canada,
- MRC/Rx&D Research Program (Phase II)
- Expansion of the Network of Centres of Excellence in the Life Sciences
- Increased Infrastructure Funding through the Canadian Foundation for Innovation
- Funding for 2000 New Canadian Research Chairs

These initiatives have tripled the amount of public sector funding for health research in Canada and provide significant support for new scientific infrastructure. They also provide excellent opportunities for academic/industrial partnerships with the pharmaceutical and biopharmaceutical industries.

This survey is prepared by Life Science Research Investments which is a joint venture of the Medical Research Council, Industry Canada and Investment Partnerships Canada. It is designed to stimulate new investment in Canada by pharmaceutical, biopharmaceutical and medical device companies. It concentrates on all aspects of the product development cycle including basic research in universities and research institutes; clinical research carried out in hospitals and by contract research organizations, and applied research in biopharmaceutical companies. In addition to **Canadian Clinical Trials Facilities and Capabilities 2000**, we also publish **Canadian Biopharmaceutical Companies - Status of Research and Clinical Trials 2000** and **Basic Health Research in Canada by Therapeutic Area 1993-1999.**

For these publications and more information on health research in Canada please contact:

Wendy Thomson
Life Science Research Investments
Medical Research Council of Canada
1600 Scott Street, Tower B, 5th Floor
Ottawa, Canada K1A 0W9

Tel: 613-941-6696
Fax: 613-941-1040
E-mail: wthomson@mrc.gc.ca

Proposed New Regulations for Clinical Trials in Canada

- Over the last six years, Health Canada through the auspices of its drug and medical device regulator, the Therapeutic Products Programme, has been engaged in a process of modernizing and strengthening Canada's processes for ensuring that the drugs and medical devices available to Canadians are safe, effective and of high quality. This process has been undertaken in full consultation with stakeholders involved in the Canadian health care system.

- In Canada, the responsibility for developing drugs relies on an effective partnership among many players including the drug industry, research granting councils, the health care provider community, the ethics community, patient groups and the federal government.

- Within this partnership, the Therapeutic Products Programme of Health Canada ensures that clinical trials are properly designed and undertaken and that participants are not exposed to undue risk.

- Currently, under the *Food and Drug Regulations*, anyone wishing to undertake a clinical trial in Canada must present a submission with full supporting documentation to the Therapeutic Products Programme. The review of submissions for clinical trials is subject to a 60-day default review period. This requires the Therapeutic Products Programme of Health Canada to notify the sponsor within 60-days if its submission is found to be deficient or else the sponsor may proceed with the clinical trial.

- If problems develop during the conduct of a trial or if the safety of a trial participant becomes a concern, Health Canada can also stop the sale of the drug to the investigator conducting the trial.

- These *Regulations* were originally developed in the 1960s and have remained essentially unchanged. In 1987, the *Regulations* were amended to introduce the 60-day default review period.

- Time and experience have demonstrated that Canadians and those involved in the conduct of clinical trials in Canada would benefit from a modernization of the *Regulations*.

- Consultations with a wide range of stakeholders on the clinical trial review process and on the roles and responsibilities of all participants within that process have been on-going since December 1993. Representatives from the ethics, medical and scientific communities, patient advocacy groups as well as the drug industry and contract research organizations have been involved.

- Consultations have already resulted in the introduction of structured changes and a number of process efficiencies into the clinical trial review process. They also ensured that the proposed regulatory amendments clearly define conditions under which all clinical trials will be reviewed and conducted.

- The new framework for clinical trials under the *Food and Drug Regulations* proposes three major elements:

  - a new registration system for Phase I dose tolerance studies in healthy adult volunteers with a 48-hour target review time;
  - a move from the current 60-day default review period to a 30-day default review period for all other clinical trial submissions; and
  - a new inspection system for all clinical trials against internationally accepted Good Clinical Practices.

- These changes will:

  - enhance the protection and safety of clinical trial participants;
  - improve access of Canadians to innovative drug therapies; and,
  - stimulate clinical drug research and development in Canada.

- Modernizing the regulatory framework will also strengthen interaction with clinical trial sponsors and improve time efficiencies without jeopardizing the health and safety of Canadians.

- Clear application requirements combined with shortened review times should also enhance Canada's competitive position in drug development, encourage the conduct of more trials and facilitate an increase in new clinical research positions in Canada.

- This could result in long-term benefits to the Canadian health system and related areas within the professional health care community.

- As mentioned earlier, these proposed amendments have resulted from a number of consultations related to the review, approval and conduct of clinical trials in Canada.

- In all instances, sponsors of clinical trials will continue to be required to submit to Health Canada for review, high quality documentation that supports the conduct of the proposed trial.

- Health Canada will have clear authority to refuse applications, suspend the sale of drugs and cancel the conduct of clinical trials in Canada, which do not meet the updated regulatory requirements.

- The Registration system will only apply to dose tolerance studies that are conducted in healthy adult volunteers. These trials include the first administration of the new drug to humans and are often referred to as Phase I trials. Their objective is to determine the tolerability of certain doses of the drug and to determine the type of adverse reactions that maybe likely to occur.

- Sponsors will be required to hold a valid certificate of registration issued by the Therapeutic Products Programme of Health Canada prior to conducting the trial.

- Reduced time frames for the review of all clinical trial submissions will require the sponsor to bear greater responsibility for the quality of its submissions. Guidelines for submission requirements will be strengthened and submissions of inadequate quality will not be accepted by the Programme for review.

- The proposed amendments would enhance the safeguards in place for clinical trial participants by incorporating internationally accepted principles of Good Clinical Practice and providing for the introduction of a new clinical trial inspection program.

- There is no evidence that the current Regulations have not adequately protected the health and safety of Canadians. However, since these Regulations were first developed in the 1960s, new standards for the conduct of clinical trials have been developed internationally. These amendments recognize these standards. They also clarify Health Canada's authority to regulate and inspect clinical trials.

- Sponsors would be required to clearly demonstrate that trials will be conducted according to these internationally accepted principles of Good Clinical Practice.

- The new inspection program would ensure compliance with these principles. It would enable Health Canada to identify problem situations sooner and take appropriate action to reduce risk to the Canadian public and clinical trial participants.

- This proposal also recognizes the important role Research Ethics Boards play in overseeing the conduct of clinical trials. These Boards are an important partner in the clinical drug development process and we will be working closely with the Medical Research Council and the National Council on Ethics in Human Research to strengthen the capacity of these groups across Canada.

- This proposal was pre-published in the Canada Gazette, Part I with a 30-day comment period on January 22, 2000. Comments received during the consultation are now being reviewed by the Therapeutic Products Programme of Health Canada. The proposed amendments will be adjusted where necessary. Implementation is proposed for September 1, 2000.

CANADA'S HEALTH CARE SYSTEM

Canada has a predominantly publicly financed, privately delivered health care system that is best described as an interlocking set of ten provincial and three territorial health insurance plans. Known to Canadians as "Medicare", the system provides access to universal, comprehensive coverage for medically necessary hospital, in-patient and out-patient physician services.

This structure results from the constitutional assignment of jurisdiction over most aspects of health care to the provincial order of government. The system is referred to as a "national" health insurance system in that all provincial/territorial hospital and medical insurance plans are linked through adherence to national principles set at the federal level.

The management and delivery of health services is the responsibility of each individual province or territory. Provinces and territories plan, finance, and evaluate the provision of hospital care, physician and allied health care services, some aspects of prescription care and public health.

The federal government's role in health care involves the setting and administering of national principles or standards for the health care system (i.e., *Canada Health Act)*, assisting in the financing of provincial health care services through fiscal transfers, and fulfilling functions for which it is constitutionally responsible. One of these functions is direct health service delivery to specific groups including veterans, native Canadians living on reserves, military personnel, inmates of federal penitentiaries and the Royal Canadian Mounted Police. Other federal government health-related functions include health protection, disease prevention, and health promotion.

PRINCIPLES OF MEDICARE

The *Canada Health Act* stipulates the criteria that provincial health insurance plans must meet in order for a province to qualify for its full federal transfer payments. The following five criteria are known as the "principles" of Canada's national health care system:

Public Administration

The health insurance plan of a province must be administered and operated on a non-profit basis by a public authority accountable to the provincial government.

Comprehensiveness

The plan must insure all medically necessary services provided by hospitals and physicians. Insured hospital services include in-patient care at the ward level (unless private or semi-private rooms are medically necessary) and all necessary drugs, supplies and diagnostic tests, as well as a broad range of out-patient services. Chronic care services are also insured, although some payment in respect of accommodation costs may be required by patients who more or less permanently reside in the institution.

Universality

The plan must entitle 100 percent of the insured population (i.e., eligible residents) to insured health services on uniform terms and conditions.

Accessibility

The plan must provide, on uniform terms and conditions, reasonable access to insured hospital and physician services without barriers. Additional charges to insured patients for insured services are not allowed. No one may be discriminated against on the basis of income, age, health status, etc.

Portability

Residents are entitled to coverage when they move to another province within Canada or when they travel within Canada or abroad. All provinces have some limits on coverage for services provided outside Canada, and may require prior approval for non-emergency out-of-province services.

How The System Works

Canada's health care system relies extensively on primary care physicians (e.g., general practitioners), who account for about 51% of all active physicians in Canada. They are usually the initial contact with the formal health care system and control access to most specialists, many allied providers, hospital admissions, diagnostic testing and prescription drug therapy.

Canada does not have a system of "*socialized medicine*", with doctors employed by the government. Most doctors are private practitioners who work in independent or group practices and enjoy a high degree of autonomy. Some doctors work in community health centres, hospital-based group practices or work in affiliation with hospital out-patient departments. Private practitioners are generally paid on a fee-for-service basis and submit their service claims directly to the provincial health insurance plan for payment. Physicians in other practice settings may also be paid on a fee-for-service basis, but are more likely to be salaried or remunerated through an alternative payment scheme.

When Canadians need medical care, in most instances, they go to the physician or clinic of their choice and present the health insurance card issued to all eligible residents of a province. Canadians do not pay directly for insured hospital and physicians' services, nor are they required to fill out forms for insured services. There are no deductibles, co-payments or dollar limits on coverage for insured services.

A number of allied health care personnel are also involved in primary health care to a certain extent. Dentists work independently of the health care system, except where in-hospital dental surgery is required. While nurses are generally employed in the hospital sector, they also provide community health care including home care and public health services. Pharmacists dispense prescribed medicines and drug preparations and also act as an independent knowledge source, by providing information on prescribed drugs, or by assisting in the purchase of non-prescription drugs.

Over 95% of Canadian hospitals are operated as private non-profit entities run by community boards of trustees, voluntary organizations or municipalities. Hospitals have control of the day-to-day allocation of resources provided they stay within the operating budgets established by the regional or provincial health authorities. Hospitals are primarily accountable to the communities they serve, not to the provincial bureaucracy. The for-profit hospital sector comprises mostly long-term care facilities or specialized services such as addiction centres.

In addition to insured hospital and physician services, provinces and territories also provide public coverage for other health services that remain outside the national health insurance framework for certain groups of the population (e.g., seniors, children and welfare recipients). These supplementary health benefits often include prescription drugs, dental care, vision care, assistive equipment and appliances (prostheses, wheelchairs, etc.) to independent living and services of allied health professionals such as podiatrists and chiropractors.

Although the provinces and territories do provide some additional benefits, supplementary health services are largely privately-financed and Canadians must pay privately for these non-insured health benefits. The individual's out-of-pocket expenses may be dependent on income or ability to pay. Individuals and families may acquire private insurance, or benefit from an employment-based group insurance plan, to offset some portion of the expenses of supplementary health services. Under most provincial laws, private insurers are restricted from offering coverage which duplicates that of the governmental programs, but they can compete in the supplementary benefits market.

Milestones in the Evolution of Universal Health Insurance

Canada's health insurance system evolved into its present form over five decades.

Prior to the late 1940's, private medicine dominated health care in Canada resulting in access to care being based on ability to pay. The trend to universal, publicly financed health insurance began in 1947 when the province of Saskatchewan introduced a public insurance plan for hospital services. In 1956, the federal government, seeking to encourage the development of hospital insurance programs in all provinces, offered to cost-share hospital and diagnostic services on a roughly fifty-fifty basis. By 1961, all ten provinces and the two territories had signed agreements establishing public insurance plans that provided universal coverage for at least in-patient hospital care that qualified for federal cost-sharing.

Public medical care insurance also began in the province of Saskatchewan, providing coverage for visits to, and services provided by, physicians outside hospitals. The federal government enacted medical care legislation in 1968 to cost-share, again on a roughly fifty-fifty basis, the costs of provincial medical care services. By 1972, all of the provincial and territorial plans had been extended to include physicians' services. Thus, by that year, the objective to have a national health insurance plan for hospital and medical care in Canada had been realized.

For the first twenty years, the federal government's financial contribution in support of Medicare was determined as a percentage—about half—of provincial expenditures on specified insured health services. In 1977, these cost sharing arrangements were replaced by per capita transfers to the provinces and territories, known as block funding. For the period 1977 to 1996, the federal contribution was based on a uniform per capita entitlement and took the form of a tax transfer (taxing power) [1] and cash payments.

With the arrival of block funding arrangements in 1977, the provinces' entitlement to the federal contribution became conditional solely on their compliance with the criteria set out in the federal hospital and medical care legislation. Because transfers were no longer tied to provincial spending on hospital and physician services, the provinces had the flexibility to invest in other approaches to health care delivery, such as extended health care services and community health centres, or to expand coverage for supplementary health benefits, such as prescription drugs for seniors or dental care for children.

In 1979, a health services review undertaken by the Hall Commission reported that health care in Canada ranked among the best in the world, but it warned that extra-billing by doctors—requiring patients to supplement what a doctor was paid by the provincial plan—and user fees levied by hospitals were creating a two-tiered system that threatened accessibility to care.

In response to these concerns, the federal government reaffirmed its commitment to a universal, accessible, comprehensive, portable, publicly-administered health insurance system when the Parliament of Canada passed the *Canada Health Act* in 1984. To discourage provincial user charges and extra-billing, the *Act* provides for a mandatory dollar-for-dollar penalty, deducted from federal transfer payments, if any province permits user charges or extra-billing for insured health services.

The federal government remains firmly committed to the principles of the *Canada Health Act.*

Funding

Health care in Canada is financed primarily through taxation, in the form of provincial and federal personal and corporate income taxes. Some provinces use ancillary funding methods which are

nominally targeted for health care, such as sales taxes, payroll levies and lottery proceeds. These funds, however, are not earmarked specifically for health and are added to the central revenues of the province. They play a relatively minor role in health care financing.

Two provinces (i.e., Alberta and British Columbia) utilize health care premiums. The premiums are not rated by risk in either province and prior payment of a premium is not a pre-condition for treatment, in accordance with the *Canada Health Act.*

For the period 1977 to 1996, the federal contribution for insured health services was combined with that for post-secondary education and provided through a block funding transfer. The federal contribution was based on an equal per capita entitlement which was adjusted annually according to changes in Gross National Product and calculated independently of provincial costs.

Beginning in fiscal year 1996-97, the federal government's contribution to provincial health and social programs was consolidated in a new single block transfer, the Canada Health and Social Transfer. Federal funding is transferred to the provinces as a combination of cash contributions and tax points. As with the previous transfer arrangement, provincial health insurance plans must adhere to the principles of the *Canada Health Act* in order to be eligible for the full federal transfer payments.

To strengthen the health care system, the federal government announced in the 1999 Budget that provinces and territories will receive an additional $11.5 billion over the period from 1999-2000 to 2003-2004, specifically for health care under the Canada Health and Social Transfer.

The schematic diagram of the Funding Structure of the Health System in Canada (found at the end of this brochure) indicates that the flow of funds from individuals (on the left hand side of the diagram) in the form of payment of taxes and premiums to governments, employers and private insurers, finance the health care delivery system and providers (on the right hand side of the diagram).

Figure A
Total Health Expenditures by Sector of Finance, Canada, 1998



* Federal Transfers are mainly the health portion of Canada Health and Social Transfer estimated using the 1995-96 distribution of Established Programs Financing (EPF) and Canada Assistance Plan (CAP).

Source: Health Canada

Figure B
Percentage Change of Real Per Capita Public and Private Health Expenditures, Canada, 1976 to 1998



Source: Health Canada

Health Spending

In 1998, total health expenditures in Canada (in current dollars) were $82.5 billion (Cdn) or $2,694 (Cdn) per capita (approximately $1,785 US per capita). Health expenditures accounted for 9.3% of Gross Domestic Product (GDP) in 1998, down from the 1992 peak level of 10.1% of GDP. Health care spending accounts for around one-third of provincial program expenditures.

Public sector funding represents about 68.7% of total health expenditures. The remaining 31.3% is financed privately through supplementary insurance, employer-sponsored benefits or directly out-of-pocket (Figure A & D). The controls inherent in the single-payer approach to health care are recognized as a major contributor to Canada's recent cost containment success.

The single-payer attribute of public insurance has enabled the provinces and territories to better control the growth of health expenditures in the public sector than has been the case in the private sector (Figure B). Provinces and territories have considerable power to manage health care spending. For example, a hospital's operating costs are paid out of the annual budget it negotiates with the provincial ministry of health, or with a regional authority given the devolution of many health planning and delivery functions to communities since the early 1990's. In most cases, proposals for the expansion of programs, services and health facilities must be approved by community and provincial authorities. The acquisition and distribution of expensive high-tech equipment among a region's hospitals is also subject to prior approval to avoid unnecessary duplication of services or their under-utilization.

Compensation for physician services is also negotiated between the provinces and the provincial medical associations on the basis of fee and utilization increases, subject to various forms of individual physician or global ceilings. Salaries for nurses' services are generally negotiated through collective bargaining between the unions and employers.

Figure C
Total Health Expenditures by Category, Canada, 1998



* Includes drugs in hospitals

Source: Health Canada

Figure D
Public and Private Shares of Health Expenditures by Category, Canada, 1998



Source: Health Canada

Benefits of Medicare

Health Status

One of the most important indicators of the system's success is the favourable health status of Canadians. The life expectancy for Canadians born in 1997 is 78.6 (81.4 years for women, and 75.8 years for men), among the highest in industrialized countries. The 1996 infant mortality rate of 5.6 per 1,000 live births is one of the lowest in the world. Canada's health care system is regarded as a major contributor to Canada's number one world ranking on the United Nations Human Development Index.[2]

Economic Benefits

Medicare provides a variety of economic benefits, which arise from efficiency and cost-savings associated with public financing and competitive

advantages it provides to Canadian business. Public financing spreads the cost of providing health services equitably across society. In addition to the benefits derived from the single-payer attributes of the Canadian health system, financing health insurance through the taxation system is efficient since it does not require the creation of a separate collection process.

> *The Canadian health care system is one of the central determinants of our industrial competitiveness and our quality of life* (Conference Board of Canada, 1998).[3]

A 1999 study by KPMG, the international business advisors, comparing business costs in North America, Europe and Japan found that Canada has the lowest business costs. A significant advantage was Canada's lower labour costs resulting from lower employee-sponsored benefits (ESB), especially medical insurance.[4]

Canadian business supports the health insurance program, not only because its efficiency has been proven, but also because it provides competitive advantages to the business sector. These advantages include lower employee benefit costs and the promotion of a healthy and mobile workforce. While universal access to quality health care services helps ensure a healthy population and, therefore, a healthy and productive labour force, the national character of Canada's health insurance system enhances labour force mobility, which can be very important in responding to changing business requirements and opportunities.

Public health insurance coverage in Canada is based solely on residency. The portability principle of the *Canada Health Act* ensures that residents are covered when they move or while they are temporarily absent from their province. Workers, therefore, need not fear losing health insurance coverage for themselves and their families because they change jobs or move to another province in search of employment.

NATIONAL FORUM ON HEALTH[5]

The National Forum on Health was launched in 1994 to engage the public and health stakeholders in a dialogue to chart a course for the future of health and health care in Canada. The Forum submitted its final report, *Canada Health Action: Building on the Legacy*, on February 4, 1997. The Forum's overall prescription for sustaining Canada's health system for the future is a balance of actions on non-medical determinants and actions within the health care system itself.

On economic grounds, the Forum says that the single-payer model of public health insurance (Medicare) is the best approach to controlling overall spending on health. The report concludes that a range of concerted actions, based on informed decisions, is needed to make the system more efficient, effective and more reflective of contemporary practice in health care delivery. Recommendations include:

- restructuring the organization, funding and delivery of primary care services; funding the care, rather than the provider or site; taking steps to bring home care and medically necessary drugs under the umbrella of the publicly funded health care system;
- a broad, integrated child and family strategy involving both programs and income support; the creation of a national foundation to strengthen community action; an Aboriginal Health Institute; and help for people trying to enter the work force; and
- the adoption of an evidence-based system at the clinical, management and policy level, and at the public information level - with federal leadership in this area through the development of a nationwide population health information system.

In the 1997 Budget, the Government of Canada provided some early responses to several forum recommendations in announcing $300 million over the next three years for: a new Health Transition Fund (focussing on evidence-based innovations in home care, pharmacare, primary care and integrated service delivery); a national strategy for an integrated Canadian Health Information System; and increased funding for community-based children and prenatal nutrition initiatives.

Renewing Canada's Health Care System

In the early 1980s, health care spending required larger portions of total provincial resources, to the point where they represented between 28% and 36% of provincial program expenditures. Accounting for such a large proportion of provincial expenditures, health care was targeted by most provinces for restraint and cost

efficiencies. Provinces were able to undertake much of this cost-control by using the power of a single-payer structure.

There is a growing comprehension of a change in future population health needs, and an understanding of the actual impact of health care on the population's general health status. This is evident in the general policy shift away from discussions of the health care system to a focus on the *health system*, which recognizes that health is more than health care. The overall orientation of new provincial policy directions is the continuance of the shift away from an emphasis on health care towards a more comprehensive and integrated view of health.

The federal and provincial governments have responded to the need to adapt the system to today's realities in several ways, notably: by adopting a determinant of health framework which recognizes that while health care is obviously an important contributor to health, its role must be placed in context as only one component of a much broader set of determinants of health; by shifting the emphasis of the health care system away from institutionally-based delivery models (i.e., physicians and hospital-based care) to integrated community-based models which place increased emphasis on health promotion and prevention; and, by developing strategies for the coordinated management of the health care workforce, including the remuneration, geographical distribution and appropriate use of various health providers.

Governments, health providers and Canadians alike agree that all efforts to preserve and enhance Canada's health care system have to build upon the five fundamental principles of the *Canada Health Act* that guide the design and operation of our national health insurance system. Canadians regard health care as a basic right and they value their health system highly. They identify strongly with their health care system because it exemplifies many of the shared values of our society, such as equity, fairness, compassion, and respect for the fundamental dignity of all. Adherence to the principles of the *Canada Health Act* will remain an important characteristic of Canada's health care system as it continues to evolve to respond to the needs of Canadians.

CANADA: SELECTED FACTS

Demographics	**#**	**Year**
Population	30.9M	1999*
% of Pop. aged 0 - 24	33.2	1998*
" " " " 25 - 44	32.3	1998*
" " " " 45 - 64	22.2	1998*
" " " " 65 +	12.3	1998*
Health Indicators		
Life expectancy at birth (yrs)	78.6	1997*
Median age of women	36.1	1996*
Median age of men	34.5	1996*
Infant mortality rate per 1,000 live births	5.6	1996*
Potential years of life lost per 100,000 pop.	3,483	1996*
Major causes of death (% of total causes)		
Cancer	27.2	1997*
Heart disease	26.6	1997*
Cerebrovascular diseases (mainly stroke)	7.4	1997*
Hospitals and other institutions		
Hospital inpatient days per 1,000 pop.	1,132.0	1996-97*
Average length of stay (inpatient days)	10.7	1996*
Hospital beds per 1,000 pop.	5.6	1993-94*
Residential care beds per 1,000 pop.	8.1	1993-94*
Average hospital costs per day	$623	1995-96+
Hospital staff per bed	3.0	1995-96+
Health care providers		
Total # of physicians	55,243	1997+
Active physicians per 100,000 pop.	183	1997+
# of GP's	28,108	1997+
% of physicians who are GP's	50.9	1997+
# of Specialists	27,135	1997+
% of physicians who are specialists	49.1	1997+
Specialists per 100,000 pop.	90	1997+
Registered nurses	229,813	1997+
Registered nurses per 100,000 pop.	763	1997+

* Statistics Canada + Canadian Institute for Health Information

Conclusion

Canada has been successful in its efforts to contain national health expenditures. In the mid-1990s health expenditures levelled off and declined somewhat further. While cost containment within specific sectors remains a priority in order to provide for the reallocation of resources, the pragmatic concerns of containing overall costs have been largely addressed. Canada is now turning its attention toward longer-term considerations about the future of the national health care system. These longer-term considerations are focusing on ensuring that the health care system remains responsive to Canadians' health needs now, and in the future, and appropriate for achieving good health outcomes and health status. There is general agreement that in order to make the health care system more responsive and accountable to the public, it is necessary to move toward an integrated, high quality health care system that can provide the needed care in an effective and affordable manner. Canadians expect to be informed of the performance of the health care system and to be involved in the transition of the system to address their needs in the twenty first century and beyond.

In the 1999 Budget, the Government of Canada announced key steps to strengthen health care in Canada, improve the health of Canadians and enhance health research. Transfer payments to the provinces/territories for health services will increase by $11.5 billion over the five year period from 1999-2000 to 2003-2004. In addition to increased transfers, the 1999 BuHShsdget injected $1.4 billion over three years into such key areas as research, information and technology, First Nations and Inuit health systems and programs, and enhancements to health promotion and health protection programs. This investment in the health of Canadians and their health care system represents the largest single new investment ever made by the Government.

It is anticipated that the Canadian health care system will continue its development through an evolutionary process as it is renewed to reflect the new vision of a health system. While health care, with its focus on hospital and medical care, continues to play a prominent and vital role, it is increasingly being recognized as one element of a larger health care system encompassing a broader range of services, providers and delivery sites. Support for, and adherence to, the national principles of the *Canada Health Act* across the country will ensure that the essential elements and character of the Canadian health care system remain as the foundation upon which the health system will evolve.

NOTES

1 "Tax transfer" refers to the transfer of a given number of income and corporate tax points from the federal government to the provinces; in other words, the federal government agrees to lower its personal and corporate income tax so that the provinces can step in and raise their own taxes by the same percentage points as the corresponding federal tax reduction.

2 The United Nations Human Development Index ranks countries according to their citizens' education, access to health care and average income. Canada has topped the index six consecutive years in a row (1994-1999). United Nations Development Programme (selected years), *Human Development Report*, New York: Oxford University Press.

3 Conference Board of Canada; *Performance and Potential 1998:* Ottawa.

4 KPMG (1999); *The Competitive Alternative: A comparison of business costs in North America, Europe and Japan*: KPMG Canada and Prospectus Inc.

5 National Forum on Health (1997); *Canada Health Action: Building on the Legacy*, Final report of the National Forum on Health, Ottawa.

Health System and Policy Division
Health Policy and Information Directorate
Policy and Consultation Branch
Health Canada
Brooke Claxton Building
PL 0910A
Ottawa, Ontario
K1A 0K9

http://www.hc-sc.gc.ca/
July 1999

Major Metropolitan Areas with Teaching Hospitals and Clinical Research Facilities - ★



CALGARY REGIONAL HEALTH AUTHORITY & UNIVERSITY OF CALGARY (FACULTY OF MEDICINE)

Date established: 1994 Number of clinical investigators:

Contact: Dr. Lloyd Sutherland, Director, Centre for Advancement of Health

Address: 602, South Tower, FMC
Calgary, AB T2N 2T9

Tel: (403) 670-1093

Fax: (403) 670-1090

E-mail: lsutherl@ucalgary.ca

Web site: www.ucalgary.ca/md/CAH/research

The Centre for Advancement of Health is the administrative research office in the Calgary Regional health Authority (CRHA) with the responsibility of facilitating and overseeing institutional/scientific approval of all adult-based clinical research in the Region. The CHRA is comprised of all acute care sites, long-term care facilities and community health centres in the city of Calgary and surrounding area. The health organization currently provides acute and non-acute health services to a growing population of approximately 1 million. The conduct of clinical trials research in the CRHA is closely linked with the University of Calgary through an affiliation agreement.

There are four acute care sites in the CRHA: Foothills Medical Centre, Peter Lougheed Centre, Rockyview General Hospital, and Alberta Children's Hospital. There are also numerous health centres as well as long-term care facilities, both contracted and CRHA managed.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis			x	x	x
Bacteriology/Parasitology			x	x	x
Blood			x	x	x
Cancer			x	x	x
Cardiovascular			x	x	x
Central Nervous System			x	x	x
Endocrinology			x	x	x
Gastrointestinal/Liver			x	x	x
Genetics			x	x	x
Immunology/Transplantation			x	x	x
Metabolism/Diabetes			x	x	x
Mental/Behavioural Diseases			x	x	x
Muscle/Bone/Joint			x	x	x
Reproduction/Pregnancy			x	x	x
Respiration			x	x	x
Women's Health			x	x	x
Vaccines			x	x	x
Dental					
Surgical			x	x	x
Geriatric			x	x	x
Paediatric			x	x	x
Devices			x	x	x
Diagnostics			x	x	x
Other Areas					

PRECLINICAL SERVICES: Medicinal & Organic Chemistry, Biological & Pharmacological Research, Animal Testing, Laboratory Services, Quality Assurance

ETHICAL REVIEW: Phase II/III

PHASE I SERVICES:

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Statistical Services, Data Management and Analysis, Drug Dosage & Control, Quality Assurance & Control

REGULATORY SERVICES:

POST MARKETING SERVICES: Pharmacoeconomic Studies, Quality of Life Studies

GEOGRAPHY: HPB, FDA

FACILITIES & CAPABILITIES

CANADIAN BACTERIAL DISEASES NETWORK

Date established: 1990 Number of clinical investigators:

Contact: Dr. Donald E. Woods, Scientific Director
Address: Room 282, heritage Medical Research Building
3330 Hospital Drive NW
Calgary, AB T2N 4N1
Tel: (403) 220-2562
Fax: (403) 283-5241
E-mail: woods@ucalgary.ca
Web site: www.cbdn.ca

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology		x			
Blood					
Cancer					
Cardiovascular					
Central Nervous System					
Endocrinology					
Gastrointestinal/Liver					
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes					
Mental/Behavioural Diseases					
Muscle/Bone/Joint					
Reproduction/Pregnancy					
Respiration					
Women's Health					
Vaccines					
Dental					
Surgical					
Geriatric					
Paediatric					
Devices					
Diagnostics					
Other Areas					

PRECLINICAL SERVICES: Medicinal & Organic Chemistry, Biological & Pharmacological Research, Animal Testing, Laboratory Services, Quality Assurance

ETHICAL REVIEW:

PHASE I SERVICES:

PHASE II / III STUDIES:

REGULATORY SERVICES:

POST MARKETING SERVICES:

GEOGRAPHY:

CANADIAN HIV TRIALS NETWORK (CTN)

Date established: 1991 Number of clinical investigators:

Contact: Dr. Donald Zarowny, Programme Head, Scientific and Industrial Liaison

Address: 620-1081 Burrard St.,
Vancouver, BC V6Z 1Y6

Tel: (604) 631-5378

Fax: (604) 631-5005

E-mail: ctn@hivnet.ubc.ca

Web site: www.hivnet.ubc.ca/ctn.html

The CTN is a non-profit organization responsible for conducting clinical trials of HIV therapies and vaccines across Canada. It was established in response to the common desire of clinical investigators, pharmaceutical companies, community physicians, regulatory agencies, laboratories and persons living with HIV to have more efficient and effective trials. Funded by Health Canada and sponsored jointly by St. Paul's Hospital and The University of British Columbia, the CTN provides experienced, highly qualified staff across a national and regional infrastructure, including six regional offices and more than 30 hospital and clinic satellites.

A National Steering Committee sets policies and priorities for the CTN. The CTN also receives guidance from the four standing committees: Scientific Review, Safety and Efficacy Review, National Ethics Review and Community Advisory. The members of each committee come from all regions of Canada and represent a wide range of expertise and affiliations.

The National Centre in Vancouver coordinates the Network's day-to-day activities through its five programs: Scientific & Industrial Liaison, Data & Methodology, Communications & Information, Administration & Finance, and Pharmacoeconomics. Regional offices in Halifax, Montréal, Ottawa, Toronto, Calgary and Vancouver provide support to the CTN's 30 adult satellite sites and six pediatric sites.

All types of clinical trials are conducted through the Network, including:

- pilot studies;
- early stage (Phase I/II) trials to assess dose tolerance, toxicity and pharmacokinetics;
- full-scale, (phase II & III) multi-centre randomized trials concerned with efficacy as well as dosage effects and safety;
- large, simple (phase IV) trials.

The CTN conducts these trials in collaboration with investigators and pharmaceutical companies. Most of Canada's HIV investigators are affiliated with the CTN.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology					
Blood					
Cancer	x	x	x	x	x
Cardiovascular					
Central Nervous System					
Endocrinology					
Gastrointestinal/Liver					
Genetics					
Immunology/Transplantation	x	x	x	x	x
Metabolism/Diabetes					
Mental/Behavioural Diseases					
Muscle/Bone/Joint					
Reproduction/Pregnancy					
Respiration					
Women's Health					
Vaccines	x	x	x	x	x
Dental					
Surgical					
Geriatric					
Paediatric					
Devices					
Diagnostics					
Other Areas	AIDS/HIV and anti-infectious (all phases)				

PRECLINICAL SERVICES: Medicinal & Organic Chemistry, Biological & Pharmacological Research, Animal Testing, Laboratory Services, Quality Assurance

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Statistical Services, Data Management and Analysis, Drug Dosage & Control, Quality Assurance & Control

REGULATORY SERVICES: Regulatory Affairs, Document, Manuscript & CANDA Preparation, IND Submission, NDA Submission, Regulatory Consulting

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies, Rx-OTC Studies, Consumer Testing Services

GEOGRAPHY: HPB, FDA, EMEA

CAPITAL HEALTH AUTHORITY (CHA) - UNIVERSITY OF ALBERTA CLINICAL TRIALS CENTRE

Date established: June 1999 Number of clinical investigators: 75

Contact: Dr. Paul Man, Professor of Medicine

Address: 2J2.00 Walter C Mackenzie Health Sciences Centre
University of Alberta
Edmonton, AB T6G 2R7

Tel: (780) 407-6266

Fax: (780) 407-6384

E-mail: paul.man@ualberta.ca

Web site: www.med.ualberta.ca/clinical

This is the reorganized combined operation for all clinical trials within all hospitals in Capital Health Authority jurisdiction (Edmonton).

Capital Health is one of 17 regional health authorities in Alberta, serving a population of 775,000 people in Edmonton, St. Albert, Leduc and Area, and Strathcona County. It provides a complete range of health services including:

- acute care services at two tertiary care hospitals, three community hospitals and a rehabilitation hospital;
- community-based health services including home care and community rehabilitation;
- health promotion and disease prevention services through public health programs and community health centres.

It coordinates continuing care services with public and private partners. It employs approximately 15,000 people - the largest employer in the region (includes contract and funded affiliates such as The Capital Care Group and Caritas Health Group). Though situated in the Capital Region, 35 per cent of all patients admitted to its hospitals live outside the region, mainly in north and central Alberta.

It has an annual budget of approximately $900 million, 90 per cent of which is provided by Alberta Health. It derives its authority from provincial legislation (Regional Health Authorities Act of Alberta).

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis	x	x	x	x	x
Bacteriology/Parasitology	x	x	x	x	x
Blood	x	x	x	x	x
Cancer	x	x	x	x	x
Cardiovascular	x	x	x	x	x
Central Nervous System	x	x	x	x	x
Endocrinology	x	x	x	x	x
Gastrointestinal/Liver	x	x	x	x	x
Genetics	x	x	x	x	x
Immunology/Transplantation	x	x	x	x	x
Metabolism/Diabetes	x	x	x	x	x
Mental/Behavioural Diseases	x	x	x	x	x
Muscle/Bone/Joint	x	x	x	x	x
Reproduction/Pregnancy	x	x	x	x	x
Respiration	x	x	x	x	x
Women's Health	x	x	x	x	x
Vaccines	x	x	x	x	x
Dental	x	x	x	x	x
Surgical	x	x	x	x	x
Geriatric	x	x	x	x	x
Paediatric	x	x	x	x	x
Devices	x	x	x	x	x
Diagnostics	x	x	x	x	x
Other Areas					

PRECLINICAL SERVICES: Medicinal & Organic Chemistry, Biological & Pharmacological Research, Animal Testing, Laboratory Services, Quality Assurance

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Statistical Services, Data Management and Analysis, Drug Dosage & Control, Quality Assurance & Control

REGULATORY SERVICES: Document, Manuscript & CANDA Preparation, IND Submission

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies, Rx-OTC Studies, Consumer Testing Services

GEOGRAPHY: HPB

CARDIOVASCULAR RESEARCH LAB., UBC

Date established: Number of clinical investigators:

Contact: Dr. Simon W. Rabkin, President
Address: D404 2733 Heather St.
Vancouver, BC V5Z 3J5
Tel: (604) 875-5847
Fax: (604) 875-5849
E-mail:
Web site:

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology					
Blood					
Cancer					
Cardiovascular	x		x	x	x
Central Nervous System					
Endocrinology					
Gastrointestinal/Liver					
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes					
Mental/Behavioural Diseases					
Muscle/Bone/Joint					
Reproduction/Pregnancy					
Respiration					
Women's Health					
Vaccines					
Dental					
Surgical					
Geriatric					
Paediatric					
Devices					
Diagnostics					
Other Areas					

PRECLINICAL SERVICES: Biological & Pharmacological Research, Animal Testing

ETHICAL REVIEW:

PHASE I SERVICES:

PHASE II / III STUDIES: Protocol & CRF Development, Clinical Trial Design, Patient Recruitment

REGULATORY SERVICES:

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies

GEOGRAPHY: HPB

CENTRE DE RECHERCHE DE L'HÔPITAL SAINTE-JUSTINE

Date established: August 1999 Number of clinical investigators: 126

Contact: Dr. Emile Levy, Director
Address: 3175, chemin Côte Ste-Catherine
Montreal, QC H3T 1C5
Tel: (514) 345-4740
Fax: (514) 345-4698
E-mail: centre@justine.umontreal.ca
Web site: www.iugm.qc.ca

Ste-Justine Hospital Research Center is part of Ste Justine Hospital, a 500-bed tertiary care teaching institution of the Université of Montréal devoted to pediatric and fetal-maternal medicine.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis	x	x	x	x	
Bacteriology/Parasitology	x	x	x	x	
Blood	x	x	x	x	
Cancer	x	x	x	x	
Cardiovascular	x	x	x	x	
Central Nervous System	x				
Endocrinology	x	x	x	x	
Gastrointestinal/Liver	x	x	x	x	
Genetics	x	x	x	x	
Immunology/Transplantation	x	x	x	x	
Metabolism/Diabetes	x				
Mental/Behavioural Diseases	x				
Muscle/Bone/Joint	x	x	x	x	
Reproduction/Pregnancy					
Respiration	x	x			
Women's Health	x				
Vaccines	x	x	x	x	
Dental					
Surgical	x	x	x	x	
Geriatric					
Paediatric	x	x	x	x	
Devices					
Diagnostics	x	x	x	x	
Other Areas					

PRECLINICAL SERVICES: Medicinal & Organic Chemistry, Biological & Pharmacological Research, Animal Testing, Laboratory Services, Quality Assurance

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Clinical Trial Design, Clinical Trials Monitoring, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Statistical Services, Data Management and Analysis, Drug Dosage & Control, Quality Assurance & Control

REGULATORY SERVICES: IND Submission

POST MARKETING SERVICES:

GEOGRAPHY: HPB, FDA

CENTRE DE RECHERCHE PHILIPPE PINEL DE MONTRÉAL

Date established: Number of clinical investigators: 1

Contact:	Dr. Gilles Côté, Director
Address:	10905 boul. Henri-Bourassa est
	Montreal, QC H1C 1H1
Tel:	(514) 881-3469
Fax:	(514) 881-3701
E-mail:	gilles_cote@uqtr.uquebec.ca
Web site:	brise.ere.umontreal.ca/~beaudetn

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology					
Blood					
Cancer					
Cardiovascular					
Central Nervous System				x	x
Endocrinology					
Gastrointestinal/Liver					
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes					
Mental/Behavioural Diseases				x	x
Muscle/Bone/Joint					
Reproduction/Pregnancy					
Respiration					
Women's Health					
Vaccines					
Dental					
Surgical					
Geriatric					
Paediatric					
Devices					
Diagnostics				x	x
Other Areas					

PRECLINICAL SERVICES:

ETHICAL REVIEW: Phase II/III

PHASE I SERVICES:

PHASE II / III STUDIES: Project Management, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Statistical Services, Data Management and Analysis

REGULATORY SERVICES:

POST MARKETING SERVICES:

GEOGRAPHY:

CENTRE FOR RESEARCH IN NEURODEGENERATIVE DISEASES (CRND)

Date established: 1990 Number of clinical investigators: 3

Contact: Dr. P. St. George Hyslop, Director

Address: Tanz Neuroscience Building
University of Toronto
6 Queens Park Crescent West
Toronto, ON M5S 3H2

Tel: (416) 978-7460

Fax: (416) 978-1878

E-mail: p.hyslop@utoronto.ca

Web site:

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology					
Blood					
Cancer					
Cardiovascular					
Central Nervous System	x	x	x	x	
Endocrinology					
Gastrointestinal/Liver					
Genetics	x		x	x	x
Immunology/Transplantation					
Metabolism/Diabetes					
Mental/Behavioural Diseases	x		x	x	x
Muscle/Bone/Joint	x				
Reproduction/Pregnancy					
Respiration					
Women's Health					
Vaccines					
Dental					
Surgical					
Geriatric	x	x	x	x	x
Paediatric					
Devices					
Diagnostics	x	x	x	x	x
Other Areas					

PRECLINICAL SERVICES: Biological & Pharmacological Research, Pharmacogenetics

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacogenetics

PHASE II / III STUDIES: Project Management, Clinical Trial Design, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Pharmacogenetics

REGULATORY SERVICES:

POST MARKETING SERVICES:

GEOGRAPHY:

CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL (CHUM)

Date established: 1997 Number of clinical investigators: 110

Contact: Mr. Pierre Larochelle, Assistant Director, Research Center
Address: Hôtel-Dieu de Montréal
3850, rue St-Urbain
Montreal, QC H2W 1T8
Tel: (514) 843-2752
Fax: (514) 843-2741
E-mail: pierre.larochelle@umontreal.ca
Web site: www.med.umontreal.ca/chum.htm

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis	x	x	x	x	x
Bacteriology/Parasitology	x	x	x	x	x
Blood		x	x	x	x
Cancer	x	x	x	x	x
Cardiovascular	x	x	x	x	x
Central Nervous System		x	x	x	x
Endocrinology	x	x	x	x	x
Gastrointestinal/Liver	x	x	x	x	x
Genetics	x	x	x	x	
Immunology/Transplantation	x	x	x	x	x
Metabolism/Diabetes	x	x	x	x	x
Mental/Behavioural Diseases		x	x	x	x
Muscle/Bone/Joint	x	x	x	x	x
Reproduction/Pregnancy	x	x	x	x	x
Respiration	x	x	x	x	x
Women's Health		x	x	x	x
Vaccines	x	x	x	x	x
Dental					
Surgical					
Geriatric			x	x	x
Paediatric					
Devices		x	x	x	x
Diagnostics	x	x	x	x	x
Other Areas	Technology assessment (I-IV), Pain (I-IV)				

PRECLINICAL SERVICES: Biological & Pharmacological Research, Animal Testing, Laboratory Services

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Statistical Services, Data Management and Analysis

REGULATORY SERVICES: IND Submission, NDA Submission (review), Regulatory Consulting

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies, Rx-OTC Studies

GEOGRAPHY:

CENTRE DE RECHERCHE DU CHUL
(CENTRE HOSPITALIER DE L'UNIVERSITÉ LAVAL)

Date established: 1970 Number of clinical investigators: 40

Contact: Dr. Fernand Labrie, Director of Research
Address: 2705 boulevard Laurier
Ste-Foy, QC G1V 4G2
Tel: (418) 654-2704
Fax: (418) 654-2735
E-mail: fernand.labrie@crchul.ulaval.ca
Web site: www.crchul.ulaval.ca

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis	x	x	x	x	x
Bacteriology/Parasitology	x	x	x	x	x
Blood					
Cancer	x	x	x	x	x
Cardiovascular		x	x		
Central Nervous System	x	x	x	x	x
Endocrinology	x	x	x	x	x
Gastrointestinal/Liver		x	x		
Genetics	x	x	x	x	x
Immunology/Transplantation	x	x	x	x	x
Metabolism/Diabetes	x	x	x	x	x
Mental/Behavioural Diseases	x	x	x		
Muscle/Bone/Joint	x	x	x	x	x
Reproduction/Pregnancy	x	x	x	x	x
Respiration					
Women's Health	x	x	x	x	x
Vaccines	x	x	x		
Dental					
Surgical		x	x		
Geriatric		x	x		
Paediatric	x	x	x		
Devices					
Diagnostics	x	x	x		
Other Areas					

PRECLINICAL SERVICES: Medicinal & Organic Chemistry, Biological & Pharmacological Research, Animal Testing, Laboratory Services (Preclinical), Quality Assurance

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services (Phase II/III), Biometric & Haematological Services, Statistical Services, Data Management and Analysis, Drug Dosage & Control, Quality Assurance & Control

REGULATORY SERVICES: Regulatory Affairs, Document, Manuscript & CANDA Preparation, IND Submission, NDA Submission

POST MARKETING SERVICES: Pharmacoeconomic Studies

GEOGRAPHY: HPB, FDA, EMEA

CHILD HEALTH RESEARCH UNIT (CHRU), ALBERTA CHILDREN'S HOSPITAL

Date established: January 1994

Number of clinical investigators: H. Dele Davies for group (multiple)

Contact: Dr. Dele Davies, Director of Child Health Research Unit

Address: 1820 Richmond Road SW
Calgary, AB T2T 5C7

Tel: (403) 229-7815

Fax: (403) 541-7508

E-mail: deld.davies@crha-health.ab.ca

Web site: www.crha-health.ab.ca/sites/ach.htm

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology		x	x	x	x
Blood					
Cancer					
Cardiovascular					
Central Nervous System					
Endocrinology					
Gastrointestinal/Liver					
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes					
Mental/Behavioural Diseases					
Muscle/Bone/Joint					
Reproduction/Pregnancy					
Respiration					
Women's Health					
Vaccines			x	x	x
Dental					
Surgical					
Geriatric					
Paediatric		x	x	x	x
Devices					
Diagnostics					
Other Areas					

PRECLINICAL SERVICES: Medicinal & Organic Chemistry, Quality Assurance

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES:

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Data Management and Analysis, Drug Dosage & Control

REGULATORY SERVICES:

POST MARKETING SERVICES:

GEOGRAPHY:

CLINICAL EPIDEMIOLOGY UNIT, LOEB HEALTH RESEARCH INSTITUTE

Date established: 1991 Number of clinical investigators: ~25

Contact: Dr. Andreas Laupacis, Director
Address: Ottawa Hospital, Civic Site
1053 Carling Ave.,
Ottawa, ON K1Y 4E9
Tel: (613) 761-5231
Fax: (613) 761-5492
E-mail: alaupacis@lri.ca
Web site: www.lri.ca

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis			x	x	x
Bacteriology/Parasitology					
Blood				x	x
Cancer		x	x	x	x
Cardiovascular				x	x
Central Nervous System				x	x
Endocrinology					
Gastrointestinal/Liver					
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes			x	x	
Mental/Behavioural Diseases					
Muscle/Bone/Joint					
Reproduction/Pregnancy					
Respiration				x	
Women's Health				x	x
Vaccines					
Dental					
Surgical					
Geriatric				x	
Paediatric					
Devices					
Diagnostics					
Other Areas					

PRECLINICAL SERVICES:

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES:

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Investigative Site Selection & Management, Patient Recruitment, Statistical Services, Data Management and Analysis

REGULATORY SERVICES: Document, Manuscript & CANDA Preparation

POST MARKETING SERVICES: Pharmacoeconomic Studies, Quality of Life Studies

GEOGRAPHY:

CLINICAL RESEARCH INSTITUTE OF MONTREAL (IRCM)

Date established: 1967 Number of clinical investigators: 13

Contact: Dr. Jean Davignon, Director of Clinical Research

Address: 110 Pine Avenue West
Montreal, QC H2W 1R7

Tel: (514) 987-5626

Fax: (514) 987-5700

E-mail: davignj@ircm.qc.ca

Web site: www.ircm.qc.ca

The Clinical Research Institute of Montreal (IRCM, *Institut de recherches cliniques de Montréal*) is a research and educational institution dedicated to the study of human diseases (diagnosis, pathophysiology, prevention and treatment). Founded by Dr. Jacques Genest, inaugurated April 17, 1967, it is funded by the Government of the Province of Québec via the Governement of Quebec as well as the FRSQ (*Fonds de la Recherche en Santé du Québec*) and by grants to laboratory directors (>30) and their associates, in about equal proportion. Dr. Yvan Guindon currently directs the IRCM (CEO and Scientific Director). It is academically affiliated with the University of Montreal and entertains close ties with McGill University. All laboratory directors have an academic appointment and some have professorial responsibilities in both Universities. Their position at the IRCM is not tenured and is conditional to being funded by agencies with peer review. With over 450 people working at the IRCM, including 160 students (MSc, PhD and post-doctoral fellows), it is oriented towards both fundamental and clinical research with a strong teaching program. The main themes of research include: atherosclerosis & dyslipidemia, bioethics, cancer, development, cardiovascular genetics, biomedical engineering, hematopoiesis, hypertension, immunology, medicinal chemistry, memory, metabolism, molecular genetics, pain, neuroendocrinology, neurosciences, protein chemistry, and virology. The IRCM has a formal collaboration agreement with the Pasteur Institute of Paris.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology					
Blood	x				
Cancer	x				
Cardiovascular	x	x	x	x	x
Central Nervous System	x	x	x		
Endocrinology					
Gastrointestinal/Liver					
Genetics	x				
Immunology/Transplantation	x	x	x		
Metabolism/Diabetes	x	x	x	x	x
Mental/Behavioural Diseases					
Muscle/Bone/Joint					
Reproduction/Pregnancy					
Respiration					
Women's Health					
Vaccines	x				
Dental					
Surgical					
Geriatric					
Paediatric					
Devices	x				
Diagnostics	x				
Other Areas	Virology (AIDS) (Preclinical-Phase III)				

PRECLINICAL SERVICES: Biological & Pharmacological Research, Animal Testing, Laboratory Services

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics, Bioavailability

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Patient Recruitment, Laboratory Services, Data Management and Analysis

REGULATORY SERVICES:

POST MARKETING SERVICES:

GEOGRAPHY: HPB, FDA

CROSS CANCER INSTITUTE

Date established: 1968 Number of clinical investigators: 35

Contact: Dr. A. L. A. Fields, Director
Address: 11560 University Ave.
Edmonton, AB T6G 1Z2
Tel: (780) 432-8763
Fax: (780) 432-8886
E-mail: alaf@cancerboard.ab.ca
Web site:

The Cross Cancer Institute is operated by the Alberta Cancer Board, which is the provincial cancer agency established by the Government of Alberta to serve the population of the province. The Alberta Cancer Board operated the Cross Cancer Institute in Edmonton, the Tom Baker Cancer Centre in Alberta, plus four Associate Cancer Centres and eight Community Cancer Clinics. In addition, the Alberta Cancer Board has a Division of Epidemiology, Prevention and Screening, with a province-wide mandate, and a Division of Research.

The Cross Cancer Institute is the comprehensive cancer centre serving Edmonton and North Alberta. It has facilities for inpatient and outpatient care, for diagnostic and treatment services, for laboratory and clinical research. It is formally affiliated with the University of Alberta, serving that facility as a teaching hospital. It houses residency training programs in Medical Oncology and Radiation Oncology.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology					
Blood					
Cancer	x	x	x	x	x
Cardiovascular					
Central Nervous System					x
Endocrinology					
Gastrointestinal/Liver					
Genetics	x	x	x	x	x
Immunology/Transplantation					
Metabolism/Diabetes					
Mental/Behavioural Diseases					
Muscle/Bone/Joint					
Reproduction/Pregnancy					
Respiration					
Women's Health					
Vaccines	x	x	x	x	x
Dental					
Surgical					
Geriatric					
Paediatric	x	x	x	x	x
Devices	x	x	x	x	x
Diagnostics		x	x	x	x
Other Areas					

PRECLINICAL SERVICES: Biological & Pharmacological Research, Laboratory Services, Quality Assurance

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Statistical Services, Data Management and Analysis, Quality Assurance & Control

REGULATORY SERVICES: Document, Manuscript & CANDA Preparation, IND Submission

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies

GEOGRAPHY: HPB, FDA

DOUGLAS HOSPITAL RESEARCH CENTRE

Date established: 1979 Number of clinical investigators: 30

Contact: Dr. Rémi Quirion, Scientific Director
Address: 6875 LaSalle boulevard
Verdun, QC H4H 1R3
Tel: (514) 762-3048, x 22934
Fax: (514) 762-3034
E-mail: mcou@musica.mcgill.ca
Web site: **www.mcgill.ca/douglas**

The Douglas Hospital Research Centre has been recognized as a "model centre" by the Fonds de la recherche en santé du Québec. We are the largest centre of the kind in Quebec, and one of the most dynamic partners in Quebec's mental health care network.

- **Over 60 scientists and clinician-researchers**
- **Over 70 trainees (Master's, PhD and post-doctoral)**
- **$6 million annual budget**
- **$3.5 million in peer-reviewed grants**
- **$1.3 million in other grants and industry contracts**
- **102 research projects and contracts**
- **274 publications: articles, chapters and books, abstracts**

There are three divisions at the Centre: Clinical Research, Neuroscience Research, and Psychosocial Research.

The Centre is affiliated with McGill University, the Fonds de la recherche en santé du Québec and the World Health Organization (WHO).

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology					
Blood					
Cancer					
Cardiovascular					
Central Nervous System	x	x	x	x	
Endocrinology					
Gastrointestinal/Liver					
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes					
Mental/Behavioural Diseases	x	x	x	x	x
Muscle/Bone/Joint					
Reproduction/Pregnancy					
Respiration					
Women's Health					
Vaccines					
Dental					
Surgical					
Geriatric					
Paediatric					
Devices					
Diagnostics					
Other Areas					

PRECLINICAL SERVICES: Biological & Pharmacological Research, Animal Testing

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Bioavailability

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Statistical Services, Data Management and Analysis, Quality Assurance & Control

REGULATORY SERVICES: Document, Manuscript & CANDA Preparation

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies, Rx-OTC Studies

GEOGRAPHY: HPB, FDA

HAMILTON HEALTH SCIENCES CORPORATION

Date established: November 1996 Number of clinical investigators: 156

Contact: Dr. Suzette Salama, Research Coordinator
Address: Henderson Site, Research Office
711 Concession St.
Hamilton, ON L8V 1C3
Tel: (905) 389-4411
Fax: (905) 389-4938
E-mail: salamsuz@hamcivhos.on.ca
Web site:

Hamilton Health Sciences Corporation (HHSC) is a multi-site academic health science centre formed in November 1996 as a result of the merger of Chedoke-McMaster and Hamilton Civic Hospitals. It is Ontario's largest provider of comprehensive health care and, through its partnership with McMaster University's Faculty of Health Sciences, is one of Canada's largest teaching hospitals.

HHSC is comprised of four campuses in the City of Hamilton - Chedoke Campus in the southwest, General Campus in the north, Henderson in the east-central Mountain and McMaster in the west.

Employees	7,900
Volunteers	1,775
Beds	
Setup and operating	1,400
Bassinets	107
Admissions and Visits	
Total admissions	41,741
Outpatient Visits	402,642
ER/Urgent care Visits	116,086
Operating Room Procedures	
Inpatient	15,630
Outpatient	26,297
Obstetrical Deliveries	3,499
1996/97 Operating Budget	$490,000,000

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis	x	x	x	x	x
Bacteriology/Parasitology	x	x	x	x	x
Blood	x	x	x	x	x
Cancer	x	x	x	x	x
Cardiovascular	x	x	x	x	x
Central Nervous System	x		x	x	x
Endocrinology	x	x	x	x	x
Gastrointestinal/Liver	x	x	x	x	x
Genetics	x	x	x	x	x
Immunology/Transplantation	x	x	x	x	x
Metabolism/Diabetes	x	x	x	x	x
Mental/Behavioural Diseases	x	x	x	x	x
Muscle/Bone/Joint	x	x	x	x	x
Reproduction/Pregnancy					
Respiration	x	x	x	x	x
Women's Health	x	x	x	x	x
Vaccines	x	x	x	x	x
Dental					
Surgical	x	x	x	x	x
Geriatric	x	x	x	x	x
Paediatric	x	x	x	x	x
Devices	x	x	x	x	x
Diagnostics	x	x	x	x	x
Other Areas					

PRECLINICAL SERVICES: Medicinal & Organic Chemistry, Biological & Pharmacological Research, Animal Testing, Laboratory Services, Quality Assurance

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Statistical Services, Data Management and Analysis, Drug Dosage & Control, Quality Assurance & Control

REGULATORY SERVICES:

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies, Rx-OTC Studies, Consumer Testing Services

GEOGRAPHY:

HAMILTON REGIONAL CANCER CENTRE

Date established: Number of clinical investigators:

Contact: Dr. Jim Wright, Head of Clinical Trials
Address: 699 Concession St.
Hamilton, ON L8V 5C2
Tel: (905) 387-9495
Fax: (905) 575-6326
E-mail: jim.wright@hrcc.on.ca
Web site: www.hrcc.on.ca

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology					
Blood					
Cancer	x	x	x	x	x
Cardiovascular					
Central Nervous System					x
Endocrinology					
Gastrointestinal/Liver					
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes					
Mental/Behavioural Diseases					
Muscle/Bone/Joint					
Reproduction/Pregnancy					
Respiration					
Women's Health					
Vaccines					
Dental					
Surgical					
Geriatric					
Paediatric					
Devices					
Diagnostics					
Other Areas					

PRECLINICAL SERVICES: Medicinal & Organic Chemistry, Biological & Pharmacological Research, Animal Testing, Laboratory Services

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Protocol & CRF Development, Clinical Trial Design, Clinical Trials Monitoring, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Drug Dosage & Control, Quality Assurance & Control

REGULATORY SERVICES:

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies

GEOGRAPHY: HPB, FDA

HEALTH SCIENCES CENTRE

Date established: 1986 Number of clinical investigators:

Contact: Dr. Luis Oppenheimer, Director of Research

Address: MS7-820 Sherbrooke Street
Winnipeg, MB R3A 1R9

Tel: (204) 787-4587

Fax: (204) 787-4547

E-mail:

Web site: www.hsc.mb.ca

Five of Western Canada's most respected health care institutions comprise the Health Sciences Centre: The Winnipeg General Hospital, The Women's Pavilion, The Children's Hospital of Winnipeg, The Manitoba Rehabilitation Hospital and the D.A. Stewart Centre (Respiratory Hospital). The Centre is one of the largest healthcare facilities in Canada and the major referral center in Manitoba for complex health problems requiring expert consultation and sophisticated investigation and management.

The Centre is formally affiliated with The University of Manitoba and the Manitoba Cancer Treatment and Research Foundation; it is administratively linked with the Health Action Centre and it is a facility integral to the Winnipeg Hospital Authority. The Centre is also associated with the its sister teaching hospital, The St. Boniface General Hospital.

The major clinical programs of the Centre are organized under Adult Medicine (including Rehabilitation and Respiratory services), Adult Surgery, Child Health, Mental Health and Women's Health designations. Comprehensive diagnostic, ambulatory and in-patient services are provided. The Centre has been designated as Manitoba's Trauma Centre and is the center for transplants and most hospital-based pediatric care.

The Centre has a special role to develop and provide Provincial Programs, to provide patient care to the core area of Winnipeg and to provide patient care to the Aboriginal peoples of Manitoba, Northwestern Ontario and the Keewatin District of the Northwest Territories. Provincial Programs are usually highly specialized services, often unique to the Centre, although some are provided in partnership with other community agencies or health facilities both within and outside Manitoba.

Detailed information about the Centre's researchers and their expertise has been assembled in the Health*Trials* Manitoba Researcher database. Various departments also able to provide specialized expertise are also described in the database.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis			x	x	
Bacteriology/Parasitology					
Blood					
Cancer		x	x	x	
Cardiovascular			x	x	
Central Nervous System			x		
Endocrinology				x	
Gastrointestinal/Liver			x	x	
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes				x	
Mental/Behavioural Diseases				x	
Muscle/Bone/Joint			x		
Reproduction/Pregnancy					
Respiration		x			
Women's Health					x
Vaccines		x			
Dental					
Surgical					
Geriatric					
Paediatric					
Devices					
Diagnostics					
Other Areas	Infectious Diseases Ph I-IV, Genitourinary Ph II, III				

PRECLINICAL SERVICES: Medicinal & Organic Chemistry, Biological & Pharmacological Research, Laboratory Services, Quality Assurance

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Statistical Services, Data Management and Analysis, Drug Dosage & Control, Quality Assurance & Control

REGULATORY SERVICES:

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies

GEOGRAPHY: HPB

HÔPITAL LAVAL

Date established: 1925 Number of clinical investigators: 30

Contact: Dr. Yvon Cormier, Director of Research
Address: 2725 chemin Ste-Foy
Ste-Foy, PQ G1Y 1L4
Tel: (418) 656-4747
Fax: (418) 656-4762
E-mail: yvon.cormier@med.ulaval.ca
Web site:

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology	x	x	x	x	x
Blood					
Cancer	x	x	x	x	x
Cardiovascular	x	x	x	x	x
Central Nervous System					x
Endocrinology					
Gastrointestinal/Liver					
Genetics					
Immunology/Transplantation	x	x	x	x	x
Metabolism/Diabetes					
Mental/Behavioural Diseases					
Muscle/Bone/Joint					
Reproduction/Pregnancy					
Respiration	x	x	x	x	x
Women's Health					
Vaccines					
Dental					
Surgical	x	x	x	x	x
Geriatric					
Paediatric					
Devices	x	x	x	x	x
Diagnostics	x	x	x	x	x
Other Areas					

PRECLINICAL SERVICES: Medicinal & Organic Chemistry, Biological & Pharmacological Research, Animal Testing, Laboratory Services, Quality Assurance

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Data Management and Analysis, Drug Dosage & Control, Quality Assurance & Control

REGULATORY SERVICES:

POST MARKETING SERVICES: Outcome Measurement Services, Quality of Life Studies, Consumer Testing Services

GEOGRAPHY: HPB, FDA

HOSPITAL FOR SICK CHILDREN

Date established: 1879 Number of clinical investigators: 250-300

Contact: Dr. Manuel Buchwald, Director, Research Institute

Address: 555 University Avenue
Toronto, ON M5G 1X8

Tel: (416) 813-6977

Fax: (416) 813-5085

E-mail: manuel.buchwald@sickkids.on.ca

Web site: www.sickkids.on.ca

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis	x	x	x	x	x
Bacteriology/Parasitology	x	x	x	x	x
Blood	x	x	x	x	x
Cancer	x	x	x	x	x
Cardiovascular	x	x	x	x	x
Central Nervous System	x	x	x	x	x
Endocrinology	x	x	x	x	x
Gastrointestinal/Liver	x	x	x	x	x
Genetics	x	x	x	x	x
Immunology/Transplantation	x	x	x	x	x
Metabolism/Diabetes	x	x	x	x	x
Mental/Behavioural Diseases	x	x	x	x	x
Muscle/Bone/Joint	x	x	x	x	x
Reproduction/Pregnancy	x	x	x	x	x
Respiration	x	x	x	x	x
Women's Health	x	x	x	x	x
Vaccines	x	x	x	x	x
Dental	x	x	x	x	x
Surgical	x	x	x	x	x
Geriatric					
Paediatric	x	x	x	x	x
Devices	x	x	x	x	x
Diagnostics	x	x	x	x	x
Other Areas					

PRECLINICAL SERVICES: Medicinal & Organic Chemistry, Biological & Pharmacological Research, Animal Testing, Laboratory Services (Preclinical), Quality Assurance

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services (Phase II/III), Biometric & Haematological Services, Statistical Services, Data Management and Analysis, Drug Dosage & Control, Quality Assurance & Control

REGULATORY SERVICES: IND Submission, NDA Submission

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies, Rx-OTC Studies, Consumer Testing Services

GEOGRAPHY: HPB, FDA

INSTITUT DE CARDIOLOGIE DE MONTRÉAL - MONTREAL HEART INSTITUTE

Date established: 1976 Number of clinical investigators: 46

Contact: Dr. Jean-Claude Tardif, Associate Director - Clinical Research

Address: 5000 est, rue Bélanger
Montreal, QC H1T 1C8

Tel: (514) 376-3330

Fax: (514) 593-2521

E-mail: tardifjc@icm.umontreal.ca

Web site: www.icm-mhi.org

The Montreal Heart Institute (MHI) is a hospital specializing in cardiovascular diseases. Its mission is to develop tertiary care in advanced cardiovascular medicine, a mission which involves important clinical, educational, and research activities. The main research focuses of the Center are: coronary artery disease, preventive cardiology, cardiovascular electrophysiology and heart failure.

The Montreal Heart Institute is affiliated with the University of Montreal. The majority of the Center's researchers are faculty of this University; some of them also teach at McGill University and at the Université du Québec à Montréal. The Center directs a variety of multicenter trials and collaborates with other research centers in Canada and throughout the world. It has several joint programs and exchanges with American and European universities. A tradition of cooperation with the private sector is well-established.

A major expansion project has recently been completed. The Center tripled in size in the spring of 1995. This expansion provided the space necessary for optimizing existing activities and enabled the recruitment of several key researchers working in fields such as molecular biology, vascular biology, bioepidemiology and biostatistics. At the end of the second millennium, the Center is in an excellent position to participate actively in the development of biomedical research that will mark the beginning of the third millennium.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology					
Blood					
Cancer					
Cardiovascular	x	x	x	x	x
Central Nervous System					
Endocrinology					
Gastrointestinal/Liver					
Genetics	x	x	x	x	x
Immunology/Transplantation	x	x	x	x	x
Metabolism/Diabetes					
Mental/Behavioural Diseases					
Muscle/Bone/Joint					
Reproduction/Pregnancy					
Respiration					
Women's Health	x	x	x	x	x
Vaccines					
Dental					
Surgical	x	x	x	x	x
Geriatric					
Paediatric					
Devices	x	x	x	x	x
Diagnostics	x	x	x	x	x
Other Areas					

PRECLINICAL SERVICES: Biological & Pharmacological Research, Animal Testing, Laboratory Services, Quality Assurance

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Statistical Services, Data Management and Analysis, Drug Dosage & Control, Quality Assurance & Control

REGULATORY SERVICES:

POST MARKETING SERVICES: Pharmacoeconomic Studies, Quality of Life Studies

GEOGRAPHY:

INSTITUT UNIVERSITAIRE DE GÉRIATRIE DE MONTRÉAL

Date established: 1978

Number of clinical investigators:

Contact: Dr. Denis Turgeon,
Address: 4565, chemin Queen-Mary
Montreal, QC H1W 1W5
Tel: (514) 340-3517
Fax: (514) 340-3525
E-mail: dturgeon@sympatico.ca
Web site: iugm.qc.ca

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis	x	x	x	x	x
Bacteriology/Parasitology					
Blood					
Cancer					
Cardiovascular					
Central Nervous System					
Endocrinology					
Gastrointestinal/Liver					
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes					
Mental/Behavioural Diseases	x	x	x	x	x
Muscle/Bone/Joint	x	x	x	x	x
Reproduction/Pregnancy					
Respiration					
Women's Health	x	x	x	x	x
Vaccines					
Dental					
Surgical					
Geriatric	x	x	x	x	x
Paediatric					
Devices					
Diagnostics					
Other Areas					

PRECLINICAL SERVICES: Medicinal & Organic Chemistry, Biological & Pharmacological Research, Animal Testing, Laboratory Services, Quality Assurance

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Statistical Services, Data Management and Analysis

REGULATORY SERVICES:

POST MARKETING SERVICES:

GEOGRAPHY:

INSTITUTE OF MENTAL HEALTH RESEARCH, ROYAL OTTAWA HEALTH CARE GROUP

Date established: 1990 Number of clinical investigators: 21

Contact: Dr. Yvon Lapierre, Director General
Address: 1145 Carling Avenue
Ottawa, ON K1Z 7K4
Tel: (613) 722-6521
Fax: (613) 722-5871
E-mail: imhr@rohcg.on.ca
Web site: www.rohcg.on.ca/imhr.html

The Institute of Mental Health Research (IMHR) at the Royal Ottawa Hospital strives to -advance basic and clinical mental health research in Canada; to develop effective diagnosis and treatment strategies for mental illness; and to encourage collaboration and professional development among mental health researchers. Over 20 IMHR investigators are currently conducting leading-edge research in the areas of depressive and manic depressive disorders, anxiety, schizophrenia, dementias, and sexual deviancies. Specifically, etiological research (including genetics), the development of new medications, the ability to predict appropriate treatment forms, and the natural course of mental illnesses have been the focus of such research to date.

Affiliations:

- University of Ottawa
- Carleton University
- The Ottawa Hospital (Civic and General sites)
- Centre hospitalier Pierre-Janet (Hull)
- S. Neuroscience Research Institute
- McGill University
- Clarke Institute of Psychiatry

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology					
Blood					
Cancer					
Cardiovascular					
Central Nervous System					
Endocrinology					
Gastrointestinal/Liver					
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes					
Mental/Behavioural Diseases	x	x	x	x	x
Muscle/Bone/Joint					
Reproduction/Pregnancy					
Respiration					
Women's Health					
Vaccines					
Dental					
Surgical					
Geriatric					
Paediatric					
Devices					
Diagnostics					
Other Areas					

PRECLINICAL SERVICES: Animal Testing Quality Assurance

ETHICAL REVIEW: Phase II/III

PHASE I SERVICES: Pharmacokinetics, Pharmacodynamics

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Statistical Services, Data Management and Analysis, Quality Assurance & Control

REGULATORY SERVICES: Document, Manuscript & CANDA Preparation, IND Submission, Regulatory Consulting

POST MARKETING SERVICES: Pharmacoeconomic Studies, Quality of Life Studies

GEOGRAPHY: HPB, Other National

IZAAK W. KILLAN & GRACE HEALTH SCIENCE CENTRE

Date established: Number of clinical investigators: over 30

Contact: Ms. Diane Nicholson, Research Coordinator

Address: 5850 University Avenue
Halifax, NS B3J 3G9

Tel: (902) 428-8765

Fax: (902) 420-6767

E-mail: dnicholson@iwicgrace.ns.ca

Web site:

The IWK Grace Health Centre provides quality care to children, women and families. It is a tertiary care health centre dedicated to education, research, family-centered care and health promotion.

Each year, there are approximately 5,000 new babies delivered at the IWK Grace and Maritime children, women and newborns spend approximately 82,000 days as inpatients at the Health Centre and make some 200,000 visits to our outpatient clinics. The IWK Grace has 111 adult beds, 135 for babies and 155 beds for children. With more than 2,000 staff and 1,000 volunteers, the Health Centre benefits from the generosity of more than 60,000 donors. There are 190 active medical and dental staff who am experts in a wide range of specialties including pediatrics, surgery, psychiatry, dentistry, laboratory medicine, diagnostic imaging, anesthesia, obstetrics, gynecology and family medicine.

New to the IWK Grace is the Women's Health Program. This service includes gynecology inpatient and operative care, ambulatory clinics, and the Well Women Clinic.

The IWK Grace is also an active and respected centre for its world-class research into disorders and disease affecting children and women, and for the services we provide concerning child and adolescent mental health.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis	x	x	x	x	x
Bacteriology/Parasitology	x	x	x	x	x
Blood		x	x	x	x
Cancer		x	x	x	x
Cardiovascular	x	x	x	x	x
Central Nervous System	x	x	x	x	x
Endocrinology	x	x	x	x	x
Gastrointestinal/Liver		x	x	x	x
Genetics	x	x	x	x	x
Immunology/Transplantation	x	x	x	x	x
Metabolism/Diabetes	x	x	x	x	x
Mental/Behavioural Diseases	x	x	x	x	x
Muscle/Bone/Joint	x	x	x	x	x
Reproduction/Pregnancy	x	x	x	x	x
Respiration		x	x	x	x
Women's Health		x	x	x	x
Vaccines	x	x	x	x	x
Dental					
Surgical		x	x	x	x
Geriatric					
Paediatric	x	x	x	x	x
Devices	x	x	x	x	x
Diagnostics	x	x	x	x	x
Other Areas					

PRECLINICAL SERVICES: Medicinal & Organic Chemistry, Biological & Pharmacological Research, Animal Testing, Laboratory Services, Quality Assurance

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Statistical Services, Data Management and Analysis, Drug Dosage & Control, Quality Assurance & Control

REGULATORY SERVICES: Regulatory Affairs, Document, Manuscript & CANDA Preparation, IND Submission, Regulatory Consulting

POST MARKETING SERVICES: Quality of Life Studies, Rx-OTC Studies

GEOGRAPHY: HPB, FDA

KINGSTON GENERAL HOSPITAL

Date established: Number of clinical investigators: 250

Contact: Dr. T. Geoffrey Flynn, Vice-President, Research Development

Address: 76 Stuart Street, Walkins 2
Kingston, ON K7L 2V7

Tel: (613) 549-6666, x 3344

Fax: (613) 548-6042

E-mail: popem@kgh.kari.net

Web site: www.kgh.on.ca

Kingston General Hospital, a 446-bed teaching and referral hospital affiliated with Queen's University and other members of the Southeastern Ontario Health Sciences Centre, provides critical care, trauma care and inpatient overnight stays. KGH offers a full-service 24-hour Emergency Department and specialized programs and services to the people of Kingston and the surrounding region and to those requiring access to tertiary care programs.

Health Sciences Centre: KGH is a partner in the Southeastern Ontario Health Sciences Centre (SEOHSC). Other SEOHSC partners include: Queen's University, Hotel Dieu Hospital, Providence Continuing Care Centre (St. Mary's of the Lake Hospital site), Kingston Psychiatric Hospital, the Kingston, Frontenac, Lennox & Addington Community Care Access Centre and the Kingston, Frontenac, Lennox & Addington Health Unit.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis	x	x	x	x	x
Bacteriology/Parasitology		x	x	x	x
Blood	x	x	x	x	x
Cancer		x	x	x	x
Cardiovascular		x	x	x	x
Central Nervous System	x	x	x	x	x
Endocrinology				x	x
Gastrointestinal/Liver	x	x	x	x	x
Genetics	x	x	x	x	x
Immunology/Transplantation					
Metabolism/Diabetes			x	x	x
Mental/Behavioural Diseases					
Muscle/Bone/Joint	x	x	x	x	x
Reproduction/Pregnancy	x	x	x	x	x
Respiration		x	x	x	x
Women's Health					
Vaccines					
Dental					
Surgical					
Geriatric			x	x	x
Paediatric					
Devices					
Diagnostics					
Other Areas					

PRECLINICAL SERVICES: Medicinal & Organic Chemistry, Biological & Pharmacological Research

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Trials Monitoring, Patient Recruitment

REGULATORY SERVICES:

POST MARKETING SERVICES: Outcome Measurement Services, Quality of Life Studies

GEOGRAPHY:

LADY DAVIS INSTITUTE FOR MEDICAL RESEARCH
(SIR MORTIMER B. DAVIS - JEWISH GENERAL HOSPITAL)

Date established: 1969 Number of clinical investigators: 55

Contact: Dr. Samuel O. Freedman, Director of Research

Address: 3755 Côte Ste-Catherine Road
Montreal, QC H3T 1E2

Tel: (514) 340-8260

Fax: (514) 340-7502

E-mail: sfreedma@ldi.jgh.mcgill.ca

Web site:

The Lady Davis Institute (LDI) for Medical Research of the Sir Mortimer B. Davis Jewish General Hospital is a McGill affiliated biomedical and clinical research institute. The Director of Research is in charge of both basic research at the Lady Davis Institute and clinical research at the Hospital. At the present time there are 75 investigators located in the Institute, as well as approximately 25 purely clinical investigators. Some of the LDI investigators are physician/scientists who conduct translational research on clinical research. The research space, both within the Institute and the Hospital occupies approximately 125,000 sq. ft. including the Institute of Psychiatry, the Clinical Epidemiology Unit, and the Clinical Research Unit.

The Clinical Research Unit has six beds primarily for Phase I and Phase II clinical trials, largely in oncology, and there is a Randomized Clinical Trials Unit within the Clinical Epidemiology Unit for Phase III and Phase IV trials. A number of investigators in the clinician/scientist category do preclinical research in their laboratories.

There are approximately 120 graduate students registered at McGill University, approximately 50 post-doctoral fellows, and about 250 support staff in the Institute, The annual amount of external funding is approximately $20 million and there were 339 publications in the most recent academic year.

In summary, we have a major interest in preclinical, Phase I through IV clinical trials as well as in clinical research listed in the following section.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis		x	x	x	x
Bacteriology/Parasitology	x	x	x	x	x
Blood	x	x	x	x	x
Cancer	x	x	x	x	x
Cardiovascular	x	x	x	x	x
Central Nervous System	x	x	x	x	x
Endocrinology	x	x	x	x	x
Gastrointestinal/Liver				x	x
Genetics	x	x	x	x	x
Immunology/Transplantation	x	x	x	x	x
Metabolism/Diabetes	x	x	x	x	x
Mental/Behavioural Diseases				x	x
Muscle/Bone/Joint	x	x	x	x	x
Reproduction/Pregnancy	x	x	x	x	x
Respiration		x	x	x	x
Women's Health	x	x	x	x	x
Vaccines	x	x	x	x	x
Dental				x	x
Surgical				x	x
Geriatric	x	x	x	x	x
Paediatric					
Devices	x	x	x	x	x
Diagnostics	x	x	x	x	x
Other Areas					

PRECLINICAL SERVICES: Biological & Pharmacological Research, Animal Testing, Laboratory Services, Quality Assurance

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Statistical Services, Data Management and Analysis, Quality Assurance & Control

REGULATORY SERVICES:

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies

GEOGRAPHY:

LAWSON RESEARCH INSTITUTE (THE)

Date established: 1983 Number of clinical investigators: 35

Contact: Ms. Michele Martin, Marketing & Public Relations

Address: 268 Grosvenor St.
London, ON N6A 4V2

Tel: (519) 646-6100, x 64680

Fax: (519) 646-6110

E-mail: lriadmin@lri.stjosephs.london.on.ca

Web site: www.stjosephs.london.on.ca/lri

The Lawson Research Institute (LRI) was founded in 1983 by the Board of the 300-bed acute care St. Joseph's Health Centre, a hospital affiliated with the Faculty of Medicine at The University of Western Ontario. The LRI has six primary research areas: Maternal and Newborn Health, Imaging, Molecular Medicine, Musculo-skeletal biology, Rehabilitation and Geriatric Care, and Clinical Research. As well, there are five core support units: Molecular Biology Laboratories, Pharmaceutical and medical device testing, Animal care facilities, Information Technology unit, and Business Management unit.

The LRI and St. Joseph's Health Centre engage in many private sector partnerships. Linkages have been developed with Abbott, GE, Pfizer, 3M, Baxter, Johnson and Johnson companies, Bayer and Pharmacia. The many industrial collaborations take the form of consultations, clinical trials (approximately 30 per year), two-way exchanges, and basic research investigations. The LRI is seeking partners interested in large and small, long and short-term collaborative ventures. The existing strong links with centres in the U.S., Europe and Asia Pacific provide an international atmosphere for training, research and development. Chair positions are being sought in Maternal and Newborn Health, Bioelectromagnetics and Urological Science (including devices and alternative medicine). Industrial membership of the institute is welcomed.

The LRI has a total staff of over 250 comprising almost 90 basic and clinical investigators and a similar number of graduate students and postdoctoral fellows. Collectively they occupy around 40,000 square ft of research space, attract over $9 million per annum in external funding, and generate approximately 270 biomedical science publications per year.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis	x	x	x	x	x
Bacteriology/Parasitology	x	x	x	x	x
Blood					
Cancer					
Cardiovascular					
Central Nervous System					
Endocrinology	x	x	x	x	x
Gastrointestinal/Liver	x	x	x	x	x
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes	x	x	x	x	x
Mental/Behavioural Diseases					
Muscle/Bone/Joint	x	x	x	x	x
Reproduction/Pregnancy	x	x	x	x	x
Respiration	x	x	x	x	x
Women's Health	x	x	x	x	x
Vaccines					
Dental	x	x	x	x	x
Surgical	x	x	x	x	x
Geriatric	x	x	x	x	x
Paediatric	x	x	x	x	x
Devices	x	x	x	x	x
Diagnostics	x	x	x	x	x
Other Areas					

PRECLINICAL SERVICES: Animal Testing, Laboratory Services

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Patient Recruitment, Laboratory Services, Biometric & Haematological Services

REGULATORY SERVICES:

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies, Rx-OTC Studies

GEOGRAPHY:

LEUKEMIA / BONE MARROW TRANSPLANT PROGRAM OF BRITISH COLUMBIA

Date established: 1984 Number of clinical investigators: 10

Contact: Dr. Michael Barnett, Director
Address: 600 Est 10th Ave.
Vancouver, BC V5Z 1L3
Tel: (604) 875-4089
Fax: (609) 875-4763
E-mail: mbarnett@bccancer.bc.ca
Web site: www.bccancer.bc.ca

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology					
Blood		x	x	x	
Cancer		x	x	x	
Cardiovascular					
Central Nervous System					
Endocrinology					
Gastrointestinal/Liver					
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes					
Mental/Behavioural Diseases					
Muscle/Bone/Joint					
Reproduction/Pregnancy					
Respiration					
Women's Health					
Vaccines					
Dental					
Surgical					
Geriatric					
Paediatric					
Devices					
Diagnostics					
Other Areas					

PRECLINICAL SERVICES:

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES:

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Statistical Services, Data Management and Analysis, Drug Dosage & Control, Quality Assurance & Control

REGULATORY SERVICES:

POST MARKETING SERVICES:

GEOGRAPHY:

LOEB HEALTH RESEARCH INSTITUTE (OTTAWA HOSPITAL)

Date established: 1988 Number of clinical investigators: 35

Contact: Mr. Robert Hanlon, Chief Administrative Officer
Address: 725 Parkdale Avenue
Ottawa, ON K1Y 4E9
Tel: (613) 761-5079
Fax: (613) 761-4920
E-mail: rhanlon@lri.ca
Web site: www.lri.ca

The Loeb Health Research Institute is the basic and clinical research facility of the Ottawa Hospital Civic Campus. It is Revenue Canada approved research institute affiliated with the University of Ottawa.

The Institute employs 39 principal investigators, 7 associate investigators, 15 affiliate investigators and 180 technicians and support staff. Over 75 graduate students and post-doctoral fellows receive training at the Institute each year.

There are four main programs at the LOEB Institute: Clinical Epidemiology; Hormones, Growth and Development; Molecular Medicine and Diseases of Aging; and Neuroscience.

The 75,000 square foot building includes: 28 laboratories, including the region's only in-vitro fertilization laboratory; an experimental surgical suite, and a transgenics facility; equipment modules for each scientist, including space for supporting technicians, graduate students, and post-doctorate fellows; office space and meeting rooms in the hospital for all clinical epidemiology researchers; and a research library. Another 10,000 square feet of space will be constructed before the new millennium.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis		x	x	x	x
Bacteriology/Parasitology					
Blood		x	x	x	x
Cancer					
Cardiovascular					
Central Nervous System	x	x	x	x	
Endocrinology	x	x	x	x	x
Gastrointestinal/Liver					
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes	x	x	x	x	x
Mental/Behavioural Diseases					
Muscle/Bone/Joint					
Reproduction/Pregnancy		x	x	x	x
Respiration					
Women's Health					
Vaccines		x	x	x	x
Dental					
Surgical		x	x	x	x
Geriatric					
Paediatric					
Devices					
Diagnostics					
Other Areas	All Epidemiology (I-IV)				

PRECLINICAL SERVICES:

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Trials Monitoring, Patient Recruitment, Statistical Services, Data Management and Analysis

REGULATORY SERVICES:

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies

GEOGRAPHY: HPB, FDA

LONDON CLINICAL TRIALS RESEARCH GROUP

Date established: 1986 Number of clinical investigators: 15

Contact: Dr. Brian Feagan, Director, London Clinical Trials Group

Address: 100 Perth Drive
London, ON N6A 5K8

Tel: (519) 663-3785

Fax: (519) 663-3789

E-mail: poznansky@rri.on.ca

Web site: www.rri.on.ca

The *London Clinical Trials Research Group* is the result of a partnership between The John P. Robarts Research Institute and London Health Sciences Centre. It is a full service, academic contract research organization with experience in conducting clinical trials since 1986. It offers a broad range of services, from basic research to Phase IV trials, for Clinician Scientists, pharmaceutical companies and government agencies. It has the resources and expertise to perform any or all of the activities involved in drug/device development, from the conception of a scientific hypothesis to the approval of new therapy. Its team consists of experienced clinicians, biostatisticians, clinical epidemiologists, information system specialists, project managers, data managers and clinical monitors.

Founded in 1986, *John P. Robarts Research Institute* is the largest private medical research institute in Canada. It is an internationally recognized reputation in the key areas of immunology and transplantation, gene therapy and neurotrauma, cardiovascular diseases and advanced imaging. RRI has over 45 principal scientists and more than 350 staff working in the Institute. The Institute is affiliated with the University of Western Ontario and London Health Sciences Centre.

London Health Sciences Centre was formed in 1995 by the merger of Victoria Hospital and University Hospital. It is one of Canada's largest teaching hospitals with 940 beds. It serves a population of over 1.5 million people in Southern Ontario. It is known internationally for core programs including cardiac and thoracic medicine, clinical neurological sciences, cancer care, children's health, reproductive medicine and multi-organ transplant service.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis	x	x	x	x	x
Bacteriology/Parasitology			x	x	
Blood			x	x	
Cancer					
Cardiovascular	x	x	x	x	x
Central Nervous System	x	x	x	x	
Endocrinology	x	x	x	x	x
Gastrointestinal/Liver					
Genetics					
Immunology/Transplantation	x	x	x	x	x
Metabolism/Diabetes	x	x	x	x	x
Mental/Behavioural Diseases			x	x	
Muscle/Bone/Joint			x	x	
Reproduction/Pregnancy					
Respiration					
Women's Health					
Vaccines	x	x	x	x	x
Dental					
Surgical	x	x	x		
Geriatric					
Paediatric					
Devices	x	x	x		
Diagnostics			x	x	
Other Areas					

PRECLINICAL SERVICES: Biological & Pharmacological Research, Animal Testing

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Data Management and Analysis, Drug Dosage & Control, Quality Assurance & Control

REGULATORY SERVICES: Regulatory Affairs, Document, Manuscript & CANDA Preparation, IND Submission, NDA Submission

POST MARKETING SERVICES: Pharmacoeconomic Studies, Quality of Life Studies

GEOGRAPHY: HPB, FDA

LONDON HEALTH SCIENCES CENTRE

Date established: 1995 Number of clinical investigators: 150

Contact: Dr. Joseph Gilbert, VP Research

Address: 375 South St.
London, ON N6A 4G5

Tel: (519) 667-6649

Fax: (519) 432-7367

E-mail: gilbertj@lhsc.on.ca

Web site: www.lhsc.on.ca

London Health Sciences Centre was formed in 1995 by the merger of Victoria Hospital and University Hospital. It is one of Canada's largest teaching hospitals with 940 beds. It serves a population of over 1.5 million people in Southern Ontario. It is known internationally for core programs including cardiac and thoracic medicine, clinical neurological sciences, cancer care, children's health, reproductive medicine and multi-organ transplant service.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis	x			x	
Bacteriology/Parasitology	x			x	
Blood			x	x	
Cancer	x			x	
Cardiovascular	x			x	
Central Nervous System	x			x	
Endocrinology	x			x	
Gastrointestinal/Liver	x			x	
Genetics	x			x	
Immunology/Transplantation	x	x	x	x	
Metabolism/Diabetes				x	
Mental/Behavioural Diseases				x	
Muscle/Bone/Joint				x	
Reproduction/Pregnancy				x	
Respiration				x	
Women's Health				x	
Vaccines					
Dental					
Surgical				x	
Geriatric				x	
Paediatric				x	
Devices		x	x	x	
Diagnostics				x	
Other Areas					

PRECLINICAL SERVICES: Biological & Pharmacological Research, Animal Testing, Laboratory Services, Quality Assurance

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Trials Monitoring, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Statistical Services, Data Management and Analysis

REGULATORY SERVICES:

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies

GEOGRAPHY: HPB, FDA

McGILL UNIVERSITY CLINICAL RESEARCH CENTRE (MUHC - CRC)

Date established: 1995 Number of clinical investigators: over 450

Contact: Dr. Phil Gold, Executive Director

Address: Clinical Research Centre
The Montreal General Hospital - McGill University Health Centre
1650 Cedar Avenue, Room D13-173
Montreal, QC H3G 1A4

Tel: (514) 937-6011, local 3061

Fax: (514) 934-8338

E-mail: mcti@musica.mcgill.ca

Web site: www.crcmgh.com

With over 450 clinical investigators, The McGill University Health Centre has Canada's largest Clinical Research Centre (MUHC-CRC), providing both state of-the-art health care to its patients and innovative biomedical and clinical research. The MUHC Research Institute and MUHC affiliated hospitals foster close collaboration between basic and clinical scientists, allowing clinical investigators to produce novel research data with major commercial potential and to attract industrial sponsorship in all four phases of clinical trials and other forms of technology transfer. The Clinical Research Centre, established in 1995, provides an infra-structure which assures services to MUHC investigators and a point of contact for industrial sponsors seeking approval for pharmaceutical agents and medical devices.

The MUHC brings together the resources of some of Canada's finest institutions. A leading edge academic health centre, the MUHC benefits from its association with one of Canada's top medical schools, integrating patient care, teaching and research as its tripartite mission. The partner hospitals provide a high level and broad scope of specialized services, focusing on the kind of expertise that has helped them attain their international reputation for excellence. At the same time, the MUHC is renowned as a world class research institution, operating at forefront of new knowledge, innovations, trends and technologies.

The McGill University Health Centre (MUHC)

The McGill University Health Centre (MUHC) represents the first and largest voluntary merger of university teaching hospitals in Canada. Merged in 1999, the five partners include: the McGill University Faculty of Medicine; three institutions serving adult patients i.e. the Montreal General Hospital, the Royal Victoria Hospital (including the Montreal Cheat Institute), and the Montreal Neurological Hospital; as well as one institution serving children, the Montreal Children's Hospital, together with their respective research institutes.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis	x		x	x	x
Bacteriology/Parasitology	x		x	x	x
Blood	x		x	x	x
Cancer	x	*	x	x	x
Cardiovascular	x	*	x	x	x
Central Nervous System	x		x	x	x
Endocrinology	x		x	x	x
Gastrointestinal/Liver	x		x	x	x
Genetics	x		x	x	x
Immunology/Transplantation	x	*	x	x	x
Metabolism/Diabetes	x		x	x	x
Mental/Behavioural Diseases	x		x	x	x
Muscle/Bone/Joint	x		x	x	x
Reproduction/Pregnancy	x		x	x	x
Respiration	x		x	x	x
Women's Health	x		x	x	x
Vaccines	x		x	x	x
Dental	x		x	x	x
Surgical	x	*	x	x	x
Geriatric	x		x	x	x
Paediatric	x		x	x	x
Devices	x	*	x	x	x
Diagnostics	x		x	x	x
Other Areas	* Phase I studies are limited to patients (not healthy volunteers) in thearpeutic areas such as Oncology, HIV/AIDS and also in the testing of life-saving medical devices in cardiovascular surgery				

PRECLINICAL SERVICES: Medicinal & Organic Chemistry, Biological & Pharmacological Research, Animal Testing, Laboratory Services, Quality Assurance

ETHICAL REVIEW: Phase I*, Phase II/III

PHASE I SERVICES: First Time in Man Studies*, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Statistical Services, Data Management and Analysis, Drug Dosage & Control, Quality Assurance & Control

REGULATORY SERVICES:

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies, Rx-OTC Studies, Consumer Testing Services

GEOGRAPHY: HPB, FDA

OTTAWA GENERAL HOSPITAL RESEARCH INSTITUTE

Date established: August 15, 1996 Number of clinical investigators: 41

Contact: Mr. Robert Cournoyer, Director, Research Administration

Address: Administration, 501 Smyth Road
Ottawa, ON K1H 8L6

Tel: (613) 737-8462

Fax: (613) 737-8803

E-mail: rcournoyer@ogh.on.ca

Web site: www.ogh.on.ca/research/index.htm

The Ottawa General Hospital Research Institute (OHRI) was created in 1996 with a mandate to develop a clinical and basic research program that will make the hospital one of the top medical research establishments in the country.

The OHRI houses the Centre for Molecular Medicine with two research themes. One is the molecular genetics of disease and development with an emphasis on diseases of the neurological and neuromuscular system. The second is in the study of HIV infection and AIDS with expertise ranging from basic viral pathogenesis through clinical trials with the latest drugs. The Hospital is also home to the University of Ottawa Eye Institute, and a third major research theme is the development of corneal laser surgery and corneal biology. A fourth area under development is Clinical Epidemiology with an emphasis on evidence-based medicine and health economics.

Affiliated with the Hospital are two other major research groups, and while not part of the OGH Research Institute, the members of these groups are cross-appointed to the Institute and form part of the Institute environment. These include the Cancer Research Group of the Ottawa Regional Cancer Center housed within the Hospital, and the Neuroscience Research Institute housed in the medical school adjacent to the Hospital.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis	x	x	x	x	x
Bacteriology/Parasitology	x	x	x	x	x
Blood			x	x	x
Cancer	x	x	x	x	x
Cardiovascular				x	x
Central Nervous System	x	x	x	x	x
Endocrinology				x	x
Gastrointestinal/Liver				x	
Genetics	x				
Immunology/Transplantation	x	x	x	x	x
Metabolism/Diabetes				x	x
Mental/Behavioural Diseases				x	x
Muscle/Bone/Joint		x	x	x	x
Reproduction/Pregnancy	x	x	x	x	x
Respiration				x	x
Women's Health	x	x	x	x	x
Vaccines	x	x	x	x	x
Dental					
Surgical	x	x	x	x	x
Geriatric				x	x
Paediatric		x	x	x	x
Devices					
Diagnostics	x	x	x	x	x
Other Areas	Virology-AIDS (I-IV), Anesthesia (I-III)				

PRECLINICAL SERVICES: Biological & Pharmacological Research, Animal Testing, Laboratory Services, Quality Assurance

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Statistical Services, Data Management and Analysis, Drug Dosage & Control, Quality Assurance & Control

REGULATORY SERVICES: Document, Manuscript & CANDA Preparation, IND Submission

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies, Rx-OTC Studies

GEOGRAPHY: HPB, FDA, Other National

PROVIDENCE HEALTH CARE, ST. PAUL'S HOSPITAL SITE

Date established: 1894 Number of clinical investigators: 68

Contact: Dr. James Hogg, Director of Research, St. Paul's Hospital
Address: Room 289, 1081 Burrard Street
Vancouver, BC V6Z 1Y6
Tel: (604) 682-2344, x 62325
Fax: (604) 806-8568
E-mail: jhogg@mrl-ubc.ca
Web site: www.pulmonary.ubc.ca

St. Paul's Hospital is a 500 bed tertiary care, research and teaching hospital affiliated with the University of British Columbia. We conduct basic research, clinical trials, translational and outcomes research. St. Paul's is particularly renowned for its research in the areas of Cardiovascular/Pulmonary Disease/Critical Care and AIDS. Research funding from all sources has been 10 million in recent years.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis				x	x
Bacteriology/Parasitology				x	
Blood				x	
Cancer					
Cardiovascular				x	x
Central Nervous System				x	
Endocrinology				x	x
Gastrointestinal/Liver				x	x
Genetics				x	x
Immunology/Transplantation				x	x
Metabolism/Diabetes				x	x
Mental/Behavioural Diseases				x	x
Muscle/Bone/Joint				x	x
Reproduction/Pregnancy					
Respiration				x	x
Women's Health				x	x
Vaccines				x	x
Dental					
Surgical				x	x
Geriatric				x	x
Paediatric					
Devices				x	x
Diagnostics				x	x
Other Areas					

PRECLINICAL SERVICES: Animal Testing, Laboratory Services

ETHICAL REVIEW: Phase II/III

PHASE I SERVICES:

PHASE II / III STUDIES: Clinical Trial Design, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Statistical Services, Data Management and Analysis

REGULATORY SERVICES:

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies, Rx-OTC Studies

GEOGRAPHY: HPB

QUEEN ELIZABETH II HEALTH SCIENCES CENTRE

Date established: 1996 Number of clinical investigators: over 100

Contact: Ms. Lisa Underwood, Director - Clinical Trials
Address: Centre for Clinical Research
5790 University Avenue
Halifax, NS B3H 1V7
Tel: (902) 473-4069
Fax: (902) 473-4497
E-mail:
Web site: www.qe2-hsc.ns.ca

The QEII Centre for Clinical Research provides research services to the QEII Health Sciences Centre, which is both the principal adult tertiary care facility for the Atlantic Provinces and the principal teaching hospital affiliated with Dalhousie University. At the QEII, research is a fundamental and integral component of improved and quality patient care. The Centre for Clinical Research has dedicated research facilities, over 100 experienced Investigators and 150 Research Coordinators.

The *Therapeutic Specialties* include the following: Anesthesia, Cardiac Sciences, Cardiovascular Surgery, Dermatology, Endocrinology and Metabolism, Gastroenterology, Geriatric Medicine, Hematology, Infectious Diseases, Microbiology, Nuclear Medicine, Nephrology, Neurosciences, Neurosurgery, Oncology, Ophthalmology, Orthopedic Surgery, Osteoporosis, Palliative Care, Pathology, Physical Medicine, Psychiatry, Rehabilitation, Respirology, Rheumatology, Transplant, Trauma, and Urology.

The QEII serves the population of the Central Region Health Board, some 400,000 people. The majority of patients are from the Halifax Region Municipality, an amalgamation of rural areas and Nova Scotia's major urban centre, which includes the twin cities of Halifax and Dartmouth.

The Centre operates Nova Scotia's only Memory Disability Clinic and it is a home to the Atlantic provinces' only Sleep Disorders Clinic. Also at the QEII is the National Centre for Enteroviruses (intestinal viruses), part of a nation-wide network of research experts; the Rob McCall Centre for HIV (the virus that can lead to AIDS) Research; and one of four world-wide Parkinson's fetal neural transplant research centres.

The QEII also operates the Atlantic AIDS Reference Lab for the Atlantic provinces; the Regional Centre for Canadian HIV Trials Network; and the Centre for Clinical Research.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology	x	x	x	x	x
Blood	x	x	x	x	x
Cancer	x	x	x	x	x
Cardiovascular	x	x	x	x	x
Central Nervous System	x	x	x	x	x
Endocrinology	x	x	x	x	x
Gastrointestinal/Liver	x	x	x	x	x
Genetics					
Immunology/Transplantation	x	x	x	x	x
Metabolism/Diabetes	x	x	x	x	x
Mental/Behavioural Diseases	x	x	x	x	x
Muscle/Bone/Joint	x	x	x	x	x
Reproduction/Pregnancy					
Respiration	x	x	x	x	x
Women's Health					
Vaccines					
Dental					
Surgical	x	x	x	x	x
Geriatric	x	x	x	x	x
Paediatric					
Devices					
Diagnostics					
Other Areas	Dermatology, Ophthalmology				

PRECLINICAL SERVICES:

ETHICAL REVIEW:

PHASE I SERVICES:

PHASE II / III STUDIES:

REGULATORY SERVICES:

POST MARKETING SERVICES:

GEOGRAPHY:

QUEEN'S UNIVERSITY GI DISEASES RESEARCH UNIT (GIDRU)

Date established: 1982 Number of clinical investigators: 17

Contact: Dr. William G. Paterson, Professor of Medicine, Director of GIDRU

Address: GI Division, Hotel Dieu Hospital
166 Brock Street
Kingston, ON K7L 5G2

Tel: (613) 544-3400, x. 2332

Fax: (613) 544-3114

E-mail: paterson@hdh.kari.net

Web site: meds.queensu.ca/gidru/gidru.htm

The Queen's Gastrointestinal Diseases Research Unit, or GIDRU, was established in 1982. It has subsequently evolved into an active collaborative group of clinicians, basic scientists, and students with a common interest in Gastroenterological research. Research activities take place in the laboratories of Hotel Dieu Hospital, in the patient care areas at both of Kingston's two general teaching hospitals, and in the Departments of Anatomy and Cell Biology, Physiology, Pathology, and Immunology and Microbiology of Queens University. At present 17 full time Queen's faculty members participate in research activities under the auspices of the GIDRU. Many members hold peer-reviewed external operating grants to carry out basic biomedical research.

There is also a very active clinical trials arm to the GIDRU. Kingston is unique in that there are no private-practice Gastroenterologists. Thus, all GI referrals are seen by a full-time Queens faculty member who is also a member of the GIDRU. In addition, clinical strengths of the Gastroenterology Division are well recognized in the referral area, which, for certain conditions, extends as far as Ottawa in the north, Cornwall in the east and Peterborough in the west. As a result, the patient base for clinical research far exceeds what one would expect for a centre the size of Queen's.

Much of the ongoing research within the GIDRU has considerable potential with respect to the development and testing of novel approaches to diseases of the gastrointestinal tract and liver. Studies to establish drug and nutrient delivery system targeted specifically to the hepatocyte have obvious direct applicability to the development of exciting new therapeutic agents. In addition, a major focus within the GIDRU is the study of the pathophysiology of GI mucosal inflammation, with the expectation that a better understanding of the fundamental mechanisms of mucosal injury will inevitably lead to improved treatment of certain gastrointestinal illnesses. Novel animal models have been developed to study mucosal injury in the esophagus, stomach, small intestine and colon. These models provide unique opportunities to evaluate the influence of new agents on various types of mucosal injury. Such agents may have future clinical applicability in the treatment of reflux esophagitis, peptic ulcer disease and the various forms of inflammatory bowel disease.

Sophisticated techniques am also available within the GIDRU to measure various immunological functions of the GI tract, GI motility, enteric nerve function, and the macro- and micro-circulation to the gut. These methodologies can readily be utilized to carefully characterize certain pharmacological properties of new agents.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology					
Blood					
Cancer					
Cardiovascular					
Central Nervous System					
Endocrinology					
Gastrointestinal/Liver	x	x	x	x	x
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes					
Mental/Behavioural Diseases					
Muscle/Bone/Joint					
Reproduction/Pregnancy					
Respiration					
Women's Health					
Vaccines					
Dental					
Surgical					
Geriatric					
Paediatric					
Devices					
Diagnostics					
Other Areas					

PRECLINICAL SERVICES: Medicinal & Organic Chemistry, Biological & Pharmacological Research, Animal Testing

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES:

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Statistical Services, Data Management and Analysis, Drug Dosage & Control, Quality Assurance & Control

REGULATORY SERVICES:

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies

GEOGRAPHY: HPB, FDA

FACILITIES & CAPABILITIES

SAMUEL LUNENFELD RESEARCH INSTITUTE/MOUNT SINAI HOSPITAL

Date established: 1923 Number of clinical investigators: ~70

Contact: Dr. Sue Ross, Co-ordinator of Clinical Research
Address: 600 University Avenue
Toronto, ON M5G 1X5
Tel: (416) 586-8852
Fax: (416) 586-8404
E-mail: ross@mshri.on.ca
Web site: www.mshri.on.ca

Mount Sinai Hospital is recognized nationally and internationally as a centre of excellence for its outstanding compassionate care, teaching and research. A University of Toronto affiliated hospital, its key priority programs are perinatology, surgical oncology (including breast cancer), musculoskeletal disease, gastrointestinal disease, molecular and sub-specialty medicine (including breast diseases), and the Samuel Lunenfeld Research Institute.

Mount Sinai Hospital's vision of research as an integral part of patient care and education led to the creation of the Mount Sinai Hospital Research Institute in 1985. The goal was to develop an internationally renowned medical research centre that would make substantial inroads into the prevention, diagnosis and treatment of disease.

In order to promote focused and integrated research activities that complement the Hospital's priority programs, researchers in the SLRI focus on three major pillars of strength: Molecular Biology and Cancer, Development and Fetal Health, and Epidemiology (the study of human populations). The goal of these interrelated programs is to understand the function of genes and how these complex pathways lead to disease such as cancer, asthma, diabetes, hypertension, premature labour and inflammatory bowel disease. An exciting new area of research at the Institute is the study of genes in the human population and how these can contribute to disease.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis	x	x	x	x	x
Bacteriology/Parasitology	x	x	x	x	x
Blood					
Cancer	x	x	x	x	x
Cardiovascular	x	x	x	x	x
Central Nervous System					
Endocrinology	x	x	x	x	x
Gastrointestinal/Liver	x	x	x	x	x
Genetics	x	x	x	x	x
Immunology/Transplantation					
Metabolism/Diabetes	x	x	x	x	x
Mental/Behavioural Diseases			x	x	x
Muscle/Bone/Joint	x	x	x	x	x
Reproduction/Pregnancy	x	x	x	x	x
Respiration	x	x	x	x	x
Women's Health	x	x	x	x	x
Vaccines					
Dental					
Surgical	x	x	x	x	x
Geriatric					
Paediatric *(neonatal)*	x	x	x	x	x
Devices			x	x	x
Diagnostics	x	x	x	x	x
Intensive Care	Phases I - IV				

PRECLINICAL SERVICES: Biological & Pharmacological Research, Animal Testing, Laboratory Services

ETHICAL REVIEW: Being developed

PHASE I SERVICES:

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Statistical Services, Data Management and Analysis, Drug Dosage & Control

REGULATORY SERVICES:

POST MARKETING SERVICES: Outcome Measurement Services, Quality of Life Studies

GEOGRAPHY: HPB, FDA

ST. BONIFACE GENERAL HOSPITAL

Date established: 1871 Number of clinical investigators: 50

Contact: Ms. April Hughes, Manager, Clinical Trials
Address: 409 Taché Avenue, Room N 1002
Winnipeg, MB R2H 2A6
Tel: (204) 235-3819
Fax: (204) 237-9860
E-mail: ahughes@gwmail.sbgh.mb.ca
Web site: www.sbrc.umanitoba.ca

St. Boniface General Hospital is the second largest health care facility in Manitoba with 599 beds, that provides patient care services to the residents of Manitoba and North Western Ontario. As a designated tertiary health care facility affiliated with the University of Manitoba, the Hospital plays a significant role as an academic and research health care facility. With over 12 clinical departments, over 50 Clinical investigators, and a staff of over 380 physicians, the patient care services, research, and teaching opportunities offered at St. Boniface are extensive. All of the staff physicians at St. Boniface General Hospital are also adjunct professors at the University of Manitoba. In addition to the St. Boniface General Hospital clinical facilities, the St. Boniface General Hospital clinical facilities, the St. Boniface General Hospital Research Centre is home to over twenty-five laboratories.

In addition to those listed in the following section St. Boniface also provides specialized research facilities and experienced Principal Investigators in the following areas: Anesthesia Research Laboratory (phase I-IV), Communication Disorders Clinic (hearing and speech), Palliative Care (II-IV), Emergency Medicine (I-IV), Sleep Disorders Clinic (II-IV), Surgical Research Laboratory (fiber optics, robotics, lasers and artificial intelligence), Pharmaceutical Innovation Laboratory (pre-clinical testing of drugs and medical devices), Neurosurgery (I-IV), Infectious Diseases (pre-clinical, II-IV), and Magnetic Resonance Imaging (I-IV).

Research at St. Boniface General Hospital is assisted by a central Research Office which provides ongoing education and support services specific to the conduct of Clinical Trials to meet Health Canada and/or FDA regulatory requirements and GCP Guidelines.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology	x				
Blood	x	x	x	x	x
Cancer		x	x	x	x
Cardiovascular	x		x	x	x
Central Nervous System	x				x
Endocrinology	x		x	x	x
Gastrointestinal/Liver	x		x	x	x
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes	x				
Mental/Behavioural Diseases	x	x	x	x	x
Muscle/Bone/Joint	x	x			
Reproduction/Pregnancy			x	x	x
Respiration			x	x	x
Women's Health			x	x	x
Vaccines			x	x	x
Dental					
Surgical	x		x	x	x
Geriatric	x		x	x	x
Paediatric					
Devices	x	x	x	x	x
Diagnostics					
Other Areas					

PRECLINICAL SERVICES: Medicinal & Organic Chemistry, Biological & Pharmacological Research, Laboratory Services, Quality Assurance

ETHICAL REVIEW: Phase II/III

PHASE I SERVICES:

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Drug Dosage & Control

REGULATORY SERVICES:

POST MARKETING SERVICES: Quality of Life Studies

GEOGRAPHY: HPB

ST. JOSEPH'S HOSPITAL

Date established: 1993 Number of clinical investigators: 123

Contact: Dr. Stuart Macleod, Director, Father Sean O'Sullivan Research Centre

Address: 50 Charleton Avenue East
Hamilton, ON L8N 4A6

Tel: (905) 521-6115

Fax: (905) 521-6136

E-mail: macleods@fhs.mcmaster.ca

Web site: www.stjosham.on.ca

St. Joseph's Hospital is a 399-bed teaching hospital affiliated with the Faculty of Health Sciences at McMaster University and Mohawk College. It is owned and operated by the St. Joseph's Health Care System.

St. Joseph's Hospital has provided high quality health care services to the people of Hamilton-Wentworth since 1890. Its Centres of Excellence include kidney and urinary disease, chest and lung disease, musculoskeletal disease, maternal/child health, mental health and general medicine. The hospital also owns St. Joseph's Community Health Centre; an outpatient facility supporting the health care needs of the residents of Stoney Creek, East Hamilton, and the broader Hamilton-Wentworth Region.

As part of its ongoing commitment to innovative clinical research, St. Joseph's has established the Father Sean O'Sullivan Research Centre. Researchers at the Centre have received international recognition for their work in chest and lung diseases, musculoskeletal diseases, kidney and urinary disease and optimal drug therapy.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis		x	x	x	x
Bacteriology/Parasitology	x		x	x	x
Blood				x	x
Cancer				x	x
Cardiovascular				x	x
Central Nervous System				x	x
Endocrinology				x	x
Gastrointestinal/Liver				x	x
Genetics					
Immunology/Transplantation			x	x	x
Metabolism/Diabetes				x	x
Mental/Behavioural Diseases			x	x	x
Muscle/Bone/Joint		x	x	x	x
Reproduction/Pregnancy				x	x
Respiration	x	x	x	x	x
Women's Health				x	x
Vaccines					x
Dental					x
Surgical			x	x	x
Geriatric			x	x	x
Paediatric				x	x
Devices			x	x	x
Diagnostics	x	x	x	x	x
Other Areas					

PRECLINICAL SERVICES: Biological & Pharmacological Research, Laboratory Services

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacodynamics

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring (with CRO partners), Investigative Site Selection & Management (with CRO partners), Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Data Management and Analysis, Drug Dosage & Control

REGULATORY SERVICES: Regulatory Affairs, Document, Manuscript & CANDA Preparation, IND Submission, NDA Submission, Regulatory Consulting

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies

GEOGRAPHY: HPB, FDA, EMEA

SUNNYBROOK & WOMEN'S COLLEGE HEALTH SCIENCES CENTRE

Date established:

Number of clinical investigators: 94 (24 full-time employees)

Contact: Dr. Philip Hebert, Chair, Research Ethics Board
Address: 5133, S-wing, 2075 Bayview Ave.,
Toronto, ON M4N 3M5
Tel: (416) 480-4276
Fax: (416) 480-5814
E-mail: philip.hebert@utoronto.ca
Web site:

The Sunnybrook & Women's College Health Sciences Centre is the amalgamation of three of Canada's more notable health care organizations: The Sunnybrook Health Sciences Centre, Women's College Hospital, and The Orthopaedic and Arthritic Hospital. The new organization, fully affiliated with the University of Toronto, is building on the reputation of each of the amalgamated institutions for excellence in patient care, education, and research. In addition to the acute care activities, S&WCHSC also houses the Toronto-Sunnybrook Regional Cancer Centre and a large chronic care and rehab facility.

Programs at the Research Centre at Sunnybrook Health Science Centre concentrate on basic research with a primary focus in four disciplinary areas: Biological Sciences, Clinical Epidemiology, Integrative Biomedical Sciences, and Imaging/Bioengineering. In addition there is a focus on six programs: Trauma, Cancer, Ageing, Heart/Circulation, Mental Health, and Community. There are strong interactions with industry and the clinical programs of the Sunnybrook Health Science Centre to ensure the application of scientific knowledge to the promotion of human health.

The Centre for Research in Women's Health at the Women's College Site has a particular focus in a number of medical disciplinary areas as they relate to women's health. The research emphasis is on women's life course (aging/chronic conditions), reproductive health (maternal and infant), cancer (specific to women), and mental health (violence against women, etc.)

Industrial Involvement Sought

- Research collaborations and joint ventures related to the disciplinary and programmatic areas of research and clinical expertise (further information on individual projects available)
- Technologies available for licensing to industry (further information on specific licensing opportunities is available)
- Clinical trials at the Sunnybrook Health Science Centre. The Health Science Centre offers a full range of clinical areas.

Research Group Profile

- 65 principal investigators
- 98 trainees
- approximately 350 research, administrative and support staff
- approximately 160,000 square feet laboratory space
- over $30 million annual budget (1998/99)

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis	x	x	x	x	x
Bacteriology/Parasitology					
Blood					
Cancer	x	x	x	x	x
Cardiovascular	x	x	x	x	x
Central Nervous System	x	x	x	x	x
Endocrinology	x	x	x	x	x
Gastrointestinal/Liver	x	x	x	x	x
Genetics	x				
Immunology/Transplantation	x	x	x	x	x
Metabolism/Diabetes	x	x	x	x	x
Mental/Behavioural Diseases	x	x	x	x	x
Muscle/Bone/Joint	x	x	x	x	x
Reproduction/Pregnancy	x	x	x	x	x
Respiration	x	x	x	x	x
Women's Health	x	x	x	x	x
Vaccines	x	x	x	x	x
Dental	x	x	x	x	x
Surgical	x	x	x	x	x
Geriatric	x	x	x	x	x
Paediatric	x	x	x	x	x
Devices	x	x	x	x	x
Diagnostics	x	x	x	x	x
Other Areas					

PRECLINICAL SERVICES: Biological & Pharmacological Research

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Clinical Trials Monitoring, Patient Recruitment, Laboratory Services

REGULATORY SERVICES:

POST MARKETING SERVICES: Outcome Measurement Services, Quality of Life Studies

GEOGRAPHY:

SURREY PLACE CENTRE

Date established: 1966 Number of clinical investigators: 10

Contact: Dr. John S. Lovering, Director, Biomedical Services and Research Division
Address: 2 Surrey Place
Toronto, ON M5S 2C2
Tel: (416) 92505141
Fax: (416) 92308476
E-mail: lovering@planeteer.com
Web site: surreyplace.on.ca

Surrey Place Centre is an interdisciplinary, community-based agency committed to enabling people with developmental disabilities and their families to enhance their quality of life through integrated service, research and education. The Medical Staff is organized in the Biomedical Services and Research Division. Represented are consultants in neurology, developmental pediatrics, genetics, psychiatry and otolaryngology. The Centre was first formed as the Mental Retardation Center in 1962 and later, Surrey Place Centre in 1967 when funding was shifted to the Ministry of Community and Social Services.

The affiliations currently relevant to the Medical Staff include:

- The Faculty of Medicine, University of Toronto
  - The Department of Psychiatry, University of Toronto
  - The Department of Pediatrics, University of Toronto
- The Hospital for Sick Children, Toronto

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology					
Blood					
Cancer					
Cardiovascular					
Central Nervous System			x	x	
Endocrinology					
Gastrointestinal/Liver					
Genetics			x	x	x
Immunology/Transplantation					
Metabolism/Diabetes					
Mental/Behavioural Diseases			x	x	x
Muscle/Bone/Joint					
Reproduction/Pregnancy					
Respiration					
Women's Health					
Vaccines					
Dental					
Surgical					
Geriatric					
Paediatric			x	x	x
Devices					
Diagnostics					
Other Areas					

PRECLINICAL SERVICES:

ETHICAL REVIEW: Phase II/III

PHASE I SERVICES:

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Trials Monitoring, Patient Recruitment, Data Management and Analysis

REGULATORY SERVICES:

POST MARKETING SERVICES:

GEOGRAPHY:

TERRY FOX LABORATORY

Date established: 1981 Number of clinical investigators: 4

Contact: Dr. Allen C. Eaves, Director
Address: 601 West 10th Ave.
Vancouver, BC V5Z 1L3
Tel: (604) 877-6070
Fax: (604) 877-0712
E-mail: aeaves@bccancer.bc.ca
Web site: www.terryfox.ubc.ca

The Terry Fox Laboratory represents a young and dynamic multidisciplinary Unit at the forefront of research to improve cancer diagnosis and treatment. Current emphasis is on the cellular and molecular mechanisms of normal cell growth, differentiation and cell-cell interactions and how these may be altered to bring about malignant transformation. Extensive sharing of research interests among staff and trainees fosters the development of collaborative projects and facilitates the dissemination of new techniques within the Unit.

The Terry Fox Laboratory was formally established in 1981 as a joint undertaking between the British Columbia Cancer Agency, the B.C. Cancer Foundation, the University of British Columbia and the National Cancer Institute of Canada. It now encompasses approximately 20,000 square feet of modern laboratories and offices, and accommodates a staff of over 100 individuals, with more than 40 students and postdoctoral fellows. An international reputation for standards of excellence in research and training has been established. In addition to its team approach, the staff of the Terry Fox Laboratory enjoy a unique interactive relationship with the clinical staff of the British Columbia Cancer Agency and the Vancouver Hospital and Health Sciences Centre. This makes possible ready access to an enormous variety of human material on a daily basis for fundamental experimentation and investigation, and provides novel opportunities for the rapid movement of new methodology from bench to bedside.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology					
Blood	x				
Cancer	x				
Cardiovascular					
Central Nervous System					
Endocrinology					
Gastrointestinal/Liver					
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes					
Mental/Behavioural Diseases					
Muscle/Bone/Joint					
Reproduction/Pregnancy					
Respiration					
Women's Health					
Vaccines					
Dental					
Surgical					
Geriatric					
Paediatric					
Devices					
Diagnostics					
Other Areas					

PRECLINICAL SERVICES: Biological & Pharmacological Research, Animal Testing, Laboratory Services

ETHICAL REVIEW:

PHASE I SERVICES:

PHASE II / III STUDIES:

REGULATORY SERVICES:

POST MARKETING SERVICES:

GEOGRAPHY:

UNIVERSITY HEALTH NETWORK
(TORONTO GENERAL, TORONTO WESTERN, PRINCESS MARGARET HOSPITALS)

Date established: Number of clinical investigators:

Contact: Dr. Christopher Paige, Vice President, Research

Address: 7-504, 610 University Avenue
Toronto, ON M5G 2M9

Tel: (416) 946-2951

Fax: (416) 946-2287

E-mail: paige@oci.utoronto.ca

Web site: www.uhealthnet.on.ca

The University Health Network (formerly The Toronto Hospital) is made up of Toronto General Hospital, Toronto Western Hospital, Princess Margaret Hospital and Toronto Medical Laboratories. Each hospital retains its identity and name within the Network.

The University Health Network's primary areas include: Cardiac Sciences; Neurosciences; Oncology; Primary, Ambulatory and Community Care; and Transplantation.

The University Health Network, through its three Research Divisions, is a full-service research organization and, while every facet of the Hospital is deeply influenced by the research enterprise, particular emphasis is applied to new technology in molecular therapy, the use of genetically engineered cells, tissues and organs. The University Health Network is also building a Clinical Informatics system that captures clinical information, integrates it, and allows it to be utilized in a meaningful way to offer unparalleled opportunities for medical advancement.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis	x	x	x	x	x
Bacteriology/Parasitology	x	x	x	x	x
Blood	x	x	x	x	x
Cancer	x	x	x	x	x
Cardiovascular	x	x	x	x	x
Central Nervous System	x	x	x	x	x
Endocrinology	x	x	x	x	x
Gastrointestinal/Liver	x	x	x	x	x
Genetics	x	x	x	x	x
Immunology/Transplantation	x	x	x	x	x
Metabolism/Diabetes	x	x	x	x	x
Mental/Behavioural Diseases	x	x	x	x	x
Muscle/Bone/Joint	x	x	x	x	x
Reproduction/Pregnancy	x	x	x	x	x
Respiration	x	x	x	x	x
Women's Health	x	x	x	x	x
Vaccines	x	x	x	x	x
Dental	x	x	x	x	x
Surgical	x	x	x	x	x
Geriatric	x	x	x	x	x
Paediatric	x	x	x	x	x
Devices	x	x	x	x	x
Diagnostics	x	x	x	x	x
Other Areas					

PRECLINICAL SERVICES: Medicinal & Organic Chemistry, Biological & Pharmacological Research, Animal Testing, Laboratory Services, Quality Assurance

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Statistical Services, Data Management and Analysis, Drug Dosage & Control, Quality Assurance & Control

REGULATORY SERVICES: Regulatory Affairs, Document, Manuscript & CANDA Preparation, IND Submission, NDA Submission, Regulatory Consulting

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies, Rx-OTC Studies, Consumer Testing Services

GEOGRAPHY: HPB, FDA, EMEA, Other National

UNIVERSITY OF OTTAWA HEART INSTITUTE

Date established: 1976 Number of clinical investigators: 42

Contact: Mr. Joe irvine, Chief, Business Development

Address: 40 Ruskin Street, Rm. H213
Ottawa, ON K1Y 4W7

Tel: (613) 761-4721

Fax: (613) 761-4214

E-mail: joirvine@ottawaheart.ca

Web site: www.heartinst.on.ca/

The University of Ottawa Heart Institute is an academic health care institution dedicated to the promotion of cardiovascular health. It is an international center of excellence for the prevention, treatment and rehabilitation of heart disease through patient care, research and education. All f the Ottawa Heart Institute's activities are integrated into a major university hospital, encouraging close interaction between scientists, clinicians and other health care professionals.

The Institute serves more than 1.5 million residents from Eastern and Northern Ontario, and Western Quebec. It is the only specialized, teaching, adult cardiac facility between Montreal and Kingston. Within the Institute there are: three clinical floors (102 beds) offering specialized cardiac care; cardiac life support areas consisting of 3 operating rooms, 3 catheterization labs, an electrophysiology procedure room, a coronary care unit (8 beds), a recovery room (6 beds), and a surgical critical care unit (8 beds).

A 90,000-sq.-ft. *Research Centre* houses research laboratories on anesthesia, arrhythmias, cardiac molecular and cellular biology, cardiac devices, hypertension, lipoproteins and atherosclerosis, and vascular biology. Research findings are integrated into clinical practice providing patients with leading-edge diagnosis and treatment. The *Prevention and Rehabilitation Centre* includes a track, counseling space, telemetry and exercise equipment. The *Diagnostic Centre* offers the most current cardiac diagnostic tools and testing. The *Nuclear Cardiology* department is home to Canada's only Cardiac Positron Emission Tomography (P.E.T.) Centre. PET offers detailed multi-angled images of the heart, allowing a surgeon to assess, prior to surgery, what parts of the heart muscle can be saved and which parts are no longer functioning. The *Cardiac Reference Centre* includes Canada's first *Chest Pain Assessment Unit*, a Day Unit (11 beds) with inpatient and short-stay beds where patients are admitted for procedures such as angiograms and cardioversions. The Cardiac Reference Centre allows the Institute to communicate with regional hospitals, providing a triage system for cardiac patients throughout the region. Patients from more than 50 area hospitals and clinical centres are referred to the Institute and admitted through the Reference Centre.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology					
Blood	x	x	x	x	x
Cancer					
Cardiovascular	x	x	x	x	x
Central Nervous System					
Endocrinology					
Gastrointestinal/Liver					
Genetics	x	x	x	x	x
Immunology/Transplantation	x	x	x	x	x
Metabolism/Diabetes				x	x
Mental/Behavioural Diseases				x	x
Muscle/Bone/Joint					
Reproduction/Pregnancy					
Respiration					
Women's Health	x	x	x	x	x
Vaccines					
Dental					
Surgical					
Geriatric					
Paediatric					
Devices	x	x	x	x	x
Diagnostics	x	x	x	x	x
Other Areas					

PRECLINICAL SERVICES: Medicinal & Organic Chemistry, Biological & Pharmacological Research, Animal Testing, Laboratory Services, Quality Assurance

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Bioavailability

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Statistical Services, Data Management and Analysis, Drug Dosage & Control, Quality Assurance & Control

REGULATORY SERVICES: Regulatory Affairs, Regulatory Consulting

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies

GEOGRAPHY: HPB, FDA

University of Saskatchewan, and the Saskatchewan Drug Research Institute

Date established: SDRI established November 1993 Number of clinical investigators: over 120

Contact: Dr. B. D. McLennan, Associate Dean, Research
Address: Office of Research Services
University of Saskatchewan, Kirk Hall
Rm. 210, 117 Science Place
Saskatoon, SK S7N 5C8
Tel: (306) 966-6576 / 978-8304
Fax: (306) 966-8597 / 978-8301
E-mail: wilsonb@aask.usask.ca
Web site: www.usask.ca/research.html

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis			x	x	x
Bacteriology/Parasitology					
Blood				x	
Cancer			x	x	x
Cardiovascular	x	x	x	x	x
Central Nervous System			x	x	x
Endocrinology			x	x	x
Gastrointestinal/Liver				x	x
Genetics					
Immunology/Transplantation		x	x	x	x
Metabolism/Diabetes			x	x	x
Mental/Behavioural Diseases		x	x	x	x
Muscle/Bone/Joint			x	x	x
Reproduction/Pregnancy			x	x	x
Respiration		x	x	x	x
Women's Health			x	x	x
Vaccines		x	x	x	x
Dental	x	x	x	x	x
Surgical			x	x	
Geriatric			x	x	x
Paediatric		x	x	x	x
Devices		x			
Diagnostics					
Other Areas					

PRECLINICAL SERVICES: Medicinal & Organic Chemistry, Biological & Pharmacological Research, Animal Testing, Laboratory Services

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Bioavailability

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Statistical Services, Drug Dosage & Control

REGULATORY SERVICES: Regulatory Affairs, IND Submission

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies Rx-OTC Studies

GEOGRAPHY: HPB

VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE (VHHSC)

Date established:. Number of clinical investigators: ~250

Contact: Dr. Karim Karmali, Director of Research Affairs

Address: 2660 Oak Street
Vancouver, BC V6H 3Z6

Tel: (604) 875-5839

Fax: (604) 875-4598

E-mail: kkarmali@interchange.ubc.ca

Web site: www.vanhosp.bc.ca

VHHSC is one of North America's leading health care centres with 1,900 beds. It is a second largest hospital in Canada. Merged with the BC Rehab Society and the clinical component of the Arthritis Society of BC & Yukon in spring of 1997. Five hospital sites in Vancouver: George Pearson Centre, GF Strong Rehab Centre, Mary Pack Arthritis Centre, UBC Hospital, and Vancouver General Hospital

VHHSC is:

- The primary referral, teaching & research hospital in the province
- Links to the Faculty of Medicine at the University of British Columbia
- Providing a wide range of medical, surgical and psychiatric services
- Covering virtually every specialty except pediatrics and maternity.

At VHHSC and the Faculty of Medicine at UBC the key areas of research emphasis are:

- Brain and Spinal Cord Research
- Cancer Research Centre (with a strong focus on prostate cancer and melanoma)
- Immunology Research Centre
- Lung Disease Research Centre
- Clinical Epidemiology & Evaluation Lung Disease
- A Discipline Development Program-which includes important new & existing research not represented in the other centres of research emphasis.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis	x	x	x	x	x
Bacteriology/Parasitology	x	x	x	x	x
Blood	x	x	x	x	x
Cancer	x	x	x	x	x
Cardiovascular	x	x	x	x	x
Central Nervous System	x	x	x	x	x
Endocrinology	x	x	x	x	x
Gastrointestinal/Liver	x	x	x	x	x
Genetics	x	x	x	x	x
Immunology/Transplantation	x	x	x	x	x
Metabolism/Diabetes	x	x	x	x	x
Mental/Behavioural Diseases	x	x	x	x	x
Muscle/Bone/Joint	x	x	x	x	x
Reproduction/Pregnancy					
Respiration	x	x	x	x	x
Women's Health	x	x	x	x	x
Vaccines	x	x	x	x	x
Dental					
Surgical	x	x	x	x	x
Geriatric	x	x	x	x	x
Paediatric					
Devices	x	x	x	x	x
Diagnostics	x	x	x	x	x
Other Areas					

PRECLINICAL SERVICES: Biological & Pharmacological Research, Animal Testing, Laboratory Services, Quality Assurance

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Statistical Services, Data Management and Analysis, Drug Dosage & Control, Quality Assurance & Control

REGULATORY SERVICES: Document, Manuscript & CANDA Preparation

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies, Rx-OTC Studies

GEOGRAPHY: HPB, FDA, EMEA

ACERNA INC.

Date established: 1995 Number of clinical investigators:

Contact: Mr. Paul Larocque, President
Address: 19 Bryant Road
Markham, ON L3P 5Y7
Tel: 905-472-5747
Fax: 905-472-2322
E-mail: paul.larocque@sympatico.ca
Web site:

ACERNA is a Canadian pharmaceutical, biological, and medical device consultancy, which provides regulatory affairs and quality assurance services.

Regulatory Affairs services include the preparation of:

- **Investigational New Drug Submissions**
- **New Drug Submissions**
- **Abbreviated New Drug Submissions**
- **Supplemental Submissions**
- **Drug Identification Number Applications**
- **Medical device submissions**
- **Provincial formulary submissions**

Quality Assurance services encompass:

- **Good Manufacturing Practice (GMP) audits**
- **Good Laboratory Practice audits**
- **Quality Assurance vendor audits**
- **FDA medical device Quality System Regulation audits**
- **GMP & QSR training**
- **Quality Control laboratory practices and method validation**
- **Pharmaceutical manufacturing systems including purified water systems**
- **Sterile product manufacturing**
- **Process validation**
- **Pre-approval inspections**

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology					
Blood					
Cancer					
Cardiovascular					
Central Nervous System					
Endocrinology					
Gastrointestinal/Liver					
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes					
Mental/Behavioural Diseases					
Muscle/Bone/Joint					
Reproduction/Pregnancy					
Respiration					
Women's Health					
Vaccines					
Dental					
Surgical					
Geriatric					
Paediatric					
Devices					
Diagnostics					

PRECLINICAL SERVICES: Quality Assurance

ETHICAL REVIEW:

PHASE I SERVICES:

PHASE II / III STUDIES: Quality Assurance & Control

REGULATORY SERVICES: Regulatory Affairs, GMP Consulting, IND Submission, NDA Submission, Regulatory Consulting

POST MARKETING SERVICES:

GEOGRAPHY: HPB, FDA

ALLIED CLINICAL RESEARCH INC.

Date established: 1990 Number of clinical investigators: 4

Contact: Dr. Piyush Patel, President

Address: Suite 410, 2000 Credit Valley Rd.,
Mississauga, ON L5M 4N4

Tel: (905) 569-8100

Fax: (905) 607-3384

E-mail: PPatel@allied-resarch.com

Web site: www.allied-research.com

Allied Clinical Research (ACR) was originally formed to organize Phase II and Phase III studies in asthma, respiratory diseases, dermatology, and allergy. The ACR Inc. was founded by Dr. Piyush Patel who started conducting clinical trials with patients from his own practice. Over the last 10 years more than 120 studies have been successfully completed in this therapeutic area. Expertise has been developed by Dr. Patel and the research staff in conducting Phase I and early Phase II studies involving extensive pulmonary function testing, PK/PD analysis, and various challenge procedures such as methacholine, antigen, and exercise.

ACR has a database of over 1,000 asthmatics who have been involved in numerous clinical trials. These patients are experienced in clinical trial methods and are very compliant.

With an exclusive network of over 35 specialists in various therapeutic areas as well as 60 primary care physicians, ACR is able to gain access to a broad spectrum of patients with diseases in various therapeutic areas. ACR's database can readily identify the type of patients needed for particular studies.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis		x	x	x	
Bacteriology/Parasitology		x			
Blood		x			
Cancer		x			
Cardiovascular		x	x	x	
Central Nervous System		x	x	x	
Endocrinology		x	x	x	
Gastrointestinal/Liver		x	x	x	
Genetics		x	x	x	
Immunology/Transplantation		x			
Metabolism/Diabetes		x	x	x	x
Mental/Behavioural Diseases		x	x	x	x
Muscle/Bone/Joint		x	x	x	x
Reproduction/Pregnancy		x	x	x	
Respiration		x	x	x	x
Women's Health		x	x	x	x
Vaccines		x	x	x	x
Dental		x	x	x	
Surgical		x			
Geriatric		x	x	x	x
Paediatric		x	x	x	
Devices		x	x	x	x
Diagnostics		x	x	x	

PRECLINICAL SERVICES:

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Investigative Site Selection & Management, Patient Recruitment, Statistical Services, Data Management and Analysis, Drug Dosage & Control

REGULATORY SERVICES: Regulatory Affairs, Document, Manuscript & CANDA Preparation, IND Submission, NDA Submission

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies, Rx-OTC Studies, Consumer Testing Services

GEOGRAPHY: HPB, FDA, EMEA, Other National

ANAPHARM INC.

Date established: 1994 Number of clinical investigators: N/A

Contact: Dr. Marc LeBel, President
Address: 2050 Rene-Levesque Blvd. W., 5th Flr.,
Ste-Foy, QC G1W 2K8
Tel: (418) 527-4000
Fax: (418) 527-3456
E-mail:
Web site: www.anapharm.com

Drawing from eighteen years of clinical and bioanalytical research in an academic environment, Anapharm Inc. was founded in 1994. It has since grown into a full service Contract Research Organization conducting trials for clients from North America, Europe and Asia. It has over 200 employees. All work is performed in accordance with GCPs (Good Clinical Practices) and GLPs (Good Laboratory Practices) compliant standard operating procedures (SOPs).

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis		x	x	x	x
Bacteriology/Parasitology		x	x	x	x
Blood		x	x	x	x
Cancer		x	x	x	x
Cardiovascular		x	x	x	x
Central Nervous System		x	x	x	x
Endocrinology		x	x	x	x
Gastrointestinal/Liver		x	x	x	x
Genetics					
Immunology/Transplantation		x	x	x	x
Metabolism/Diabetes		x	x	x	x
Mental/Behavioural Diseases		x	x	x	x
Muscle/Bone/Joint		x	x	x	x
Reproduction/Pregnancy		x	x	x	x
Respiration		x	x	x	x
Women's Health		x	x	x	x
Vaccines		x	x	x	x
Dental					
Surgical		x	x	x	x
Geriatric		x	x	x	x
Paediatric			x	x	x
Devices		x	x	x	x
Diagnostics		x	x	x	x

PRECLINICAL SERVICES: Laboratory Services

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Statistical Services, Data Management and Analysis Quality Assurance & Control

REGULATORY SERVICES:

POST MARKETING SERVICES:

GEOGRAPHY: HPB, FDA, EMEA, Japan

CANADIAN REFERENCE LABORATORY LTD.

Date established: 1996 Number of clinical investigators:

Contact: Dr. David W. Seccombe, President

Address: 307 - 2083 Alma St.,
Vancouver, BC V6R 4N6

Tel: (604) 222-1355

Fax: (604) 222-1373

E-mail: dws@eqa.com

Web site:

The Canadian Reference Laboratory (1996) Ltd. (CRL) is a Canadian health care company with roots in academic Pathology and Laboratory Medicine. It originated as a collaborative initiative of laboratory professionals in Canada and companies from the pharmaceutics, diagnostics and food industries.

CRL partners with its customers to develop and provide high quality products and services that support the quality objectives of laboratory medicine-The company designs and implements internal and external quality assessment programs that monitor performance, assure quality and promote the standardization of process.

The company's systems have been used by major pharmaceutical companies in Europe and North America and are currently mandated for use by all clinical laboratories in Western Canada and Quebec. CRL's Reference Method Laboratory serves as an accuracy base for its programs. This laboratory operates a number of reference methods for human chemistries and is a member of the Cholesterol Reference Method Laboratory Network - an international network of Reference Method Laboratories,

Through this affiliation and certification, the company's laboratory has documented traceability for lipid measurements to the accuracy base at the Centers for Disease Control and Prevention in Atlanta, Georgia. The company provides a full range of pathology and laboratory services in support of phase II-IV studies and analytical services in support of the discovery process. The company excels in remote data entry and the design of systems that standardize process and adherence to protocol.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology					
Blood					
Cancer					
Cardiovascular					
Central Nervous System					
Endocrinology					
Gastrointestinal/Liver					
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes					
Mental/Behavioural Diseases					
Muscle/Bone/Joint					
Reproduction/Pregnancy					
Respiration					
Women's Health					
Vaccines					
Dental					
Surgical					
Geriatric					
Paediatric					
Devices	x	x	x	x	x
Diagnostics	x	x	x	x	x

PRECLINICAL SERVICES: Laboratory Services, Quality Assurance

ETHICAL REVIEW:

PHASE I SERVICES:

PHASE II / III STUDIES: Project Management, Clinical Packaging & Supplies, Clinical Trials Monitoring, Laboratory Services, Biometric & Haematological Services Data Management and Analysis Quality Assurance & Control

REGULATORY SERVICES:

POST MARKETING SERVICES:

GEOGRAPHY:

CANTOX HEALTH SCIENCES INTERNATIONAL

Date established: 1977 Number of clinical investigators: 85

Contact: Dr. John Daniels,
Address: 2233 Argentia Road, Suite 308
Mississauga, ON L5N 2X7
Tel: (905) 542-2900
Fax: (905) 542-1011
E-mail: jdaniels@cantox.com
Web site: www.cantox.com

With a stuff of 85, CANTOX HEALTH SCIENCES INTERNATIONAL has been providing global toxicology, scientific and regulatory consulting services related to pharmaceuticals, food, industrial chemicals, cosmetics, agrochemicals, and medical devices for over 20 years, and has clients and projects in 108 countries across 6 continents.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis	x				
Bacteriology/Parasitology	x				
Blood	x				
Cancer	x				
Cardiovascular	x				
Central Nervous System	x				
Endocrinology	x				
Gastrointestinal/Liver	x				
Genetics	x				
Immunology/Transplantation	x				
Metabolism/Diabetes	x				
Mental/Behavioural Diseases	x				
Muscle/Bone/Joint	x				
Reproduction/Pregnancy	x				
Respiration	x				
Women's Health	x				
Vaccines	x				
Dental	x				
Surgical	x				
Geriatric	x				
Paediatric	x				
Devices	x				
Diagnostics	x				

PRECLINICAL SERVICES: Toxicology Testing program management, Biological & Pharmacological Research, Animal Testing, Toxicology, Quality Assurance

ETHICAL REVIEW:

PHASE I SERVICES:

PHASE II / III STUDIES: Project Management

REGULATORY SERVICES: Regulatory Affairs, Document, Manuscript & CANDA Preparation, IND Submission, NDA Submission, Regulatory Consulting, Toxicology Consulting, Nutraceuticals/Supplements

POST MARKETING SERVICES: Rx-OTC Studies

GEOGRAPHY: HPB, FDA, EMEA, Asia

CATO RESEARCH CANADA

Date established: 1992 Number of clinical investigators:

Contact: Dr. Luc Vachon, Vice President & General Manager
Address: Cavendish Corporate Centre
9900 Cavendish Blvd., Ste. 201
St. Laurent, QC H4M 2V2
Tel: (514) 856-2286
Fax: (514) 856-0100
E-mail: lvachon@mail.cato.com
Web site: www.cato.com

Cato Research Canada (CRC) is a Contract Research Organization with scientific, clinical and regulatory personnel in Montreal as well as clinical monitors in Toronto, London (Ont.), Halifax, Winnipeg, Edmonton, Calgary, and Vancouver. CRC is a sister company of Cato Research Ltd., founded in 1988 and based in Research Triangle Park, NC. The other sister companies are located in Washington, San Francisco and Israel. The Cato Group has a combined staff of 190 people.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology					
Blood		x	x	x	
Cancer	x	x	x	x	
Cardiovascular				x	
Central Nervous System	x	x	x		
Endocrinology	x				
Gastrointestinal/Liver	x		x	x	
Genetics					
Immunology/Transplantation	x	x	x		
Metabolism/Diabetes					
Mental/Behavioural Diseases					
Muscle/Bone/Joint					
Reproduction/Pregnancy			x		
Respiration	x			x	x
Women's Health					
Vaccines				x	
Dental					
Surgical					
Geriatric					
Paediatric					
Devices	x	x	x	x	
Diagnostics	x	x	x	x	

PRECLINICAL SERVICES: Quality Assurance

ETHICAL REVIEW:

PHASE I SERVICES: Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Statistical Services, Data Management and Analysis Quality Assurance & Control

REGULATORY SERVICES: Regulatory Affairs, Document, Manuscript & CANDA Preparation, IND Submission, NDA Submission, Regulatory Consulting

POST MARKETING SERVICES:

GEOGRAPHY: HPB, FDA

CLINIMETRICS RESEARCH ASSOCIATES INC.

Date established:	1996 - Canada (1988 - US)	Number of clinical investigators:	database - multiple therapeutic areas

Contact: Mr. C. Talbot, Director, Canadian Operations
Address: 1193 Lambeth Rd.
Oakville, ON L6H 2C9
Tel: (905) 849-6018
Fax: (905) 849-3847
E-mail: ctalbot@clinimetrics.com
Web site: www.clinimetrics.com

Clinimetrics, an international clinical research organization, was founded in 1988 to provide clinical research services to the pharmaceutical, biotechnology and medical device industries.

Clinimetrics has successfully completed numerous clinical trials for our clients in a wide range of complex therapeutic areas. We provide a complete selection of clinical research support from clinical trial development through final report and regulatory submission.

Clinimetrics has enjoyed a close working relationship with several major international pharmaceutical companies as well as numerous biotechnology and medical device firms. Over the past decade, we have successfully enabled our clients to complete more than 400 Phase I through IV clinical trials in a wide range of therapeutic areas.

Clinimetrics has provided clinical research services to more than 50 pharmaceutical, biotechnology and medical device companies in the US, Canada and Europe

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis		x	x	x	x
Bacteriology/Parasitology					
Blood					
Cancer		x	x	x	x
Cardiovascular		x	x	x	x
Central Nervous System		x	x	x	x
Endocrinology		x	x	x	x
Gastrointestinal/Liver		x	x	x	x
Genetics		x	x	x	x
Immunology/Transplantation		x	x	x	x
Metabolism/Diabetes		x	x	x	x
Mental/Behavioural Diseases		x	x	x	x
Muscle/Bone/Joint		x	x	x	x
Reproduction/Pregnancy		x	x	x	x
Respiration		x	x	x	x
Women's Health		x	x	x	x
Vaccines			x	x	x
Dental					x
Surgical				x	x
Geriatric				x	x
Paediatric			x	x	x
Devices		x	x	x	x
Diagnostics			x	x	x

PRECLINICAL SERVICES:

ETHICAL REVIEW:

PHASE I SERVICES: Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Statistical Services, Data Management and Analysis Quality Assurance & Control

REGULATORY SERVICES: Regulatory Affairs Regulatory Consulting

POST MARKETING SERVICES:

GEOGRAPHY: HPB, FDA, EMEA, Other National

CLINTRIALS BIORESEARCH, LTD. (CTBR) & CLINTRIALS RESEARCH, INC. (CCRO)

Date established: CTBR - 1965 / CCRO - 1989

Number of clinical investigators: Database of ~500 investigators

Contact: Mr. Michael F. Ankcorn, President

Address: 87 Senneville Rd.,
Senneville, QC H9X 3R3

Tel: (514) 630-8200

Fax: (514) 630-8230

E-mail: marketing@CTBR.COM

Web site: www.ctbr.com

CLINTRIALS BIORESEARCH, LTD.

For nearly 35 years, CTBR has been performing preclinical research for pharmaceutical, biopharmaceutical and chemical companies, in addition to specialized segments of the healthcare industry. CTBR is a premier contract research laboratory for drug safety and efficacy assessment, including general toxicology, inhalation, infusion, reproductive and neurotoxicology studies. In addition, CTBR is a recognized world leader in assessing the safety and efficacy of drugs for treating osteoporosis, obesity and ocular diseases. Support services for preclinical and clinical studies include pathology, analytical chemistry and bioanalysis, in vitro and in vivo drug metabolism and pharmacokinetics, immunology and clinical laboratories. CTBR is setting the pace in preclinical research and continue to provide clients with better than 98% on-time reporting of data. All studies are conducted according to GLP Guidelines at our modern 205,000 sq. ft research centre located in Montreal, Canada, which has been inspected and approved by the US EPA, US FDA, Japan MHW, OECD/EU, Health Canada, Environment Canada, and accredited by AAALAC and CCAC.

CLINTRIALS RESEARCH, INC.

ClinTrials Research is a leading global product development company offering preclinical, clinical, and market support services to the pharmaceutical, biotechnology, and medical device industries. Headquartered near Research Triangle Park in Cary, NC, ClinTrials Research has conducted more than 10,000 preclinical studies for more than 1,500 clients and over 850 clinical projects for more than 150 clients across the globe.

ClinTrials Research is a full-service organization that designs, monitors, and manages all phases of clinical trials and provides unparalleled clinical data management and biostatistical services for each client's unique needs. Our staff of over 1,400 employees, located throughout the United States, Europe, Australia, Canada, Asia-Pacific, and South America, have extensive expertise in product development, including program management, medical and regulatory affairs, product safety, clinical monitoring, data management, biostatistics, medical writing, and quality assurance. With more than 10 years of experience, we have proven that we can meet the research needs of pharmaceutical, biotechnology, device, and consumer healthcare companies in all therapeutic areas around the globe.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis	x		x	x	x
Bacteriology/Parasitology	x		x	x	x
Blood	x		x	x	x
Cancer	x	x	x	x	x
Cardiovascular	x		x	x	x
Central Nervous System	x		x	x	x
Endocrinology	x		x	x	x
Gastrointestinal/Liver	x		x	x	x
Genetics					
Immunology/Transplantation	x		x	x	x
Metabolism/Diabetes	x		x	x	x
Mental/Behavioural Diseases	x	x		x	x
Muscle/Bone/Joint	x		x	x	x
Reproduction/Pregnancy	x		x	x	x
Respiration	x		x	x	x
Women's Health	x		x	x	x
Vaccines			x	x	x
Dental	x		x	x	x
Surgical	x		x	x	x
Geriatric	x		x	x	x
Paediatric	x		x	x	x
Devices	x		x	x	x
Diagnostics	x		x	x	x

PRECLINICAL SERVICES: Medicinal & Organic Chemistry, Biological & Pharmacological Research, Animal Testing, Laboratory Services, Quality Assurance

ETHICAL REVIEW:

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Statistical Services, Data Management and Analysis, Drug Dosage & Control, Quality Assurance & Control

REGULATORY SERVICES: Regulatory Consulting

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies, Rx-OTC Studies, Consumer Testing Services

GEOGRAPHY: HPB, FDA, EMEA, Other National (Japan, Europe)

CMX RESEARCH INC.

Date established: 1992 Number of clinical investigators: 17

Contact: Mr. Tom Ekers, President
Address: 1235 Trafalgar Road North, Suite 405
Oakville, ON L6H 3P1
Tel: (905) 338-1078
Fax: (905) 338-0054
E-mail: tekers@cmxres.com
Web site: www.cmxres.com

CMX Research Inc. is a Site Management Organization (SMO), professionally and effectively conducting pharmaceutical, biotech and medical device research at our 17 sites in Canada. Our Services cover a broad range of study conduct activities that meet FDA, HPB and ICH standards. Our research efforts are segmented into clinical specialties to better serve our clients. Studies are initiated quickly with the aid of our relationship with Trafalgar Ethics Board Inc., one of Canada's oldest non-academic ethics boards.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis				x	x
Bacteriology/Parasitology					
Blood					
Cancer				x	
Cardiovascular				x	x
Central Nervous System				x	
Endocrinology			x	x	
Gastrointestinal/Liver					
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes			x	x	x
Mental/Behavioural Diseases				x	
Muscle/Bone/Joint				x	x
Reproduction/Pregnancy					
Respiration				x	x
Women's Health			x	x	
Vaccines				x	
Dental					
Surgical				x	
Geriatric					
Paediatric					
Devices				x	
Diagnostics					

PRECLINICAL SERVICES:

ETHICAL REVIEW: Phase II/III

PHASE I SERVICES:

PHASE II / III STUDIES: Clinical Trial Design, Investigative Site Selection & Management

REGULATORY SERVICES:

POST MARKETING SERVICES: Quality of Life Studies

GEOGRAPHY: HPB, FDA

COVANCE (CANADA) INC.

Date established: December 1996

Number of clinical investigators: 27, 3 Project Directors

Contact: Dr. Richard Lacombe, Managing Director
Address: 1405 Trans-Canada Highway, Ste. 600,
Dorval, QC H9P 2V9
Tel: (514) 421-8150
Fax: (514) 421-8170
E-mail:
Web site: www.covance.com

Covance Canada is the Canadian subsidiary of Covance Inc. of Princeton, New Jersey. Covance Canada offers product development services to Canadian and international pharmaceutical and biotechnology companies. Services offered in Canada are Phase II-IV clinical trials, project and site management, feasibility studies, monitoring, biostatistics, medical safety monitoring, and regulatory affairs.

Covance Canada can draw upon the collective and individual staff experience and expertise within the global organization to offer a wide range of services such as strategic product development, preclinical studies, Phase I-IV clinical trials, bioanalytical support, central laboratories, pharmacoeconomics, biomanufacturing, packaging, and commercialization.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis			x	x	x
Bacteriology/Parasitology			x	x	x
Blood			x	x	x
Cancer			x	x	x
Cardiovascular			x	x	x
Central Nervous System			x	x	x
Endocrinology			x	x	x
Gastrointestinal/Liver			x	x	x
Genetics			x	x	x
Immunology/Transplantation			x	x	x
Metabolism/Diabetes			x	x	x
Mental/Behavioural Diseases			x	x	x
Muscle/Bone/Joint			x	x	x
Reproduction/Pregnancy			x	x	x
Respiration			x	x	x
Women's Health			x	x	x
Vaccines			x	x	x
Dental			x	x	x
Surgical			x	x	x
Geriatric			x	x	x
Paediatric			x	x	x
Devices			x	x	x
Diagnostics			x	x	x

PRECLINICAL SERVICES:

ETHICAL REVIEW:

PHASE I SERVICES:

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Statistical Services

REGULATORY SERVICES: Regulatory Affairs, Document, Manuscript & CANDA Preparation (part of Global Services), IND Submission, NDA Submission, Regulatory Consulting

POST MARKETING SERVICES:

GEOGRAPHY: HPB, FDA, EMEA (part of Global Services), Other National (part of Global Services)

CROMEDICA INC. (CANADA)

Date established: 1995 Number of clinical investigators: N/A

Contact:	Mr. Ken Newport, President
Address:	1145 Hunt Club, Suite 100 Ottawa, ON K1V 0Y3 K1V 0Y3
Tel:	(613) 739-8162
Fax:	(613) 739-8163
E-mail:	info@cromedica.com
Web site:	ww.cromedica.com

The CroMedica Group of Medicines Development Companies offers comprehensive, integrated drug development services on a global scale. Clinical trial activities on five continents are co-ordinated through our global headquarters in Canada. All operations have strong capabilities in managing and monitoring clinical trials of all phases. Global operations include: Canada, United States, Europe, South Africa, Australia/New Zealand, & Japan

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis			x	x	x
Bacteriology/Parasitology	x				
Blood		x	x	x	x
Cancer		x	x	x	x
Cardiovascular		x	x	x	x
Central Nervous System		x	x	x	x
Endocrinology		x	x	x	x
Gastrointestinal/Liver		x	x	x	x
Genetics		x			
Immunology/Transplantation		x	x	x	x
Metabolism/Diabetes		x			
Mental/Behavioural Diseases		x	x	x	x
Muscle/Bone/Joint		x			
Reproduction/Pregnancy		x			
Respiration		x			
Women's Health		x	x	x	x
Vaccines		x	x	x	x
Dental		x			
Surgical		x			
Geriatric		x	x	x	x
Paediatric		x			
Devices		x	x	x	x
Diagnostics		x			

PRECLINICAL SERVICES:

ETHICAL REVIEW:

PHASE I SERVICES: Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Statistical Services, Data Management and Analysis Quality Assurance & Control

REGULATORY SERVICES: Regulatory Affairs, Document, Manuscript & CANDA Preparation, IND Submission, NDA Submission, Regulatory Consulting

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies, Rx-OTC Studies

GEOGRAPHY: HPB, FDA, EMEA, MCCC-RSA, Australia

DYNACARE CLINICAL RESEARCH INC.

Date established: Number of clinical investigators:

Contact: Ms. Mary Jo Dunlop, President
Address: 245 Pall Mall Street,
London, ON N6A 1P4
Tel: (519) 679-2759
Fax: (519) 679-9482
E-mail:
Web site:

Dynacare, one of the leading providers of medical diagnostic laboratory services in North America, offers hospitals a unique solution to today's health care challenges. In 1997, Dynacare's 3,550 employees performed over 38 million diagnostic tests. Dynacare is a private company owned by the Latner Group of Toronto and Golder, Thoma, Cressey, Rauner, Inc. of Chicago.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology					
Blood					
Cancer					
Cardiovascular					
Central Nervous System					
Endocrinology					
Gastrointestinal/Liver					
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes					
Mental/Behavioural Diseases					
Muscle/Bone/Joint					
Reproduction/Pregnancy					
Respiration					
Women's Health					
Vaccines					
Dental					
Surgical					
Geriatric					
Paediatric					
Devices					
Diagnostics					

PRECLINICAL SERVICES: Medicinal & Organic Chemistry, Biological & Pharmacological Research, Animal Testing, Laboratory Services, Quality Assurance

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Statistical Services, Data Management and Analysis, Drug Dosage & Control, Quality Assurance & Control

REGULATORY SERVICES: Regulatory Affairs, Document, Manuscript & CANDA Preparation, IND Submission, NDA Submission, Regulatory Consulting

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies, Rx-OTC Studies, Consumer Testing Services

GEOGRAPHY: HPB, FDA, EMEA, Other National

DYNACARE KASPER MEDICAL LABS (DKML)

Date established: Jnauary, 1996

Number of clinical investigators: N/A (diagnostic and analytical services)

Contact: Ms. Lorrie Given, Director - Clinical Trials
Address: 14940-123 Ave.,
Edmonton, AB T5V 1B4
Tel: (780) 451-3702
Fax: (780) 452-8488
E-mail: lgiven@dkml.com
Web site: www.dkml.com

DKML is a large, multi-disciplinary laboratory offering comprehensive lab services to communities and hospitals in central and northern Alberta, as well as industry and pharmaceutical clients. Our clinical trials services are provided in North America and Europe through a partnership of two large, private sector laboratories, Dynacare Kasper Medical Laboratories, Canada and Wagner & Partner, Germany, in association with two highly respected academic centres, the University of Alberta Laboratory and the Georg-August-Universität Laboratory in Göttingen, Germany. This partnership allows us to offer our clients significantly expanded services and a unique approach to clinical trials services. DKML can offer a wide spectrum of standardized services in both North America and Europe. The partnership of private and public sector brings to our clients the most efficient and comprehensive services along with academic excellence and strong research experience. All of our partner laboratories are staffed by highly skilled medical practitioners, clinical chemists, toxicologists and registered medical technologists, working with highly automated, computerized laboratory technology.

DKML offers:

- **Comprehensive, cost-effective laboratory services**
- **Extensive test menu offering both routine and specialty testing**
- **Custom services tailored to your protocol**
- **Dedicated, experienced Clinical Trials staff**
- **Professional consultation from our large on-staff medical team**
- **Fully accredited by both the College of American Pathologists (CAP) and the College of Physicians and Surgeons for the Province of Alberta, as well as European accreditation.**
- **Proven expertise in servicing large multi-centre clinical trials**
- **Laboratories in North America and Europe to accommodate your International Clinical Trial needs**

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis	x	x	x	x	x
Bacteriology/Parasitology	x	x	x	x	x
Blood	x	x	x	x	x
Cancer	x	x	x	x	x
Cardiovascular	x	x	x	x	x
Central Nervous System	x	x	x	x	x
Endocrinology	x	x	x	x	x
Gastrointestinal/Liver	x	x	x	x	x
Genetics	x	x	x	x	x
Immunology/Transplantation	x	x	x	x	x
Metabolism/Diabetes	x	x	x	x	x
Mental/Behavioural Diseases	x	x	x	x	x
Muscle/Bone/Joint	x	x	x	x	x
Reproduction/Pregnancy	x	x	x	x	x
Respiration	x	x	x	x	x
Women's Health	x	x	x	x	x
Vaccines					
Dental					
Surgical	x	x	x	x	x
Geriatric	x	x	x	x	x
Paediatric	x	x	x	x	x
Devices					
Diagnostics	x	x	x	x	x

PRECLINICAL SERVICES: Laboratory Services

ETHICAL REVIEW:

PHASE I SERVICES: Pharmacokinetics - analytical, Pharmacodynamics - analytical, Bioavailability - analytical, Bioequivalence - analytical

PHASE II / III STUDIES: Protocol & CRF Development Laboratory Services, Biometric & Haematological Services

REGULATORY SERVICES:

POST MARKETING SERVICES:

GEOGRAPHY: HPB EMEA

ELEMENTAL RESEARCH INC.

Date established: 1987 Number of clinical investigators:

Contact: Dr. David Gray, Vice President

Address: 309-267 West Esplanade
Vancouver, BC V7M 1A5

Tel: (604) 986-0445

Fax: (604) 986-0071

E-mail: eri@eri-icpms.com

Web site: www.eri-icpms.com

Elemental Research Inc. (ERI) provides advanced analytical services and contract research to the pharmaceutical, biotechnology and medical sectors. ERI performs both method development and validation of unique and routine analysis of clinical samples using advanced inorganic mass spectrometry (ICP-MS), organic mass spectrometry (GC/LC-MS/MS), proprietary laser ablation ICP-MS (for direct solid analysis providing resolution down to 5 μm) and a wide variety of standard analytical methods.

ERI principally focuses on ultra-low level metals analysis in support of pharmacokinetic studies in clinical trials. ICP-MS is applied to the determination of metals in biological fluids and of residual metals at low concentration in small quantities of research peptides. Hydride generation ICP-MS is used to determine specific and critical elements such as Se, Hg, Bi, As, Te, Sb, Sn and Ge when the lowest limits of quantitation are required. Laser ablation ICP-MS, which provides concentration and spatial distribution, is applied in the analysis of biological tissue sections and solid state materials.

ERI's quality assurance unit ensures that projects and programs are conducted under the requirements necessary in the pharmaceutical development, ERI is GMP and GLP compliant as well as IS09002/94 registered.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology					
Blood					
Cancer					
Cardiovascular					
Central Nervous System					
Endocrinology					
Gastrointestinal/Liver					
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes					
Mental/Behavioural Diseases					
Muscle/Bone/Joint					
Reproduction/Pregnancy					
Respiration					
Women's Health					
Vaccines					
Dental					
Surgical					
Geriatric					
Paediatric					
Devices					
Diagnostics					

PRECLINICAL SERVICES: Laboratory Services, Method development/Validation

ETHICAL REVIEW:

PHASE I SERVICES: Method development/Validation, Laboratory Services

PHASE II / III STUDIES: Laboratory Services, Method development/Validation

REGULATORY SERVICES:

POST MARKETING SERVICES:

GEOGRAPHY:

ENDPOINT RESEARCH LTD.

Date established: 1990 Number of clinical investigators:

Contact: Ms. Wendy Porter, President

Address: 5409 Eglinton Ave. W., Ste. 200,
Toronto, ON M9C 5K6

Tel: (416) 626-0299

Fax: (416) 626-2063

E-mail:

Web site: www.endpoint.com

Endpoint Research Ltd. specialises in clinical trial management servicing the pharmaceutical industry. Our clients include multinationals, 3 of whom are within the top 10 ranked pharmaceutical companies in the world, as well as some of the leading doctors, hospitals, and biotechnology firms world-wide. Endpoint Research has experience managing Phase II to Phase IV trials (including pivotal trials to the FDA) with pharmaceuticals including narcotics, biologics and medical devices.

We manage studies in Canada, the United States, Europe and South America on behalf of our clients. Endpoint Research Ltd. is a multilingual Clinical Research Organization based in Toronto, Canada with a branch office in Glasgow, Scotland.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis			x	x	x
Bacteriology/Parasitology			x	x	x
Blood			x	x	x
Cancer		x	x	x	x
Cardiovascular			x	x	x
Central Nervous System			x	x	x
Endocrinology			x	x	x
Gastrointestinal/Liver			x	x	x
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes			x	x	x
Mental/Behavioural Diseases			x	x	x
Muscle/Bone/Joint			x	x	x
Reproduction/Pregnancy			x	x	x
Respiration					
Women's Health			x	x	x
Vaccines		x	x	x	x
Dental			x	x	x
Surgical			x	x	x
Geriatric			x	x	x
Paediatric			x	x	x
Devices	x		x	x	x
Diagnostics					

PRECLINICAL SERVICES:

ETHICAL REVIEW:

PHASE I SERVICES:

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Statistical Services, Data Management and Analysis Quality Assurance & Control

REGULATORY SERVICES: Regulatory Affairs, Document, Manuscript & CANDA Preparation, IND Submission, NDA Submission, Regulatory Consulting

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies

GEOGRAPHY: HPB, FDA MEC

HILL TOP RESEARCH, INC.

Date established: Number of clinical investigators: ~ 10

Contact:	Ms. Wendy Lazer, Branch Manager
Address:	236 Osborne Street, Suite A
	Winnipeg, MB R3L 2W2
Tel:	(204) 453-1835
Fax:	(204) 475-4029
E-mail:	wendy_lazer@hill-top.com
Web site:	www.hill-top.com

Hill Top Research, Inc. is the world's largest consumer product testing company and a leading pharmaceutical clinical research Site Management Organization (SMO). The company provides complete clinical trial services and is a valued partner to hundreds of firms manufacturing such products as pharmaceuticals, medical devices and consumer products.

- **$40+ million in revenue with a track record of profitability**
- **51-year old privately-owned company**
- **Over 30 company-owned clinical research centers and growing**
- **650 employees in North America and Europe**

The Manitoba site does not have a physician on staff, but it contracts with a growing number of MD's who serve as Investigators/consultants. Currently, there are 10 approximately 10 doctors in a wide range of specialities who will consider serving as investigators.

Please, note that all data in the following section describes worldwide capabilities of Hill Top Research, Inc.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology			X	X	X
Blood					
Cancer					
Cardiovascular			X	X	X
Central Nervous System					
Endocrinology			X	X	X
Gastrointestinal/Liver			X	X	X
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes					
Mental/Behavioural Diseases					
Muscle/Bone/Joint					
Reproduction/Pregnancy					
Respiration			X	X	X
Women's Health			X	X	X
Vaccines					
Dental					
Surgical					
Geriatric					
Paediatric					
Devices					
Diagnostics					

PRECLINICAL SERVICES:

ETHICAL REVIEW: Phase II

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Statistical Services, Data Management and Analysis, Drug Dosage & Control, Quality Assurance & Control

REGULATORY SERVICES; Regulatory Affairs, Document, Manuscript & CANDA Preparation, IND Submission, NDA Submission, Regulatory Consulting

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Pharmacoeconomic Studies, Rx-OTC Studies, Consumer Testing Services

GEOGRAPHY: HPB, HPB, EMEA

INNOVUS RESEARCH INC.

Date established: 1984 Number of clinical investigators: 35

Contact: Ms. Lauren Cuddy, President

Address: 1016-A Sutton Drive, Suite 200,
Burlington, ON L7L 6B8

Tel: (905) 331-9911

Fax: (905) 331-9912

E-mail: info@innovus.com

Web site: www.innovus.com

INNOVUS is a provider of research services for the international pharmaceutical, biotechnology and medical device industries. INNOVUS specializes in the management and execution of clinical trials and health economic and outcomes evaluations. Since 1984, INNOVUS has been providing full service support for Phases II, III and IV research. In total, INNOVUS has over 35 in-house researchers.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis			x	x	x
Bacteriology/Parasitology					
Blood					
Cancer			x	x	x
Cardiovascular			x	x	x
Central Nervous System			x	x	x
Endocrinology			x	x	x
Gastrointestinal/Liver			x	x	x
Genetics					
Immunology/Transplantation			x	x	x
Metabolism/Diabetes			x	x	x
Mental/Behavioural Diseases			x	x	x
Muscle/Bone/Joint			x	x	x
Reproduction/Pregnancy			x	x	x
Respiration			x	x	x
Women's Health			x	x	x
Vaccines			x	x	x
Dental					
Surgical			x	x	x
Geriatric			x	x	x
Paediatric			x	x	x
Devices			x	x	x
Diagnostics			x	x	x

PRECLINICAL SERVICES:

ETHICAL REVIEW:

PHASE I SERVICES:

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Statistical Services, Data Management and Analysis

REGULATORY SERVICES:

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies

GEOGRAPHY: HPB

ITR LABORATORIES CANADA INC.

Date established: 1989 Number of clinical investigators:

Contact: Mrs. Ginette Bain, V. P. Administration

Address: 19601 Clark-Graham Blvd., Baie d'Urfé
Montréal, QC H9X 3T1

Tel: (514) 457-7400

Fax: (514) 457-7303

E-mail: itrlab@axcess.com

Web site: www.virtualmarketplace.com/home/itrlabor

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology					
Blood					
Cancer					
Cardiovascular					
Central Nervous System					
Endocrinology					
Gastrointestinal/Liver					
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes					
Mental/Behavioural Diseases					
Muscle/Bone/Joint					
Reproduction/Pregnancy					
Respiration					
Women's Health					
Vaccines					
Dental					
Surgical					
Geriatric					
Paediatric					
Devices					
Diagnostics					

PRECLINICAL SERVICES: Biological & Pharmacological Research, Animal Testing, Laboratory Services, Quality Assurance

ETHICAL REVIEW:

PHASE I SERVICES:

PHASE II / III STUDIES:

REGULATORY SERVICES:

POST MARKETING SERVICES:

GEOGRAPHY:

LAB PRE-CLINICAL RESEARCH INTERNATIONAL INC.

Date established: July 1998 Number of clinical investigators:

Contact: Mr. Leigh Berryman, President

Address: 560 Boulvard Cartier West
Laval, QC H7V 1J1

Tel: (450) 973-2240

Fax: (450) 973-2259

E-mail: businessdevelopment@preclin.com

Web site:

Located on the campus of the University of Quebec, LAB Pre-Clinical Research International Inc. has access to the highest levels of scientific expertise which may be applied to any particular program.

LAB Pre-Clinical Research International Inc.'s animal facility was built in 1995 and consists of more than 7000 m3 of state-of-the-art animal research capability. There are 51 animal rooms divided over 5 modules of which 3 are dedicated rodent/lagomorph modules and 2 are designed to hold large animals such as dogs, pigs and monkeys. All facilities are AAALAC accredited and CCAC approved and operated in accordance with GLP guidelines.

Of particular interest are the certified Biosafety Level 2 and 3 containment suites which enable research to be performed with either highly infectious animal models or immunologically compromised animals (e.g. nude or SCID mice).

Work performed at LAB Pre-Clinical Research International Inc. is focused on early stage drug development and pre-clinical safety evaluation. Early stage drug development includes early efficacy testing or screening of materials for potency in a number of disease states such as Alzheimer's disease, multiple sclerosis, asthma and stroke. With our high housing capacity and level of expertise, the development of animal models is ongoing and further models are continually being added to our capabilities.

LAB Pre-Clinical Research International Inc. also maintains the capability of screening anti-cancer drugs for efficacy using a variety of human cancer cell lines. Cell lines are grown in-vitro and implanted sub-cutaneously into immunodeficient mice. Typical study end points include tumor shrinkage and survivability.

Toxicity studies are also conducted in rats, mice, dogs, rabbits and non-human primates often as part of the requirement for an IND submission in Canada or USA. Common routes of administration include oral (gavage and pill/tablet), intravenous (bolus and infusion), sub-cutaneous and intra-muscular. Such studies are typically 28 days to 26 weeks in duration though studies of longer duration are well within our abilities.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology	x				
Blood					
Cancer	x				
Cardiovascular	x				
Central Nervous System	x				
Endocrinology					
Gastrointestinal/Liver					
Genetics					
Immunology/Transplantation	x				
Metabolism/Diabetes	x				
Mental/Behavioural Diseases					
Muscle/Bone/Joint	x				
Reproduction/Pregnancy					
Respiration					
Women's Health					
Vaccines	x				
Dental					
Surgical	x				
Geriatric					
Paediatric					
Devices					
Diagnostics					

PRECLINICAL SERVICES: Biological & Pharmacological Research, Animal Testing, Laboratory Services

ETHICAL REVIEW:

PHASE I SERVICES:

PHASE II / III STUDIES:

REGULATORY SERVICES:

POST MARKETING SERVICES:

GEOGRAPHY:

McCarthy Consulting Services

Date established: 1981 Number of clinical investigators: N/A

Contact: Mr. David McCarthy, President

Address: 1151 Gorham Street, Unit 8
Newmarket, ON L3Y 7V1

Tel: 905-836-0033

Fax: 905-836-0006

E-mail: mccarthy@mccarthyconsultant.com

Web site: www.mccarthyconsultant.com

Since 1981, the Staff and Associates of McCarthy Consultant Services have provided expert assistance in Canadian Regulatory Affairs and Quality Assurance to the Pharmaceutical, Medical Device, Food, Biotechnology and Cosmetic industries. Services include the preparation of Drug Submissions, (NDS, S/NDS, IND, OTC), Plant and Product Master Files, GMP/ISO/QSR audits against FDA and HPB requirements, Government liaison and trouble shooting, regulatory strategic planning, writing and assessing SOP's, regulatory and GMP training programs, assessing and preparing validation protocols.

Strategic alliances now provide our clients full regulatory access to the USA, the EC, Japan, Australia and the Nordic countries.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology					
Blood					
Cancer					
Cardiovascular					
Central Nervous System					
Endocrinology					
Gastrointestinal/Liver					
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes					
Mental/Behavioural Diseases					
Muscle/Bone/Joint					
Reproduction/Pregnancy					
Respiration					
Women's Health					
Vaccines					
Dental					
Surgical					
Geriatric					
Paediatric					
Devices					
Diagnostics					

PRECLINICAL SERVICES:

ETHICAL REVIEW:

PHASE I SERVICES:

PHASE II / III STUDIES:

REGULATORY SERVICES: Regulatory Affairs, Document, Manuscript & CANDA Preparation, IND Submission, NDA Submission, Regulatory Consulting

POST MARKETING SERVICES:

GEOGRAPHY: HPB, FDA, EMEA, Japan, Australia

McDougall Scientific Ltd.

Date established: 1984 Number of clinical investigators: N/A

Contact: Ms. Janet McDougall, President
Address: 90 Thorncliffe Park Drive
Toronto, ON M4H 1M5
Tel: 416-424-2092
Fax: 416-424-2095
E-mail: mcdougall@mcd-sci.on.ca
Web site: www.mcd-sci.on.ca

McDougall Scientific Limited has provided innovative statistical and data management support to the pharmaceutical and biotechnical research communities since 1984. We not only understand, but consistently keep current, with the complex, dynamic needs of our national and international clients.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology					
Blood					
Cancer					
Cardiovascular					
Central Nervous System					
Endocrinology					
Gastrointestinal/Liver					
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes					
Mental/Behavioural Diseases					
Muscle/Bone/Joint					
Reproduction/Pregnancy					
Respiration					
Women's Health					
Vaccines					
Dental					
Surgical					
Geriatric					
Paediatric					
Devices					
Diagnostics					

PRECLINICAL SERVICES:

ETHICAL REVIEW:

PHASE I SERVICES:

PHASE II / III STUDIES: Protocol & CRF Development, Clinical Trial Design, Statistical Services, Data Management and Analysis

REGULATORY SERVICES:

POST MARKETING SERVICES:

GEOGRAPHY:

PAREXEL INTERNATIONAL

Date established: 1983 Number of clinical investigators:

Contact: Ms. Judy Rubin, Director, Client relations Group

Address: 4263 Sherwoodtowne Blvd., Suite 200,
Mississauga, ON L4Z 1Y5

Tel: (905) 276-8087

Fax: (905) 276-1609

E-mail: judy.rubin@parexel.com

Web site: www.parexel.com

PAREXEL International Corporation is the third largest Contract Research, Medical Marketing and Consulting Services Organization in the world, providing customized, integrated and expertise-based Product Development and Launch Services to the international pharmaceutical, biotechnology and medical device industries. Over the past 16 years, PAREXEL has developed significant expertise' in clinical trials management, data management, biostatistical analysis, regulatory and medical affairs consulting, medical writing, health economics, medical marketing, clinical pharmacology, industry training and publishing, and other drug development consulting services. Headquartered near Boston, MA, PAREXEL has over 45 offices located throughout the world, with staff on the ground in over 25 countries. Our clients can thus be assured of local service and world class knowledge and expertise.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis			x	x	x
Bacteriology/Parasitology			x	x	x
Blood			x	x	x
Cancer			x	x	x
Cardiovascular			x	x	x
Central Nervous System			x	x	x
Endocrinology			x	x	x
Gastrointestinal/Liver			x	x	x
Genetics			x	x	x
Immunology/Transplantation			x	x	x
Metabolism/Diabetes			x	x	x
Mental/Behavioural Diseases			x	x	x
Muscle/Bone/Joint			x	x	x
Reproduction/Pregnancy			x	x	x
Respiration			x	x	x
Women's Health			x	x	x
Vaccines			x	x	x
Dental			x	x	x
Surgical			x	x	x
Geriatric			x	x	x
Paediatric			x	x	x
Devices			x	x	x
Diagnostics			x	x	x

PRECLINICAL SERVICES:

ETHICAL REVIEW:

PHASE I SERVICES:

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Biometric & Haematological Services

REGULATORY SERVICES: Regulatory Affairs, Document, Manuscript & CANDA Preparation, IND Submission, NDA Submission, Regulatory Consulting

POST MARKETING SERVICES:

GEOGRAPHY: HPB, FDA, EMEA

PHARMA MEDICA RESEARCH INC.

Date established: 1997 Number of clinical investigators:

Contact: Dr. Ian W. French, President and COO

Address: 966 Pantera Drive, Unit 31
Mississauga, ON L4W 2S1

Tel: (905) 624-9115

Fax: (905) 624-4433

E-mail: ifrench@pharmamedica.com

Web site: www.pharmamedica.com

Pharma Medical is an Ontario-based, contract research organization (CRO) that provides pharmaceutical research services to the pharmaceutical, biotechnology and medical device industries. In response to the rapidly expanding demands of the pharmaceutical and biotechnology industries, Pharma Medica has assembled a distinguished team of research specialists to provide a complete array of clinical and regulatory services to its clients. The company had several facilities in Greater Toronto Region, including:

- **Mississauga - In addition to its administrative offices at this location, Pharma Medica has a 10,000 sq. ft. bio-analytical laboratory, complete with state-of-the-art HPLC and LC/MS equipment**
- **Scarborough - The company has a 25,000 sq. ft. facility located in Scarborough area of Toronto. This facility also has 3 independent clinics with a capacity of 150 beds**

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis		x	x	x	x
Bacteriology/Parasitology					
Blood					
Cancer			x	x	
Cardiovascular		x	x	x	x
Central Nervous System		x	x	x	
Endocrinology		x	x	x	x
Gastrointestinal/Liver		x	x	x	x
Genetics					
Immunology/Transplantation				x	
Metabolism/Diabetes		x	x	x	x
Mental/Behavioural Diseases					
Muscle/Bone/Joint		x	x	x	x
Reproduction/Pregnancy					
Respiration					
Women's Health					
Vaccines					
Dental					
Surgical					
Geriatric		x		x	
Paediatric					
Devices		x	x	x	
Diagnostics		x		x	

PRECLINICAL SERVICES:

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Biometric & Haematological Services, Statistical Services, Data Management and Analysis, Drug Dosage & Control, Quality Assurance & Control

REGULATORY SERVICES: Regulatory Affairs, Document, Manuscript & CANDA Preparation, IND Submission, NDA Submission, Regulatory Consulting

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies, Rx-OTC Studies

GEOGRAPHY: HPB, FDA, EMEA

PHOENIX INTERNATIONAL LIFE SCIENCES INC.

Date established: 1989 Number of clinical investigators: 10,000

Contact: Dr. Amine Yacine, Senior Director, Medical and Scientific Affairs

Address: 4800 Dobrin
Montreal, QC H4R 2P8

Tel: (514) 333-0042

Fax: (514) 335-8328

E-mail: yacinea@pils.com

Web site:

Phoenix International is a multidisciplinary contract research organization (CRO) serving the pharmaceutical, biotechnology, and generic drug industries. Founded in Montreal in 1989 by a group of 20 scientists led by Dr. John Hooper, Phoenix International's headquarters are located in Montreal, Quebec. The company is present in 13 countries including Canada, the United States, major European countries, South Africa, Israel, and Australia. Over 2,000 people make up its experienced and highly qualified workforce.

Phoenix International gained recognition within the past decade as the world's leading Phase I and bioanalytical CRO, and currently ranks as the fifth largest CRO in the world

Phoenix International provides world-scale services in all drug development phases, from discovery through preclinical and clinical studies to registration for marketing. Its full range of specialized services includes: Drug Discovery Support/Preclinical Services; Bioanalytical Services, Biomedical Services, Immunochemistry and Cell-based Assay Services, Phase I Clinical Studies, Phase II-IV Clinical Research, Clinical Data Management.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology					
Blood			x		
Cancer			x	x	
Cardiovascular		x	x	x	x
Central Nervous System				x	
Endocrinology		x		x	x
Gastrointestinal/Liver		x		x	x
Genetics					
Immunology/Transplantation					x
Metabolism/Diabetes		x		x	
Mental/Behavioural Diseases				x	
Muscle/Bone/Joint			x	x	
Reproduction/Pregnancy					
Respiration			x	x	x
Women's Health		x		x	x
Vaccines		x			
Dental		x			
Surgical					
Geriatric		x			
Paediatric					
Devices					
Diagnostics					

PRECLINICAL SERVICES: Medicinal & Organic Chemistry, Biological & Pharmacological Research, Animal Testing, Laboratory Services, Quality Assurance

ETHICAL REVIEW: Phase I, Phase II/III

PHASE I SERVICES: First Time in Man Studies, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence

PHASE II / III STUDIES: Project Management, Protocol & CRF Development, Clinical Trial Design, Clinical Packaging & Supplies, Clinical Trials Monitoring, Investigative Site Selection & Management, Patient Recruitment, Laboratory Services, Biometric & Haematological Services Data Management and Analysis Quality Assurance & Control

REGULATORY SERVICES: Document, Manuscript & CANDA Preparation, IND Submission, NDA Submission, Regulatory Consulting

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies, Rx-OTC Studies, Consumer Testing Services

GEOGRAPHY: HPB, FDA, EMEA (through UK office)

PROBITY MEDICAL RESEARCH

Date established: 1992

Number of clinical investigators: 25

Contact:	Dr. Kim Papp, President
Address:	30 Union Street East
	Waterloo, ON N2J 1B7
Tel:	(519) 579-9535
Fax:	(519) 579-8312
E-mail:	kimpapp@netscape.net
Web site:	

Probity Medical Research began conducting clinical trials in 1992. Dr. Kim Papp, MD, PhD, FRCPC, MACP, DABD, the president of the company, has since conducted over 50 clinical trials. The company now contracts physicians to conduct studies in a wide variety of therapeutic areas. Probity has several sites set up to conduct clinical trials and is growing rapidly as the need for efficient clinical trial centres grows. All our sites are fully equipped to handle the conduct of clinical trials and are staffed by experienced clinical trial co-ordinators. Our- headquarters in Waterloo, Ontario handles processing of all regulatory documentation to accelerate the initiation of new clinical trials. Our sites use a central IR Board that follows ICH and FDA guidelines and meets frequently.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis			x	x	x
Bacteriology/Parasitology			x	x	x
Blood					
Cancer					
Cardiovascular			x	x	x
Central Nervous System			x	x	
Endocrinology			x	x	x
Gastrointestinal/Liver			x	x	x
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes			x	x	x
Mental/Behavioural Diseases			x	x	x
Muscle/Bone/Joint				x	x
Reproduction/Pregnancy				x	x
Respiration			x	x	x
Women's Health				x	x
Vaccines		x	x	x	x
Dental					
Surgical				x	x
Geriatric				x	x
Paediatric				x	x
Devices					
Diagnostics					

PRECLINICAL SERVICES:

ETHICAL REVIEW:

PHASE I SERVICES: First Time in Man Studies

PHASE II / III STUDIES: Protocol & CRF Development, Clinical Trial Design, Investigative Site Selection & Management, Patient Recruitment

REGULATORY SERVICES:

POST MARKETING SERVICES:

GEOGRAPHY: HPB, FDA

R.J.A. MEDICENTRES CANADA INC.

Date established: 1992 Number of clinical investigators: 12

Contact: Dr. D. McCarty, Associate Director, Clinical Research
Address: c/o Belvedere Medicentre, 12720 66 Street
Edmonton, AB T5C 0A3
Tel: (780) 473-5202
Fax: (780) 478-7271
E-mail: research@mdeicentres.com
Web site: www.medicentres.com

Medicentres Clinical Research, established in 1992 has successfully participated in over 40 phase III and IV trials.

Medicentres is a network of primary health care clinics and its large patient base provides recruitment potential for many therapeutic areas. The experienced research team of investigators and nurses take pride in the quality of the data they collect and ensure adherence to GGP and ICH guidelines, in compliance with regulatory agencies requirements.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis				x	x
Bacteriology/Parasitology					
Blood					
Cancer					
Cardiovascular				x	x
Central Nervous System				x	
Endocrinology				x	x
Gastrointestinal/Liver			x	x	
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes				x	x
Mental/Behavioural Diseases					
Muscle/Bone/Joint				x	x
Reproduction/Pregnancy				x	x
Respiration				x	x
Women's Health				x	x
Vaccines					
Dental					
Surgical					
Geriatric					
Paediatric					
Devices				x	x
Diagnostics					

PRECLINICAL SERVICES:

ETHICAL REVIEW:

PHASE I SERVICES:

PHASE II / III STUDIES: Patient Recruitment

REGULATORY SERVICES:

POST MARKETING SERVICES: Outcome Measurement Services, Pharmacoeconomic Studies, Quality of Life Studies, Rx-OTC Studies

GEOGRAPHY: HPB, FDA

RANDY STROUD CONSULTING INC.

Date established:

Number of clinical investigators:

Contact: Dr. Randy Stroud, President
Address: 72 Merkley Square
Scarborough, ON M1G 2Y7
Tel: 416-439-4434
Fax: 416-439-4435
E-mail:
Web site:

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology					
Blood					
Cancer					
Cardiovascular					
Central Nervous System					
Endocrinology					
Gastrointestinal/Liver					
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes					
Mental/Behavioural Diseases					
Muscle/Bone/Joint					
Reproduction/Pregnancy					
Respiration					
Women's Health					
Vaccines					
Dental					
Surgical					
Geriatric					
Paediatric					
Devices					
Diagnostics					

PRECLINICAL SERVICES:

ETHICAL REVIEW:

PHASE I SERVICES:

PHASE II / III STUDIES: Drug Dosage & Control, Quality Assurance & Control

REGULATORY SERVICES: Regulatory Affairs, Document, Manuscript & CANDA Preparation, IND Submission, NDA Submission, Regulatory Consulting

POST MARKETING SERVICES:

GEOGRAPHY: HPB

TRAFALGAR ETHICS BOARD INC.

Date established:	**Number of clinical investigators:**
Contact:	Mr. Tom Ekers, President
Address:	1235 Trafalgar Road North, Suite 405
	Oakville, ON L6H 3P1
Tel:	(905) 338-1078
Fax:	(905) 338-0054
E-mail:	tekars@cmxres.com
Web site:	

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis					
Bacteriology/Parasitology					
Blood					
Cancer					
Cardiovascular					
Central Nervous System					
Endocrinology					
Gastrointestinal/Liver					
Genetics					
Immunology/Transplantation					
Metabolism/Diabetes					
Mental/Behavioural Diseases					
Muscle/Bone/Joint					
Reproduction/Pregnancy					
Respiration					
Women's Health					
Vaccines					
Dental					
Surgical					
Geriatric					
Paediatric					
Devices					
Diagnostics					

PRECLINICAL SERVICES:

ETHICAL REVIEW: Phase II/III

PHASE I SERVICES:

PHASE II / III STUDIES:

REGULATORY SERVICES:

POST MARKETING SERVICES:

GEOGRAPHY:

TRIAL MANAGEMENT GROUP INC.

Date established: 1995 Number of clinical investigators: 135

Contact: Mr. John C. Akitt, President
Address: 35 Waterman Ave., Suite 19,
London, ON N6C 5T3
Tel: (519) 685-3840
Fax: (519) 685-2298
E-mail: john@tmginvestigators.com
Web site: www.tmginvestigators.com

Trial Management Group Inc. is a company formed four years ago to take advantage of inefficiencies in the conduct of phase III and phase IV clinical trials, and to actively promote the participation of primary care physicians in medical research. TMG does this by acting as agents, and as a central administration center, for general and family practitioners who have an interest and a commitment to conducting research in new drug trials. By promoting the quality and accessibility of the network, and monitoring the patient demographics of each physicians' practice, we can provide for the manufacturers' needs of lower costs and fast, reliable, and convenient investigator recruitment nation-wide. TMG is truly a national network of physicians: with investigators in Newfoundland, PEI, New Brunswick, Nova Scotia, Qu6bec, Ontario, Saskatchewan, Alberta and BC, TMG has 60 sites and 135 clinical investigators.

THERAPEUTIC AREAS

Area of Research /Stage of Research	Pre-clinical	Phase I	Phase II	Phase III	Phase IV
Arthritis			x	x	x
Bacteriology/Parasitology			x	x	x
Blood				x	x
Cancer					
Cardiovascular			x	x	x
Central Nervous System			x	x	
Endocrinology			x	x	x
Gastrointestinal/Liver			x	x	x
Genetics			x	x	x
Immunology/Transplantation					
Metabolism/Diabetes			x	x	x
Mental/Behavioural Diseases			x	x	x
Muscle/Bone/Joint			x	x	x
Reproduction/Pregnancy			x	x	x
Respiration			x	x	x
Women's Health			x	x	x
Vaccines			x	x	x
Dental					
Surgical					
Geriatric			x	x	x
Paediatric			x	x	x
Devices			x	x	x
Diagnostics			x	x	x

PRECLINICAL SERVICES: Quality Assurance

ETHICAL REVIEW: Phase II/III

PHASE I SERVICES:

PHASE II / III STUDIES: Project Management, Investigative Site Selection & Management, Patient Recruitment Quality Assurance & Control

REGULATORY SERVICES:

POST MARKETING SERVICES: Pharmacoeconomic Studies, Quality of Life Studies, Rx-OTC Studies, Consumer Testing Services

GEOGRAPHY: HPB, FDA

BioTools Inc.

Date established: September 1995 Number of employees: 20

Contact: Mr. Victor Dorian
Manager, MRD Project
Address: 420 Sun Life Place, 10123 - 99 Street
Edmonton
AB T5J 3H1
Tel: (780) 423-1133
Fax: (780) 423-1333
E-mail: dorianv@biotools.com
Web site: www.biotools.com

THERAPEUTIC AREAS

PRODUCT TYPES

BIOLOGICAL/CHEMICAL ANALYSIS

DRUG DEVELOPMENT

MANUFACTURING

DOSAGE FORMS

PACKAGING

BIOVAIL CONTRACT RESEARCH

Date established: 1989

Number of employees: 187

Contact: Dr. David MacDonald
Assistant General Manager
Address: 460 Comstock Road
Toronto
ON
Tel: (416) 752-3636
Fax: (416) 752-7610
E-mail:
Web site:

THERAPEUTIC AREAS

PRODUCT TYPES

BIOLOGICAL/CHEMICAL ANALYSIS
Pharmacokinetics
Pharmacokinetics
Method Development

DRUG DEVELOPMENT

MANUFACTURING

DOSAGE FORMS

PACKAGING

BODYCOTE ORTECH INC.

Date established: 1928 Number of employees: 215 (Canada)

Contact: Dr. Richard G. McKeag
Business Development Manager
Address: 2395 Speakman Dr., Sheridan Park
Mississauga
ON L5K 1B3
Tel: (905) 822-4111
Fax: (905) 823-1446
E-mail: mckeag.r@bodycote-mt.com
Web site: www.bodycote-mt.com

THERAPEUTIC AREAS

PRODUCT TYPES

BIOLOGICAL/CHEMICAL ANALYSIS

DRUG DEVELOPMENT

Formulation Development
Pilot Scale Production
Analytical Testing

MANUFACTURING

DOSAGE FORMS

Granules
Powders
Dispersible Powders
Hard Capsules
Chewables
Tablets
Effervescent Tablets
Liquids/Solutions
Suspensions/Emulsions
Lotions
Syrups
Creams/Oitments/Gels
Emulsifiable Concentrates
Controlled Release Formulations

PACKAGING

DIAGNOSTIC CHEMICALS LIMITED

Date established: 1970

Number of employees: 37

Contact: Dr. Regis Duffy
President
Address: 16 McCarville Street
Charlottetown
PE C1E 2A6
Tel: (902) 566-1396
Fax: (902) 566-2498
E-mail: rduffy@dclchem.com
Web site: www.dclchem.com

THERAPEUTIC AREAS

PRODUCT TYPES
Diagnostics

BIOLOGICAL/CHEMICAL ANALYSIS
Biochemistry - Blood
Biochemistry - Urine
Virology
Method Development

DRUG DEVELOPMENT
Pilot Scale Production
Scale-up Production
Chemical Synthesis
Intermediate Synthesis
Analytical Testing

MANUFACTURING
Prescription Products
Process Development

DOSAGE FORMS

PACKAGING

DiLAN CLINCAL PACKAGING LIMITED.

Date established: May 1994 Number of employees: 12

Contact:	Mr. Terry Dixon
	President
Address:	385 Admiral Blvd., Unit 5,
	Mississauga
	ON L5T 2M8
Tel:	(905) 564-2131
Fax:	(905) 564-2132
E-mail:	tdixon@dilancp.com
Web site:	www.dilancp.com

THERAPEUTIC AREAS

PRODUCT TYPES
Prescription Pharmaceuticals
OTC Products
Biologicals/Vaccines/Biotech

BIOLOGICAL/CHEMICAL ANALYSIS

DRUG DEVELOPMENT
Clinical Trial Supply Packaging

MANUFACTURING

DOSAGE FORMS

PACKAGING
Bottles
Syringes
Capsules
Pumps/Sprays
Pots
Tubes
Sachets
Blister Packs
Dispenser Packs
Ampoules/Vials

GELDA SCIENTIFIC & INDUST. DEV. CORP.

Date established: February 28, 1978 Number of employees: 2

Contact: Mr. Arvino Gelda
Address: 6320 Northwest Dr.,
Mississauga
ON L4V 1J7
Tel: (905) 673-9320
Fax: (905) 673-8114
E-mail: gelda@globalserve.net
Web site: www.gelda.com

THERAPEUTIC AREAS

PRODUCT TYPES
Prescription Pharmaceuticals
OTC Products

BIOLOGICAL/CHEMICAL ANALYSIS
Microbiology
Method Development

DRUG DEVELOPMENT
Formulation Development
Pilot Scale Production
Scale-up Production
Analytical Testing
Warehousing
Distribution

MANUFACTURING
OTC Products
Process Development

DOSAGE FORMS
Powders
Hard Capsules
Soft Capsules
Tablets
Coated Tablets
Sterile Manufacture

PACKAGING
Bottles
Capsules

GENEKA BIOTECHNOLOGY INC.

Date established: August 1996 Number of employees:

Contact:	Dr. Rino N. Camato
	President
Address:	5445 Delorimier Dr., Ste. 401,
	Montréal
	QC H2H 2S5
Tel:	(514) 528-9233
Fax:	(514) 528-9225
E-mail:	leblanc@geneka.com
Web site:	www.geneka.com

THERAPEUTIC AREAS
Cancer
Cardiovascular
Endocrinology
Genetics
Immunology

PRODUCT TYPES
Biologicals/Vaccines/Biotech

BIOLOGICAL/CHEMICAL ANALYSIS
Immunology/Antibody Screens
Method Development
Product Analysis

DRUG DEVELOPMENT

MANUFACTURING

DOSAGE FORMS

PACKAGING

KGK SYNERGIZE INC.

Date established: May 1997 Number of employees: 17

Contact: Ms. Najla Guthrie
President/CEO
Address: 100 Collip Circle, Suite 130,
The University of Western Ontario Research Park
London
ON N6G 4X8
Tel: (519) 858-5044
Fax: (519) 858-5197
E-mail: nguthrie@julian.uwo.ca
Web site:

THERAPEUTIC AREAS
Arthritis
Blood
Cancer
Cardiovascular

PACKAGING
Bottles
Capsules
Pumps/Sprays

PRODUCT TYPES
Prescription Pharmaceuticals
OTC Products
Biologicals/Vaccines/Biotech

BIOLOGICAL/CHEMICAL ANALYSIS
Biochemistry - Blood
Histology
Pharmacokinetics
Pharmacokinetics
Method Development
Animal Toxicology Analysis
Product Analysis

DRUG DEVELOPMENT
Formulation Development
Chemical Synthesis
Analytical Testing

MANUFACTURING
Process Development

DOSAGE FORMS
Soft Capsules
Chewables
Tablets
Effervescent Tablets
Liquids/Solutions
Suspensions/Emulsions
Lotions
Creams/Oitments/Gels

MDS Clinical Trial Laboratories

Date established: 1992 Number of employees: 200

Contact: Mr. Hugh Crosthwait
Vice President and General Manager
Address: 100 International Blvd.
Toronto
ON M9W 6J6
Tel: (416) 213-4671
Fax: (416) 213-2480
E-mail: hcrosthwait@mdsctl.com
Web site: www.mdsintl.com

THERAPEUTIC AREAS
Bacteriology/Parasitology
Blood
Cancer
Cardiovascular
CNS
Gastrointestinal/Liver
Endocrinology
Genetics
Immunology/Transplantation
Metabolism/Diabetes
Mental/Behavioural Diseases
Muscle/Bone/Joint

PRODUCT TYPES
Prescription Pharmaceuticals
Biologicals/Vaccines/Biotech

BIOLOGICAL/CHEMICAL ANALYSIS
Haematology
Clotting Factors
Biochemistry - Blood
Biochemistry - Urine
Endocrinology
MicrobiologyVirology
CytologyHistology
Immunology/Antibody Screens
Allergy
Blood Typing
Genotyping
Method Development

DRUG DEVELOPMENT
Analytical Testing
Some warehousing
Some distribution

MANUFACTURING

DOSAGE FORMS

PACKAGING

MDS NEO-PHARM

Date established: 1990 Number of employees: 145

Contact: Mr. Gilbert Godin
VP, General Manager
Address: 865 Bouievard Michèle-Bohel,
Blainville
QC J7C 5J6
Tel: (450) 435-2425
Fax: (450) 435-7595
E-mail:
Web site: neopharm.com

THERAPEUTIC AREAS

PRODUCT TYPES

BIOLOGICAL/CHEMICAL ANALYSIS
Bio-analysis - Blood
Bio-analysis - Urine
Microbiology
Method Development
Product Analysis

DRUG DEVELOPMENT
Analytical Testing

MANUFACTURING

DOSAGE FORMS

PACKAGING

PBR LABORATORIES INC.

Date established: 1984

Number of employees: 8

Contact:	Dr. Rajan Gupta
	Director
Address:	4290-91 A Street
	Edmonton
	AB T6E 5V2
Tel:	(403) 450-3957
Fax:	(403) 450-3960
E-mail:	pbr@canet.com
Web site:	www.ispex.ca/pbr

THERAPEUTIC AREAS

Blood
Cardiovascular
Endocrinology
Genetics
Immunology/Transplantation
Mental/Behavioural Diseases
Reproduction/Pregnancy

PRODUCT TYPES

Diagnostics

BIOLOGICAL/CHEMICAL ANALYSIS

Biochemistry - Blood
Biochemistry - Urine
Endocrinology
Immunology/Antibody Screens
Pharmacokinetics
Pharmacokinetics
Method Development
Animal Toxicology Analysis
Product Analysis

DRUG DEVELOPMENT

Analytical Testing

MANUFACTURING

DOSAGE FORMS

PACKAGING

PROMETIC PHARMA INC.

Date established: 1994

Number of employees:

Contact: Mr. Pierre Laurin
CEO
Address: 6100 Royalmount Avenue
Montréal
QC H4P 2R2
Tel: (514) 496-2115
Fax: (514) 496-2079
E-mail: Plaurin@prometric.com
Web site:

THERAPEUTIC AREAS
Arthritis
Blood
Cancer
Gastrointestinal/Liver
Immunology/Transplantation

PRODUCT TYPES
Prescription Pharmaceuticals
OTC Products
Biologicals/Vaccines/Biotech
Devices

BIOLOGICAL/CHEMICAL ANALYSIS

DRUG DEVELOPMENT
Formulation Development
Pilot Scale Production
Scale-up Production
Clinical Trial Supply Manufacturing
Clinical Trial Supply Packaging
Packaging Development
Chemical Synthesis
Dosage Form Manufacture
Analytical Testing
Packaging-Finished Product
Printing/LabellingWarehousing
Distribution

MANUFACTURING
Prescription Products
OTC Products
Cosmetics/Toiletries
Controlled Release Formulations
Galenic Development
Process Development

DOSAGE FORMS
Powders
Dispersible Powders
Liquids/Solutions
Suspensions/Emulsions
Lotions
Syrups
Creams/Oitments/Gels
Emulsifiable Concentrates
Controlled Release Formulations
Syringes
Sterile Manufacture

PACKAGING
Bottles
Syringes
Pumps/Sprays
Pots
Tubes
Ampoules/Vials

RAYLO CHEMICALS INC.

Date established: 1963 Number of employees: 180

Contact:	Mr. Greg Klak
	Commercial Manager
Address:	8045 Argyll Rd.
	Edmonton
	AB T6C 4A9
Tel:	(780) 468-6060
Fax:	(780) 468-4784
E-mail:	g_klak.raylo@laporteplc.com
Web site:	www.laporteplc.com

THERAPEUTIC AREAS

PRODUCT TYPES

BIOLOGICAL/CHEMICAL ANALYSIS

DRUG DEVELOPMENT
Pilot Scale Production
Scale-up Production
Clinical Trial Supply Manufacturing
Chemical Synthesis
Intermediate Synthesis
Analytical Testing

MANUFACTURING
Process Development

DOSAGE FORMS

PACKAGING

SAFETY TESTING SERVICES INC.

Date established: August 1996 Number of employees: 2

Contact:	Dr. Barry Osborne
	President
Address:	2639 Place Belmont
	St-Lazare
	QC J7T 2A1
Tel:	(450) 458-1837
Fax:	(450) 458-4137
E-mail:	toxozzy@consult-toxicology.com
Web site:	consult-toxicology.com

THERAPEUTIC AREAS

Blood
Cancer
Cardiovascular
CNS
Gastrointestinal/Liver
Endocrinology
Immunology/Transplantation
Muscle/Bone/Joint
Reproduction/Pregnancy

PRODUCT TYPES

BIOLOGICAL/CHEMICAL ANALYSIS

Animal Toxicology Analysis

DRUG DEVELOPMENT

MANUFACTURING

DOSAGE FORMS

PACKAGING

TORCAN CHEMICAL LTD.

Date established: 1980 Number of employees:

Contact: Dr. Jan Oudenes
President
Address: P.O. Box 308, 110 Industrial Pkwy, N.,
Aurora
ON L4G 3H4
Tel: (905) 727-9417
Fax: (905) 727-7545
E-mail: torcan@istar.ca
Web site: www.torcanchemical.on.ca

THERAPEUTIC AREAS

PRODUCT TYPES

BIOLOGICAL/CHEMICAL ANALYSIS

DRUG DEVELOPMENT
Pilot Scale Production
Scale-up Production
Clinical Trial Supply Manufacturing
Chemical Synthesis
Intermediate Synthesis
Analytical Testing

MANUFACTURING
Process Development

DOSAGE FORMS

PACKAGING

TORONTO RESEARCH CHEMICALS INC.

Date established: 1982

Number of employees:

Contact: Dr. David Dime
President
Address: 2 Brisbane Road
Toronto
ON M3J 2J8
Tel: (416) 665-9696
Fax: (416) 665-4439
E-mail: torresch@interlog.com
Web site: www.trc-canada.com

THERAPEUTIC AREAS
Cancer
Cardiovascular

PRODUCT TYPES
Diagnostics

BIOLOGICAL/CHEMICAL ANALYSIS

DRUG DEVELOPMENT
Pilot Scale Production
Chemical Synthesis
Intermediate Synthesis

MANUFACTURING
Process Development

DOSAGE FORMS

PACKAGING

Therapeutic Areas

ARTHRITIS

Sites

Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre hospitalier de l'université de Montréal (CHUM)
Clinical Epidemiology Unit, Loeb Health Research Institute
Hamilton Health Sciences Corporation
Health Sciences Centre
Hospital for Sick Children
Institut universitaire de gériatrie de Montréal
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
Loeb Health Research Institute (Ottawa Civic Hospital)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Queen Elizabeth II Health Sciences Centre
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's

Allied Clinical Research Inc.
Anapharm Inc.
Cantox Health Sciences International
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CMX Research Inc.
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Kasper Medical Labs
Endpoint Research Ltd.
Innovus Research Inc.
Parexel International
Pharma Medica Research Inc.
Probity Medical Research
R.J.A. Medicentres Canada Inc.
Trial Management Group Inc.

BACTERIOLOGY / PARASITOLOGY

Sites

Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Canadian Bacterial Diseases Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre hospitalier de l'université de Montréal (CHUM)
Child Health Research Unit (CHRU), Alberta Children's Hospital
Hamilton Health Sciences Corporation
Hôpital Laval
Hospital for Sick Children
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Queen Elizabeth II Health Sciences Centre
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital
St. Joseph's Hospital
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's

Allied Clinical Research Inc.
Anapharm Inc.
Cantox Health Sciences International
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Kasper Medical Labs
Endpoint Research Ltd.
Hill Top Research, Inc.
LAB Pre-Clinical Research International Inc.
Parexel International
Probity Medical Research
Trial Management Group Inc.

BLOOD

Sites

Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre hospitalier de l'université de Montréal (CHUM)
Clinical Epidemiology Unit, Loeb Health Research Institute
Clinical Research Institute of Montreal (IRCM)
Hamilton Health Sciences Corporation
Hospital for Sick Children
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Leukemia / Bone Marrow Transplant Program of British Columbia
Loeb Health Research Institute (Ottawa Civic Hospital)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Queen Elizabeth II Health Sciences Centre
St. Boniface General Hospital
St. Joseph's Hospital
Terry Fox Laboratory
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's

Allied Clinical Research Inc.
Anapharm Inc.
Cantox Health Sciences International
Cato Research Canada
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Kasper Medical Labs
Endpoint Research Ltd.
Parexel International
Phoenix International Life Sciences Inc.
Trial Management Group Inc.

CANCER

Sites

Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre hospitalier de l'université de Montréal (CHUM)
Clinical Epidemiology Unit, Loeb Health Research Institute
Clinical Research Institute of Montreal (IRCM)
Cross Cancer Institute
Hamilton Health Sciences Corporation
Hamilton Regional Cancer Centre
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Leukemia / Bone Marrow Transplant Program of British Columbia
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Queen Elizabeth II Health Sciences Centre
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
Terry Fox Laboratory
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's

Allied Clinical Research Inc.
Anapharm Inc.
Cantox Health Sciences International
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CMX Research Inc.
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Kasper Medical Labs
Endpoint Research Ltd.
Innovus Research Inc.
LAB Pre-Clinical Research International Inc.
Parexel International
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.

CARDIOVASCULAR

Sites

Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Cardiovascular Research Lab., UBC
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre hospitalier de l'université de Montréal (CHUM)
Clinical Epidemiology Unit, Loeb Health Research Institute
Clinical Research Institute of Montreal (IRCM)
Hamilton Health Sciences Corporation
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Queen Elizabeth II Health Sciences Centre
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's

Allied Clinical Research Inc.
Anapharm Inc.
Cantox Health Sciences International
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CMX Research Inc.
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Kasper Medical Labs
Endpoint Research Ltd.
Hill Top Research, Inc.
Innovus Research Inc.
LAB Pre-Clinical Research International Inc.
Parexel International
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.
Probity Medical Research
R.J.A. Medicentres Canada Inc.
Trial Management Group Inc.

CENTRAL NERVOUS SYSTEM

Sites

Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre de Recherche Philippe Pinel de Montréal
Centre for Research in Neurodegenerative Diseases (CRND)
Centre hospitalier de l'université de Montréal (CHUM)
Clinical Epidemiology Unit, Loeb Health Research Institute
Clinical Research Institute of Montreal (IRCM)
Douglas Hospital Research Centre
Hamilton Health Sciences Corporation
Health Sciences Centre
Hospital for Sick Children
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Loeb Health Research Institute (Ottawa Civic Hospital)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Queen Elizabeth II Health Sciences Centre
St. Boniface General Hospital
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
Surrey Place Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's

Allied Clinical Research Inc.
Anapharm Inc.
Cantox Health Sciences International
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CMX Research Inc.
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Kasper Medical Labs
Endpoint Research Ltd.
Innovus Research Inc.
LAB Pre-Clinical Research International Inc.
Parexel International
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.
Probity Medical Research
R.J.A. Medicentres Canada Inc.
Trial Management Group Inc.

ENDOCRINOLOGY

Sites

Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre hospitalier de l'université de Montréal (CHUM)
Hamilton Health Sciences Corporation
Health Sciences Centre
Hospital for Sick Children
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
Loeb Health Research Institute (Ottawa Civic Hospital)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Queen Elizabeth II Health Sciences Centre
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's

Allied Clinical Research Inc.
Anapharm Inc.
Cantox Health Sciences International
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CMX Research Inc.
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Kasper Medical Labs
Endpoint Research Ltd.
Hill Top Research, Inc.
Innovus Research Inc.
Parexel International
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.
Probity Medical Research
R.J.A. Medicentres Canada Inc.
Trial Management Group Inc.

GASTROINTESTINAL / LIVER

Sites

Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre hospitalier de l'université de Montréal (CHUM)
Hamilton Health Sciences Corporation
Health Sciences Centre
Hospital for Sick Children
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Queen Elizabeth II Health Sciences Centre
Queen's University GI Diseases Research Unit (GIDRU)
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's

Allied Clinical Research Inc.
Anapharm Inc.
Cantox Health Sciences International
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Kasper Medical Labs
Endpoint Research Ltd.
Hill Top Research, Inc.
Innovus Research Inc.
Parexel International
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.
Probity Medical Research
R.J.A. Medicentres Canada Inc.
Trial Management Group Inc.

GENETICS

Sites

Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre for Research in Neurodegenerative Diseases (CRND)
Centre hospitalier de l'université de Montréal (CHUM)
Clinical Research Institute of Montreal (IRCM)
Cross Cancer Institute
Hamilton Health Sciences Corporation
Hospital for Sick Children
Institut de Cardiologie de Montréal
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
Sunnybrook & Women's College Health Sciences Centre
Surrey Place Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's

Allied Clinical Research Inc.
Cantox Health Sciences International
Clinimetrics Research Associates Inc.
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Kasper Medical Labs
Parexel International
Trial Management Group Inc.

IMMUNOLOGY / TRANSPLANTATION

Sites

Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre hospitalier de l'université de Montréal (CHUM)
Clinical Research Institute of Montreal (IRCM)
Hamilton Health Sciences Corporation
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Izaak W. Killan & Grace Health Science Centre
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Queen Elizabeth II Health Sciences Centre
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's

Allied Clinical Research Inc.
Anapharm Inc.
Cantox Health Sciences International
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Kasper Medical Labs
Innovus Research Inc.
LAB Pre-Clinical Research International Inc.
Parexel International
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.

MENTAL / BEHAVIOURAL DISEASES

Sites

Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre de Recherche Philippe Pinel de Montréal
Centre for Research in Neurodegenerative Diseases (CRND)
Centre hospitalier de l'université de Montréal (CHUM)
Douglas Hospital Research Centre
Hamilton Health Sciences Corporation
Health Sciences Centre
Hospital for Sick Children
Institut universitaire de gériatrie de Montréal
Institute of Mental Health Research, Royal Ottawa Health Care Group
Izaak W. Killan & Grace Health Science Centre
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Queen Elizabeth II Health Sciences Centre
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
Surrey Place Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's

Allied Clinical Research Inc.
Anapharm Inc.
Cantox Health Sciences International
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CMX Research Inc.
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Kasper Medical Labs
Endpoint Research Ltd.
Innovus Research Inc.
Parexel International
Phoenix International Life Sciences Inc.
Probity Medical Research
Trial Management Group Inc.

METABOLISM / DIABETES

Sites

Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre hospitalier de l'université de Montréal (CHUM)
Clinical Epidemiology Unit, Loeb Health Research Institute
Clinical Research Institute of Montreal (IRCM)
Hamilton Health Sciences Corporation
Health Sciences Centre
Hospital for Sick Children
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
Loeb Health Research Institute (Ottawa Civic Hospital)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Queen Elizabeth II Health Sciences Centre
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's

Allied Clinical Research Inc.
Anapharm Inc.
Cantox Health Sciences International
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CMX Research Inc.
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Kasper Medical Labs
Endpoint Research Ltd.
Innovus Research Inc.
LAB Pre-Clinical Research International Inc.
Parexel International
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.
Probity Medical Research
R.J.A. Medicentres Canada Inc.
Trial Management Group Inc.

MUSCLE / BONE / JOINT

Sites

Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre for Research in Neurodegenerative Diseases (CRND)
Centre hospitalier de l'université de Montréal (CHUM)
Hamilton Health Sciences Corporation
Health Sciences Centre
Hospital for Sick Children
Institut universitaire de gériatrie de Montréal
Izaak W. Killan & Grace Health Science Cenfre
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Queen Elizabeth II Health Sciences Centre
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's

Allied Clinical Research Inc.
Anapharm Inc.
Cantox Health Sciences International
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CMX Research Inc.
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Kasper Medical Labs
Endpoint Research Ltd.
Innovus Research Inc.
LAB Pre-Clinical Research International Inc.
Parexel International
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.
Probity Medical Research
R.J.A. Medicentres Canada Inc.
Trial Management Group Inc.

REPRODUCTION / PREGNANCY

Sites

Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre hospitalier de l'université de Montréal (CHUM)
Hospital for Sick Children
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
Loeb Health Research Institute (Ottawa Civic Hospital)
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Saskatchewan, and the Saskatchewan Drug Research Institute

CRO's and SMO's

Allied Clinical Research Inc.
Anapharm Inc.
Cantox Health Sciences International
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Kasper Medical Labs
Endpoint Research Ltd.
Innovus Research Inc.
Parexel International
Probity Medical Research
R.J.A. Medicentres Canada Inc.
Trial Management Group Inc.

RESPIRATION

Sites

Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre hospitalier de l'université de Montréal (CHUM)
Clinical Epidemiology Unit, Loeb Health Research Institute
Hamilton Health Sciences Corporation
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Queen Elizabeth II Health Sciences Centre
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's

Allied Clinical Research Inc.
Anapharm Inc.
Cantox Health Sciences International
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CMX Research Inc.
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Kasper Medical Labs
Hill Top Research, Inc.
Innovus Research Inc.
Parexel International
Phoenix International Life Sciences Inc.
Probity Medical Research
R.J.A. Medicentres Canada Inc.
Trial Management Group Inc.

WOMEN'S HEALTH

Sites

Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre hospitalier de l'université de Montréal (CHUM)
Clinical Epidemiology Unit, Loeb Health Research Institute
Hamilton Health Sciences Corporation
Health Sciences Centre
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institut universitaire de gériatrie de Montréal
Izaak W. Killan & Grace Health Science Centre
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's

Allied Clinical Research Inc.
Anapharm Inc.
Cantox Health Sciences International
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CMX Research Inc.
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Kasper Medical Labs
Endpoint Research Ltd.
Hill Top Research, Inc.
Innovus Research Inc.
Parexel International
Phoenix International Life Sciences Inc.
Probity Medical Research
R.J.A. Medicentres Canada Inc.
Trial Management Group Inc.

VACCINES

Sites

Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre hospitalier de l'université de Montréal (CHUM)
Child Health Research Unit (CHRU), Alberta Children's Hospital
Clinical Research Institute of Montreal (IRCM)
Cross Cancer Institute
Hamilton Health Sciences Corporation
Health Sciences Centre
Hospital for Sick Children
Izaak W. Killan & Grace Health Science Centre
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Loeb Health Research Institute (Ottawa Civic Hospital)
London Clinical Trials Research Group
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
St. Boniface General Hospital
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's

Allied Clinical Research Inc.
Anapharm Inc.
Cantox Health Sciences International
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CMX Research Inc.
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Endpoint Research Ltd.
Innovus Research Inc.
LAB Pre-Clinical Research International Inc.
Parexel International
Phoenix International Life Sciences Inc.
Probity Medical Research
Trial Management Group Inc.

DENTAL

Sites

Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Hospital for Sick Children
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
McGill University Clinical Research Centre (MUHC)
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Saskatchewan, and the Saskatchewan Drug Research Institute

CRO's and SMO's

Allied Clinical Research Inc.
Cantox Health Sciences International
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Endpoint Research Ltd.
Parexel International
Phoenix International Life Sciences Inc.

SURGICAL

Sites

Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Hamilton Health Sciences Corporation
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Izaak W. Killan & Grace Health Science Centre
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
Loeb Health Research Institute (Ottawa Civic Hospital)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Queen Elizabeth II Health Sciences Centre
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's

Allied Clinical Research Inc.
Anapharm Inc.
Cantox Health Sciences International
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CMX Research Inc.
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Kasper Medical Labs
Endpoint Research Ltd.
Innovus Research Inc.
LAB Pre-Clinical Research International Inc.
Parexel International
Probity Medical Research

GERIATRIC

Sites

Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre for Research in Neurodegenerative Diseases (CRND)
Centre hospitalier de l'université de Montréal (CHUM)
Clinical Epidemiology Unit, Loeb Health Research Institute
Hamilton Health Sciences Corporation
Institut universitaire de gériatrie de Montréal
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Queen Elizabeth II Health Sciences Centre
St. Boniface General Hospital
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's

Allied Clinical Research Inc.
Anapharm Inc.
Cantox Health Sciences International
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Kasper Medical Labs
Endpoint Research Ltd.
Innovus Research Inc.
Parexel International
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.
Probity Medical Research
Trial Management Group Inc.

PAEDIATRIC

Sites

Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Child Health Research Unit (CHRU), Alberta Children's Hospital
Cross Cancer Institute
Hamilton Health Sciences Corporation
Hospital for Sick Children
Izaak W. Killan & Grace Health Science Centre
Lawson Research Institute (The)
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
Surrey Place Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Saskatchewan, and the Saskatchewan Drug Research Institute

CRO's and SMO's

Allied Clinical Research Inc.
Anapharm Inc.
Cantox Health Sciences International
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Kasper Medical Labs
Endpoint Research Ltd.
Innovus Research Inc.
Parexel International
Probity Medical Research
Trial Management Group Inc.

DEVICES

Sites

Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre hospitalier de l'université de Montréal (CHUM)
Clinical Research Institute of Montreal (IRCM)
Cross Cancer Institute
Hamilton Health Sciences Corporation
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Izaak W. Killan & Grace Health Science Centre
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Providence Health Care, St. Paul's Hospital site
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's

Allied Clinical Research Inc.
Anapharm Inc.
Canadian Reference Laboratory Ltd.
Cantox Health Sciences International
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CMX Research Inc.
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Endpoint Research Ltd.
Innovus Research Inc.
Parexel International
Pharma Medica Research Inc.
R.J.A. Medicentres Canada Inc.
Trial Management Group Inc.

DIAGNOSTICS

Sites

Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre de Recherche Philippe Pinel de Montréal
Centre for Research in Neurodegenerative Diseases (CRND)
Centre hospitalier de l'université de Montréal (CHUM)
Clinical Research Institute of Montreal (IRCM)
Cross Cancer Institute
Hamilton Health Sciences Corporation
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Izaak W. Killan & Grace Health Science Centre
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's

Allied Clinical Research Inc.
Anapharm Inc.
Canadian Reference Laboratory Ltd.
Cantox Health Sciences International
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Kasper Medical Labs
Innovus Research Inc.
Parexel International
Pharma Medica Research Inc.
Trial Management Group Inc.

Clinical Trial Stages

PRE-CLINICAL

Sites

Capital Health Authority (CHA) - University of Alberta Clinical Trials Centred
Cardiovascular Research Lab., UBC
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre for Research in Neurodegenerative Diseases (CRND)
Centre hospitalier de l'université de Montréal (CHUM)
Clinical Research Institute of Montreal (IRCM)
Cross Cancer Institute
Douglas Hospital Research Centre
Hamilton Health Sciences Corporation
Hamilton Regional Cancer Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institut universitaire de gériatrie de Montréal
Institute of Mental Health Research, Royal Ottawa Health Care Group
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
Loeb Health Research Institute (Ottawa Civic Hospital)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Queen Elizabeth II Health Sciences Centre
Queen's University GI Diseases Research Unit (GIDRU)
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
Terry Fox Laboratory
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's

Allied Clinical Research Inc.
Anapharm Inc.
Canadian Reference Laboratory Ltd.
Cantox Health Sciences International
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Kasper Medical Labs
Endpoint Research Ltd.
Hill Top Research, Inc.
Innovus Research Inc.
LAB Pre-Clinical Research International Inc.
Parexel International

Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.
Probity Medical Research
R.J.A. Medicentres Canada Inc.
Trial Management Group Inc.

PHASE I

Sites

Canadian Bacterial Diseases Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre for Research in Neurodegenerative Diseases (CRND)
Centre hospitalier de l'université de Montréal (CHUM)
Child Health Research Unit (CHRU), Alberta Children's Hospital
Clinical Epidemiology Unit, Loeb Health Research Institute
Clinical Research Institute of Montreal (IRCM)
Cross Cancer Institute
Douglas Hospital Research Centre
Hamilton Health Sciences Corporation
Hamilton Regional Cancer Centre
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institut universitaire de gériatrie de Montréal
Institute of Mental Health Research, Royal Ottawa Health Care Group
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
Leukemia / Bone Marrow Transplant Program of British Columbia
Loeb Health Research Institute (Ottawa Civic Hospital)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Queen Elizabeth II Health Sciences Centre
Queen's University GI Diseases Research Unit (GIDRU)
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's

Allied Clinical Research Inc.
Anapharm Inc.
Canadian Reference Laboratory Ltd.
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CroMedica Inc. (Canada)
Dynacare Kasper Medical Labs
Endpoint Research Ltd.
Pharma Medica Research Inc.

Phoenix International Life Sciences Inc.
Probity Medical Research

PHASE II

Sites
Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Cardiovascular Research Lab., UBC
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre for Research in Neurodegenerative Diseases (CRND)
Centre hospitalier de l'université de Montréal (CHUM)
Child Health Research Unit (CHRU), Alberta Children's Hospital
Clinical Epidemiology Unit, Loeb Health Research Institute
Clinical Research Institute of Montreal (IRCM)
Cross Cancer Institute
Douglas Hospital Research Centre
Hamilton Health Sciences Corporation
Hamilton Regional Cancer Centre
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institut universitaire de gériatrie de Montréal
Institute of Mental Health Research, Royal Ottawa Health Care Group
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
Leukemia / Bone Marrow Transplant Program of British Columbia
Loeb Health Research Institute (Ottawa Civic Hospital)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Queen Elizabeth II Health Sciences Centre
Queen's University GI Diseases Research Unit (GIDRU)
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
Surrey Place Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Allied Clinical Research Inc.
Anapharm Inc.
Canadian Reference Laboratory Ltd.
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CMX Research Inc.
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Kasper Medical Labs
Endpoint Research Ltd.
Hill Top Research, Inc.
Innovus Research Inc.

Parexel International
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.
Probity Medical Research
R.J.A. Medicentres Canada Inc.
Trial Management Group Inc.

PHASE III

Sites
Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Cardiovascular Research Lab:, UBC
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre de Recherche Philippe Pinel de Montréal
Centre for Research in Neurodegenerative Diseases (CRND)
Centre hospitalier de l'université de Montréal (CHUM)
Child Health Research Unit (CHRU), Alberta Children's Hospital
Clinical Epidemiology Unit, Loeb Health Research Institute
Clinical Research Institute of Montreal (IRCM)
Cross Cancer Institute
Douglas Hospital Research Centre
Hamilton Health Sciences Corporation
Hamilton Regional Cancer Centre
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institut universitaire de gériatrie de Montréal
Institute of Mental Health Research, Royal Ottawa Health Care Group
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
Leukemia / Bone Marrow Transplant Program of British Columbia
Loeb Health Research Institute (Ottawa Civic Hospital)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Queen Elizabeth II Health Sciences Centre
Queen's University GI Diseases Research Unit (GIDRU)
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
Surrey Place Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Allied Clinical Research Inc.
Anapharm Inc.
Canadian Reference Laboratory Ltd.
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CMX Research Inc.
Covance (Canada) Inc.

CroMedica Inc. (Canada)
Dynacare Kasper Medical Labs
Endpoint Research Ltd.
Hill Top Research, Inc.
Innovus Research Inc.
Parexel International
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.
Probity Medical Research
R.J.A. Medicentres Canada Inc.
Trial Management Group Inc.

PHASE IV

Sites

Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Cardiovascular Research Lab., UBC
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre de Recherche Philippe Pinel de Montréal
Centre for Research in Neurodegenerative Diseases (CRND)
Centre hospitalier de l'université de Montréal (CHUM)
Child Health Research Unit (CHRU), Alberta Children's Hospital
Clinical Epidemiology Unit, Loeb Health Research Institute
Clinical Research Institute of Montreal (IRCM)
Cross Cancer Institute
Douglas Hospital Research Centre
Hamilton Health Sciences Corporation
Hamilton Regional Cancer Centre
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institut universitaire de gériatrie de Montréal
Institute of Mental Health Research, Royal Ottawa Health Care Group
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
Loeb Health Research Institute (Ottawa Civic Hospital)
London Clinical Trials Research Group
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Queen Elizabeth II Health Sciences Centre
Queen's University GI Diseases Research Unit (GIDRU)
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
Surrey Place Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's

Allied Clinical Research Inc.
Anapharm Inc.
Canadian Reference Laboratory Ltd.
Cato Research Canada
Clinimetrics Research Associates Inc.

ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CMX Research Inc.
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Kasper Medical Labs
Endpoint Research Ltd.
Hill Top Research, Inc.
Innovus Research Inc.
Parexel International
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.
Probity Medical Research
R.J.A. Medicentres Canada Inc.
Trial Management Group Inc.

Other Services

Pre-clinical Services

MEDICINAL & ORGANIC CHEMISTRY

Sites
Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Canadian Bacterial Diseases Network
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Child Health Research Unit (CHRU), Alberta Children's Hospital
Hamilton Health Sciences Corporation
Hamilton Regional Cancer Centre
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institut universitaire de gériatrie de Montréal
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
McGill University Clinical Research Centre (MUHC)
Queen's University GI Diseases Research Unit (GIDRU)
St. Boniface General Hospital
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute

CRO's and SMO's
Cantox Health Sciences International
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Dynacare Clinical Research Inc.
Phoenix International Life Sciences Inc.

BIOLOGICAL & PHARMACOLOGICAL RESEARCH

Sites
Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Canadian Bacterial Diseases Network
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Cardiovascular Research Lab., UBC
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre for Research in Neurodegenerative Diseases (CRND)
Centre hospitalier de l'université de Montréal (CHUM)
Clinical Research Institute of Montreal (IRCM)
Cross Cancer Institute
Douglas Hospital Research Centre
Hamilton Health Sciences Corporation
Hamilton Regional Cancer Centre
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institut universitaire de gériatrie de Montréal
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital

Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Queen's University GI Diseases Research Unit (GIDRU)
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
Terry Fox Laboratory
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Cantox Health Sciences International
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Dynacare Clinical Research Inc.
ITR Laboratories Canada Inc.
LAB Pre-Clinical Research International Inc.
Phoenix International Life Sciences Inc.

ANIMAL TESTING

Sites
Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Canadian Bacterial Diseases Network
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Cardiovascular Research Lab., UBC
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre hospitalier de l'université de Montréal (CHUM)
Clinical Research Institute of Montreal (IRCM)
Douglas Hospital Research Centre
Hamilton Health Sciences Corporation
Hamilton Regional Cancer Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institut universitaire de gériatrie de Montréal
Institute of Mental Health Research, Royal Ottawa Health Care Group
Izaak W. Killan & Grace Health Science Centre
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Queen's University GI Diseases Research Unit (GIDRU)
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
Terry Fox Laboratory
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Cantox Health Sciences International
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Dynacare Clinical Research Inc.
ITR Laboratories Canada Inc.
LAB Pre-Clinical Research International Inc.
Phoenix International Life Sciences Inc.

LABORATORY SERVICES

Sites
Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Canadian Bacterial Diseases Network
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre hospitalier de l'université de Montréal (CHUM)
Clinical Research Institute of Montreal (IRCM)
Cross Cancer Institute
Hamilton Health Sciences Corporation
Hamilton Regional Cancer Centre
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institut universitaire de gériatrie de Montréal
Izaak W. Killan & Grace Health Science Centre
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital
St. Joseph's Hospital
Terry Fox Laboratory
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Anapharm Inc.
Canadian Reference Laboratory Ltd.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Dynacare Clinical Research Inc.
Dynacare Kasper Medical Labs
Elemental Research Inc.
ITR Laboratories Canada Inc.
LAB Pre-Clinical Research International Inc.
Phoenix International Life Sciences Inc.

QUALITY ASSURANCE

Sites
Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Canadian Bacterial Diseases Network
Canadian HIV Trials Network

Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre for Research in Neurodegenerative Diseases (CRND)
Child Health Research Unit (CHRU), Alberta Children's Hospital
Cross Cancer Institute
Hamilton Health Sciences Corporation
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institut universitaire de gériatrie de Montréal
Institute of Mental Health Research, Royal Ottawa Health Care Group
Izaak W. Killan & Grace Health Science Centre
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
St. Boniface General Hospital
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Acerna Inc.
Canadian Reference Laboratory Ltd.
Cantox Health Sciences International
Cato Research Canada
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Dynacare Clinical Research Inc.
Elemental Research Inc.
ITR Laboratories Canada Inc.
Phoenix International Life Sciences Inc.
Trial Management Group Inc.

Ethical Review

PHASE I

Sites
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre for Research in Neurodegenerative Diseases (CRND)
Centre hospitalier de l'université de Montréal (CHUM)
Child Health Research Unit (CHRU), Alberta Children's Hospital
Clinical Epidemiology Unit, Loeb Health Research Institute
Clinical Research Institute of Montreal (IRCM)
Cross Cancer Institute
Douglas Hospital Research Centre
Hamilton Health Sciences Corporation
Hamilton Regional Cancer Centre
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institut universitaire de gériatrie de Montréal
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital

Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
Leukemia / Bone Marrow Transplant Program of British Columbia
Loeb Health Research Institute (Ottawa Civic Hospital)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Queen's University GI Diseases Research Unit (GIDRU)
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Allied Clinical Research Inc.
Anapharm Inc.
Dynacare Clinical Research Inc.
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.

PHASE II & III

Sites
Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre de Recherche Philippe Pinel de Montréal
Centre for Research in Neurodegenerative Diseases (CRND)
Centre hospitalier de l'université de Montréal (CHUM)
Child Health Research Unit (CHRU), Alberta Children's Hospital
Clinical Epidemiology Unit, Loeb Health Research Institute
Clinical Research Institute of Montreal (IRCM)
Cross Cancer Institute
Douglas Hospital Research Centre
Hamilton Health Sciences Corporation
Hamilton Regional Cancer Centre
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institut universitaire de gériatrie de Montréal
Institute of Mental Health Research, Royal Ottawa Health Care Group
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
Leukemia / Bone Marrow Transplant Program of British Columbia
Loeb Health Research Institute (Ottawa Civic Hospital)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Queen's University GI Diseases Research Unit (GIDRU)
St. Boniface General Hospital
St. Joseph's Hospital

Sunnybrook & Women's College Health Sciences Centre
Surrey Place Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Allied Clinical Research Inc.
Anapharm Inc.
CMX Research Inc.
Dynacare Clinical Research Inc.
Hill Top Research, Inc.
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.
Trafalgar Ethics Board Inc.
Trial Management Group Inc.

Phase I Services

FIRST-TIME-IN-MAN STUDIES

Sites
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre for Research in Neurodegenerative Diseases (CRND)
Centre hospitalier de l'université de Montréal (CHUM)
Clinical Research Institute of Montreal (IRCM)
Cross Cancer Institute
Douglas Hospital Research Centre
Hamilton Health Sciences Corporation
Hamilton Regional Cancer Centre
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institut universitaire de gériatrie de Montréal
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
Loeb Health Research Institute (Ottawa Civic Hospital)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
St. Joseph's Hospital
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Allied Clinical Research Inc.
Anapharm Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Dynacare Clinical Research Inc.
Hill Top Research, Inc.

Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.
Probity Medical Research

PHARMACOKINETICS

Sites
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre hospitalier de l'université de Montréal (CHUM)
Clinical Research Institute of Montreal (IRCM)
Cross Cancer Institute
Hamilton Health Sciences Corporation
Hamilton Regional Cancer Centre
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institut universitaire de gériatrie de Montréal
Institute of Mental Health Research, Royal Ottawa Health Care Group
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Sunnybrook & Women's College Health Sciences Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Allied Clinical Research Inc.
Anapharm Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Dynacare Clinical Research Inc.
Hill Top Research, Inc.
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.
Probity Medical Research

PHARMACODYNAMICS

Sites
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre hospitalier de l'université de Montréal (CHUM)
Clinical Research Institute of Montreal (IRCM)
Cross Cancer Institute
Hamilton Health Sciences Corporation
Hamilton Regional Cancer Centre
Health Sciences Centre
Hôpital Laval

Hospital for Sick Children
Institut de Cardiologie de Montréal
Institut universitaire de gériatrie de Montréal
Institute of Mental Health Research, Royal Ottawa Health Care Group
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Allied Clinical Research Inc.
Anapharm Inc.
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CroMedica Inc. (Canada)
Dynacare Clinical Research Inc.
Dynacare Kasper Medical Labs
Hill Top Research, Inc.
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.

BIOAVAILABILITY

Sites
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre hospitalier de l'université de Montréal (CHUM)
Clinical Research Institute of Montreal (IRCM)
Cross Cancer Institute
Douglas Hospital Research Centre
Hamilton Health Sciences Corporation
Hamilton Regional Cancer Centre
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institut universitaire de gériatrie de Montréal
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lawson Research Institute (The)
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Sunnybrook & Women's College Health Sciences Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Allied Clinical Research Inc.
Anapharm Inc.
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CroMedica Inc. (Canada)
Dynacare Clinical Research Inc.
Dynacare Kasper Medical Labs
Elemental Research Inc.
Hill Top Research, Inc.
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.

BIOEQUIVALENCE

Sites
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre hospitalier de l'université de Montréal (CHUM)
Cross Cancer Institute
Hamilton Health Sciences Corporation
Hamilton Regional Cancer Centre
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institut universitaire de gériatrie de Montréal
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lawson Research Institute (The)
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Sunnybrook & Women's College Health Sciences Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Allied Clinical Research Inc.
Anapharm Inc.
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CroMedica Inc. (Canada)
Dynacare Clinical Research Inc.
Dynacare Kasper Medical Labs
Elemental Research Inc.
Hill Top Research, Inc.
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.

Phase II / III Studies

PROJECT MANAGEMENT

Sites

Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre de Recherche Philippe Pinel de Montréal
Centre for Research in Neurodegenerative Diseases (CRND)
Child Health Research Unit (CHRU), Alberta Children's Hospital
Clinical Epidemiology Unit, Loeb Health Research Institute
Clinical Research Institute of Montreal (IRCM)
Cross Cancer Institute
Douglas Hospital Research Centre
Hamilton Health Sciences Corporation
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institut universitaire de gériatrie de Montréal
Institute of Mental Health Research, Royal Ottawa Health Care Group
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
Leukemia / Bone Marrow Transplant Program of British Columbia
Loeb Health Research Institute (Ottawa Civic Hospital)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Queen's University GI Diseases Research Unit (GIDRU)
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital
St. Joseph's Hospital
Surrey Place Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's

Allied Clinical Research Inc.
Anapharm Inc.
Canadian Reference Laboratory Ltd.
Cantox Health Sciences International
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Clinical Research Inc.
Endpoint Research Ltd.
Hill Top Research, Inc.
Innovus Research Inc.
Parexel International
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.

PROTOCOL & CRF DEVELOPMENT

Sites
Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Cardiovascular Research Lab., UBC
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre hospitalier de l'université de Montréal (CHUM)
Child Health Research Unit (CHRU), Alberta Children's Hospital
Clinical Epidemiology Unit, Loeb Health Research Institute
Clinical Research Institute of Montreal (IRCM)
Cross Cancer Institute
Douglas Hospital Research Centre
Hamilton Health Sciences Corporation
Hamilton Regional Cancer Centre
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institut universitaire de gériatrie de Montréal
Institute of Mental Health Research, Royal Ottawa Health Care Group
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Leukemia / Bone Marrow Transplant Program of British Columbia
Loeb Health Research Institute (Ottawa Civic Hospital)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Queen's University GI Diseases Research Unit (GIDRU)
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital
St. Joseph's Hospital
Surrey Place Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Allied Clinical Research Inc.
Anapharm Inc.
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Clinical Research Inc.
Endpoint Research Ltd.
Hill Top Research, Inc.
Innovus Research Inc.
Parexel International
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.

CLINICAL TRIAL DESIGN

Sites

Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Cardiovascular Research Lab., UBC
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre for Research in Neurodegenerative Diseases (CRND)
Centre hospitalier de l'université de Montréal (CHUM)
Child Health Research Unit (CHRU), Alberta Children's Hospital
Clinical Epidemiology Unit, Loeb Health Research Institute
Clinical Research Institute of Montreal (IRCM)
Cross Cancer Institute
Douglas Hospital Research Centre
Hamilton Health Sciences Corporation
Hamilton Regional Cancer Centre
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institut universitaire de gériatrie de Montréal
Institute of Mental Health Research, Royal Ottawa Health Care Group
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Leukemia / Bone Marrow Transplant Program of British Columbia
Loeb Health Research Institute (Ottawa Civic Hospital)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Queen's University GI Diseases Research Unit (GIDRU)
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital
St. Joseph's Hospital
Surrey Place Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's

Allied Clinical Research Inc.
Anapharm Inc.
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CMX Research Inc.
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Clinical Research Inc.
Endpoint Research Ltd.
Hill Top Research, Inc.
Innovus Research Inc.
McDougall Scientific Ltd.
Parexel International
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.
Probity Medical Research

CLINICAL PACKAGING & SUPPLIES

Sites

Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre hospitalier de l'université de Montréal (CHUM)
Child Health Research Unit (CHRU), Alberta Children's Hospital
Douglas Hospital Research Centre
Hamilton Health Sciences Corporation
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institut universitaire de gériatrie de Montréal
Izaak W. Killan & Grace Health Science Centre
Leukemia / Bone Marrow Transplant Program of British Columbia
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Queen's University GI Diseases Research Unit (GIDRU)
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Joseph's Hospital
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's

Canadian Reference Laboratory Ltd.
Cato Research Canada
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CroMedica Inc. (Canada)
Dynacare Clinical Research Inc.
Endpoint Research Ltd.
Hill Top Research, Inc.
Innovus Research Inc.
Parexel International
Phoenix International Life Sciences Inc.

CLINICAL TRIALS MONITORING

Sites

Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre de Recherche Philippe Pinel de Montréal
Centre for Research in Neurodegenerative Diseases (CRND)
Child Health Research Unit (CHRU), Alberta Children's Hospital
Cross Cancer Institute
Douglas Hospital Research Centre
Hamilton Health Sciences Corporation
Hamilton Regional Cancer Centre
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institut universitaire de gériatrie de Montréal
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)

Leukemia / Bone Marrow Transplant Program of British Columbia
Loeb Health Research Institute (Ottawa Civic Hospital)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Queen's University GI Diseases Research Unit (GIDRU)
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
Surrey Place Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Anapharm Inc.
Canadian Reference Laboratory Ltd.
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Clinical Research Inc.
Endpoint Research Ltd.
Hill Top Research, Inc.
Innovus Research Inc.
Parexel International
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.

INVESTIGATIVE SITE SELECTION & MANAGEMENT

Sites
Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre de Recherche Philippe Pinel de Montréal
Centre for Research in Neurodegenerative Diseases (CRND)
Child Health Research Unit (CHRU), Alberta Children's Hospital
Clinical Epidemiology Unit, Loeb Health Research Institute
Cross Cancer Institute
Douglas Hospital Research Centre
Hamilton Health Sciences Corporation
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institut universitaire de gériatrie de Montréal
Institute of Mental Health Research, Royal Ottawa Health Care Group
Izaak W. Killan & Grace Health Science Centre
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Leukemia / Bone Marrow Transplant Program of British Columbia
London Clinical Trials Research Group
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Joseph's Hospital
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute

University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Allied Clinical Research Inc.
Anapharm Inc.
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CMX Research Inc.
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Clinical Research Inc.
Endpoint Research Ltd.
Hill Top Research, Inc.
Innovus Research Inc.
Parexel International
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.
Probity Medical Research
Trial Management Group Inc.

PATIENT RECRUITMENT

Sites
Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Cardiovascular Research Lab., UBC
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre de Recherche Philippe Pinel de Montréal
Centre for Research in Neurodegenerative Diseases (CRND)
Centre hospitalier de l'université de Montréal (CHUM)
Child Health Research Unit (CHRU), Alberta Children's Hospital
Clinical Epidemiology Unit, Loeb Health Research Institute
Clinical Research Institute of Montreal (IRCM)
Cross Cancer Institute
Douglas Hospital Research Centre
Hamilton Health Sciences Corporation
Hamilton Regional Cancer Centre
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institut universitaire de gériatrie de Montréal
Institute of Mental Health Research, Royal Ottawa Health Care Group
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
Leukemia / Bone Marrow Transplant Program of British Columbia
Loeb Health Research Institute (Ottawa Civic Hospital)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Queen's University GI Diseases Research Unit (GIDRU)
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital

St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
Surrey Place Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Allied Clinical Research Inc.
Anapharm Inc.
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Clinical Research Inc.
Endpoint Research Ltd.
Hill Top Research, Inc.
Innovus Research Inc.
Parexel International
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.
Probity Medical Research
R.J.A. Medicentres Canada Inc.
Trial Management Group Inc.

LABORATORY SERVICES

Sites
Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre for Research in Neurodegenerative Diseases (CRND)
Centre hospitalier de l'université de Montréal (CHUM)
Child Health Research Unit (CHRU), Alberta Children's Hospital
Clinical Research Institute of Montreal (IRCM)
Cross Cancer Institute
Douglas Hospital Research Centre
Hamilton Health Sciences Corporation
Hamilton Regional Cancer Centre
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institut universitaire de gériatrie de Montréal
Institute of Mental Health Research, Royal Ottawa Health Care Group
Izaak W. Killan & Grace Health Science Centre
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
Leukemia / Bone Marrow Transplant Program of British Columbia
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Queen's University GI Diseases Research Unit (GIDRU)
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital
St. Joseph's Hospital

Sunnybrook & Women's College Health Sciences Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Canadian Reference Laboratory Ltd.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Dynacare Clinical Research Inc.
Dynacare Kasper Medical Labs
Elemental Research Inc.
Hill Top Research, Inc.
Parexel International
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.

BIOMETRIC & HAEMATOLOGICAL SERVICES

Sites
Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre for Research in Neurodegenerative Diseases (CRND)
Centre hospitalier de l'université de Montréal (CHUM)
Child Health Research Unit (CHRU), Alberta Children's Hospital
Cross Cancer Institute
Hamilton Health Sciences Corporation
Hamilton Regional Cancer Centre
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institut universitaire de gériatrie de Montréal
Izaak W. Killan & Grace Health Science Centre
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
Leukemia / Bone Marrow Transplant Program of British Columbia
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Queen's University GI Diseases Research Unit (GIDRU)
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital
St. Joseph's Hospital
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Canadian Reference Laboratory Ltd.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Dynacare Clinical Research Inc.
Dynacare Kasper Medical Labs
Elemental Research Inc.
Hill Top Research, Inc.
Parexel International
Pharma Medica Research Inc.

Phoenix International Life Sciences Inc.

STATISTICAL SERVICES

Sites
Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre de Recherche Philippe Pinel de Montréal
Centre hospitalier de l'université de Montréal (CHUM)
Clinical Epidemiology Unit, Loeb Health Research Institute
Cross Cancer Institute
Douglas Hospital Research Centre
Hamilton Health Sciences Corporation
Health Sciences Centre
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institut universitaire de gériatrie de Montréal
Institute of Mental Health Research, Royal Ottawa Health Care Group
Izaak W. Killan & Grace Health Science Centre
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Leukemia / Bone Marrow Transplant Program of British Columbia
Loeb Health Research Institute (Ottawa Civic Hospital)
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Queen's University GI Diseases Research Unit (GIDRU)
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Allied Clinical Research Inc.
Anapharm Inc.
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Clinical Research Inc.
Endpoint Research Ltd.
Hill Top Research, Inc.
Innovus Research Inc.
McDougall Scientific Ltd.
Pharma Medica Research Inc.

DATA MANAGEMENT & ANALYSIS

Sites
Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre de Recherche Philippe Pinel de Montréal

Centre hospitalier de l'université de Montréal (CHUM)
Child Health Research Unit (CHRU), Alberta Children's Hospital
Clinical Epidemiology Unit, Loeb Health Research Institute
Clinical Research Institute of Montreal (IRCM)
Cross Cancer Institute
Douglas Hospital Research Centre
Hamilton Health Sciences Corporation
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institut universitaire de gériatrie de Montréal
Institute of Mental Health Research, Royal Ottawa Health Care Group
Izaak W. Killan & Grace Health Science Centre
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Leukemia / Bone Marrow Transplant Program of British Columbia
Loeb Health Research Institute (Ottawa Civic Hospital)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Queen's University GI Diseases Research Unit (GIDRU)
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Joseph's Hospital
Surrey Place Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Allied Clinical Research Inc.
Anapharm Inc.
Canadian Reference Laboratory Ltd.
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CroMedica Inc. (Canada)
Dynacare Clinical Research Inc.
Endpoint Research Ltd.
Hill Top Research, Inc.
Innovus Research Inc.
McDougall Scientific Ltd.
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.

DRUG DOSAGE & FORMULATION

Sites
Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Child Health Research Unit (CHRU), Alberta Children's Hospital
Hamilton Health Sciences Corporation
Hamilton Regional Cancer Centre
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal

Izaak W. Killan & Grace Health Science Centre
Leukemia / Bone Marrow Transplant Program of British Columbia
London Clinical Trials Research Group
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Queen's University GI Diseases Research Unit (GIDRU)
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital
St. Joseph's Hospital
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Allied Clinical Research Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Dynacare Clinical Research Inc.
Hill Top Research, Inc.
Pharma Medica Research Inc.
Randy Stroud Consulting Inc.

QUALITY ASSURANCE & CONTROL

Sites
Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Cross Cancer Institute
Douglas Hospital Research Centre
Hamilton Health Sciences Corporation
Hamilton Regional Cancer Centre
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institute of Mental Health Research, Royal Ottawa Health Care Group
Izaak W. Killan & Grace Health Science Centre
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Leukemia / Bone Marrow Transplant Program of British Columbia
London Clinical Trials Research Group
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Queen's University GI Diseases Research Unit (GIDRU)
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Acerna Inc.
Anapharm Inc.
Canadian Reference Laboratory Ltd.
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CroMedica Inc. (Canada)
Dynacare Clinical Research Inc.
Endpoint Research Ltd.
Hill Top Research, Inc.

Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.
Randy Stroud Consulting Inc.
Trial Management Group Inc.

Regulatory Services

REGULATORY AFFAIRS

Sites
Canadian HIV Trials Network
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Izaak W. Killan & Grace Health Science Centre
London Clinical Trials Research Group
St. Joseph's Hospital
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute

CRO's and SMO's
Acerna Inc.
Allied Clinical Research Inc.
Cantox Health Sciences International
Cato Research Canada
Clinimetrics Research Associates Inc.
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Clinical Research Inc.
Endpoint Research Ltd.
Hill Top Research, Inc.
McCarthy Consulting Services
Parexel International
Pharma Medica Research Inc.
Randy Stroud Consulting Inc.

DOCUMENT, MANUSCRIPT & CANDA PREPARATION

Sites
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Clinical Epidemiology Unit, Loeb Health Research Institute
Cross Cancer Institute
Douglas Hospital Research Centre
Institute of Mental Health Research, Royal Ottawa Health Care Group
Izaak W. Killan & Grace Health Science Centre
London Clinical Trials Research Group
Ottawa General Hospital Research Institute
St. Joseph's Hospital
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Acerna Inc.
Allied Clinical Research Inc.
Cantox Health Sciences International
Cato Research Canada
Covance (Canada) Inc.
CroMedica Inc. (Canada)

Dynacare Clinical Research Inc.
Endpoint Research Ltd.
Hill Top Research, Inc.
McCarthy Consulting Services
Parexel International
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.
Randy Stroud Consulting Inc.

IND SUBMISSION

Sites
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre hospitalier de l'université de Montréal (CHUM)
Cross Cancer Institute
Hospital for Sick Children
Institute of Mental Health Research, Royal Ottawa Health Care Group
Izaak W. Killan & Grace Health Science Centre
London Clinical Trials Research Group
Ottawa General Hospital Research Institute
St. Joseph's Hospital
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Saskatchewan, and the Saskatchewan Drug Research Institute

CRO's and SMO's
Acerna Inc.
Allied Clinical Research Inc.
Cantox Health Sciences International
Cato Research Canada
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Clinical Research Inc.
Endpoint Research Ltd.
Hill Top Research, Inc.
McCarthy Consulting Services
Parexel International
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.
Randy Stroud Consulting Inc.

NDA SUBMISSION

Sites
Canadian HIV Trials Network
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre hospitalier de l'université de Montréal (CHUM)
Hospital for Sick Children
London Clinical Trials Research Group
St. Joseph's Hospital
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
CRO's and SMO's
Acerna Inc.
Allied Clinical Research Inc.
Anapharm Inc.
Canadian Reference Laboratory Ltd.
Cantox Health Sciences International

Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CMX Research Inc.
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Clinical Research Inc.
Dynacare Kasper Medical Labs
Elemental Research Inc.
Endpoint Research Ltd.
Hill Top Research, Inc.
Innovus Research Inc.
ITR Laboratories Canada Inc.
LAB Pre-Clinical Research International Inc.
Maxxam Clinical Research Inc.
McCarthy Consulting Services
McDougall Scientific Ltd.
Parexel International
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.
Probity Medical Research
R.J.A. Medicentres Canada Inc.
Randy Stroud Consulting Inc.
Trafalgar Ethics Board Inc.
Trial Management Group Inc.

REGULATORY CONSULTING

Sites
Canadian HIV Trials Network
Centre hospitalier de l'université de Montréal (CHUM)
Institute of Mental Health Research, Royal Ottawa Health Care Group
Izaak W. Killan & Grace Health Science Centre
St. Joseph's Hospital
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute

CRO's and SMO's
Acerna Inc.
Cantox Health Sciences International
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Clinical Research Inc.
Endpoint Research Ltd.
Hill Top Research, Inc.
McCarthy Consulting Services
Parexel International
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.
Randy Stroud Consulting Inc.

Post-Marketing Services

OUTCOME MEASUREMENT STUDIES

Sites
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Cardiovascular Research Lab., UBC
Centre hospitalier de l'université de Montréal (CHUM)
Cross Cancer Institute
Douglas Hospital Research Centre
Hamilton Health Sciences Corporation
Hamilton Regional Cancer Centre
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
Loeb Health Research Institute (Ottawa Civic Hospital)
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Queen's University GI Diseases Research Unit (GIDRU)
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Allied Clinical Research Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CroMedica Inc. (Canada)
Dynacare Clinical Research Inc.
Endpoint Research Ltd.
Hill Top Research, Inc.
Innovus Research Inc.
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.
R.J.A. Medicentres Canada Inc.

PHARMAECONOMIC STUDIES

Sites
Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Cardiovascular Research Lab., UBC
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Centre hospitalier de l'université de Montréal (CHUM)
Clinical Epidemiology Unit, Loeb Health Research Institute
Cross Cancer Institute
Douglas Hospital Research Centre
Hamilton Health Sciences Corporation
Hamilton Regional Cancer Centre
Health Sciences Centre

Hospital for Sick Children
Institut de Cardiologie de Montréal
Institute of Mental Health Research, Royal Ottawa Health Care Group
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
Loeb Health Research Institute (Ottawa Civic Hospital)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Queen's University GI Diseases Research Unit (GIDRU)
St. Joseph's Hospital
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Allied Clinical Research Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CroMedica Inc. (Canada)
Dynacare Clinical Research Inc.
Endpoint Research Ltd.
Hill Top Research, Inc.
Innovus Research Inc.
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.
R.J.A. Medicentres Canada Inc.
Trial Management Group Inc.

QUALITY OF LIFE STUDIES

Sites
Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre hospitalier de l'université de Montréal (CHUM)
Clinical Epidemiology Unit, Loeb Health Research Institute
Cross Cancer Institute
Douglas Hospital Research Centre
Hamilton Health Sciences Corporation
Hamilton Regional Cancer Centre
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institut de Cardiologie de Montréal
Institute of Mental Health Research, Royal Ottawa Health Care Group
Izaak W. Killan & Grace Health Science Centre
Kingston General Hospital
Lady Davis Institute for Medical Research (Sir Mortimer B. Davis - Jewish General Hospital)
Lawson Research Institute (The)
Loeb Health Research Institute (Ottawa Civic Hospital)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Queen's University GI Diseases Research Unit (GIDRU)
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital

St. Joseph's Hospital
Sunnybrook & Women's College Health Sciences Centre
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Allied Clinical Research Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CMX Research Inc.
CroMedica Inc. (Canada)
Dynacare Clinical Research Inc.
Endpoint Research Ltd.
Hill Top Research, Inc.
Innovus Research Inc.
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.
R.J.A. Medicentres Canada Inc.
Trial Management Group Inc.

RX-OTC STUDIES

Sites
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Centre hospitalier de l'université de Montréal (CHUM)
Douglas Hospital Research Centre
Hamilton Health Sciences Corporation
Hospital for Sick Children
Izaak W. Killan & Grace Health Science Centre
Lawson Research Institute (The)
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Allied Clinical Research Inc.
Cantox Health Sciences International
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CroMedica Inc. (Canada)
Dynacare Clinical Research Inc.
Hill Top Research, Inc.
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.
R.J.A. Medicentres Canada Inc.
Trial Management Group Inc.

CONSUMER TESTING SERVICES

Sites
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Hamilton Health Sciences Corporation
Hôpital Laval
Hospital for Sick Children
McGill University Clinical Research Centre (MUHC)

University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)

CRO's and SMO's
Allied Clinical Research Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Dynacare Clinical Research Inc.
Hill Top Research, Inc.
Phoenix International Life Sciences Inc.
Trial Management Group Inc.

Geography

HPB

Sites
Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Canadian HIV Trials Network
Capital Health Authority (CHA) - University of Alberta Clinical Trials Centre
Cardiovascular Research Lab., UBC
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Clinical Research Institute of Montreal (IRCM)
Cross Cancer Institute
Douglas Hospital Research Centre
Hamilton Regional Cancer Centre
Health Sciences Centre
Hôpital Laval
Hospital for Sick Children
Institute of Mental Health Research, Royal Ottawa Health Care Group
Izaak W. Killan & Grace Health Science Centre
Loeb Health Research Institute (Ottawa Civic Hospital)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Providence Health Care, St. Paul's Hospital site
Queen's University GI Diseases Research Unit (GIDRU)
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Boniface General Hospital
St. Joseph's Hospital
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
University of Saskatchewan, and the Saskatchewan Drug Research Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Acerna Inc.
Allied Clinical Research Inc.
Anapharm Inc.
Cantox Health Sciences International
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CMX Research Inc.
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Clinical Research Inc.
Dynacare Kasper Medical Labs
Endpoint Research Ltd.
Hill Top Research, Inc.

Innovus Research Inc.
McCarthy Consulting Services
Parexel International
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.
Probity Medical Research
R.J.A. Medicentres Canada Inc.
Randy Stroud Consulting Inc.
Trial Management Group Inc.

FDA

Sites

Calgary Regional Health Authority & University of Calgary (Faculty of Medicine)
Canadian HIV Trials Network
Centre de recherche de l'Hôpital Sainte-Justine
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
Clinical Research Institute of Montreal (IRCM)
Cross Cancer Institute
Douglas Hospital Research Centre
Hamilton Regional Cancer Centre
Hôpital Laval
Hospital for Sick Children
Izaak W. Killan & Grace Health Science Centre
Loeb Health Research Institute (Ottawa Civic Hospital)
London Clinical Trials Research Group
London Health Sciences Centre
McGill University Clinical Research Centre (MUHC)
Ottawa General Hospital Research Institute
Queen's University GI Diseases Research Unit (GIDRU)
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
St. Joseph's Hospital
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
University of Ottawa Heart Institute
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's

Acerna Inc.
Allied Clinical Research Inc.
Anapharm Inc.
Cantox Health Sciences International
Cato Research Canada
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
CMX Research Inc.
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Clinical Research Inc.
Endpoint Research Ltd.
Hill Top Research, Inc.
McCarthy Consulting Services
Parexel International
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.
Probity Medical Research
R.J.A. Medicentres Canada Inc.
Trial Management Group Inc.

EMEA

Sites
Canadian HIV Trials Network
Centre de Recherche du CHUL (Centre hospitalier de l'université Laval)
St. Joseph's Hospital
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)
Vancouver Hospital and Health Sciences Centre

CRO's and SMO's
Allied Clinical Research Inc.
Anapharm Inc.
Cantox Health Sciences International
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Clinical Research Inc.
Dynacare Kasper Medical Labs
Hill Top Research, Inc.
McCarthy Consulting Services
Parexel International
Pharma Medica Research Inc.
Phoenix International Life Sciences Inc.

OTHER NATIONAL

Sites
Canadian HIV Trials Network
Institute of Mental Health Research, Royal Ottawa Health Care Group
Ottawa General Hospital Research Institute
University Health Network (Toronto General, Toronto Western, Princess Margaret Hospitals)

CRO's and SMO's
Allied Clinical Research Inc.
Anapharm Inc.
Cantox Health Sciences International
Clinimetrics Research Associates Inc.
ClinTrials BioResearch, Ltd. (CTBR) & ClinTrials Research, Inc. (CCRO)
Covance (Canada) Inc.
CroMedica Inc. (Canada)
Dynacare Clinical Research Inc.
Endpoint Research Ltd.
McCarthy Consulting Services

QUEEN R 854 .C3 C37 2000
Life Sciences Research Inves
Canadian clinical trials fac

DATE DUE
DATE DE RETOUR

CARR McLEAN 38-296

INDUSTRY CANADA/INDUSTRIE CANADA
174977